CN115960223A - anti-C5 antibodies and methods of use - Google Patents
anti-C5 antibodies and methods of use Download PDFInfo
- Publication number
- CN115960223A CN115960223A CN202211018018.5A CN202211018018A CN115960223A CN 115960223 A CN115960223 A CN 115960223A CN 202211018018 A CN202211018018 A CN 202211018018A CN 115960223 A CN115960223 A CN 115960223A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- amino acid
- hvr
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 186
- 230000007935 neutral effect Effects 0.000 claims abstract description 60
- 230000002378 acidificating effect Effects 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 29
- 229920001184 polypeptide Polymers 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 282
- 238000009739 binding Methods 0.000 claims description 210
- 230000027455 binding Effects 0.000 claims description 210
- 241000282414 Homo sapiens Species 0.000 claims description 133
- 238000006467 substitution reaction Methods 0.000 claims description 90
- 150000001413 amino acids Chemical class 0.000 claims description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
- 230000004913 activation Effects 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 48
- 230000000295 complement effect Effects 0.000 claims description 44
- 230000001404 mediated effect Effects 0.000 claims description 39
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 101100177112 Caenorhabditis elegans his-70 gene Proteins 0.000 claims description 13
- 101100069975 Caenorhabditis elegans his-72 gene Proteins 0.000 claims description 13
- 229910052727 yttrium Inorganic materials 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 102220471255 Guanine nucleotide exchange factor subunit RIC1_E48A_mutation Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 abstract description 29
- 150000007523 nucleic acids Chemical class 0.000 abstract description 29
- 102000039446 nucleic acids Human genes 0.000 abstract description 29
- 241001465754 Metazoa Species 0.000 abstract description 23
- 230000003053 immunization Effects 0.000 abstract description 10
- 238000012258 culturing Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 119
- 239000000427 antigen Substances 0.000 description 104
- 108091007433 antigens Proteins 0.000 description 103
- 102000036639 antigens Human genes 0.000 description 103
- 235000001014 amino acid Nutrition 0.000 description 81
- 229960002224 eculizumab Drugs 0.000 description 59
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 57
- 238000003556 assay Methods 0.000 description 55
- 102100031506 Complement C5 Human genes 0.000 description 52
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 52
- 239000000203 mixture Substances 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 47
- 230000001419 dependent effect Effects 0.000 description 45
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 41
- 239000002502 liposome Substances 0.000 description 40
- 238000003780 insertion Methods 0.000 description 38
- 230000037431 insertion Effects 0.000 description 38
- 238000012217 deletion Methods 0.000 description 36
- 230000037430 deletion Effects 0.000 description 36
- 238000012360 testing method Methods 0.000 description 35
- 230000009089 cytolysis Effects 0.000 description 31
- 230000024203 complement activation Effects 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 28
- 238000010494 dissociation reaction Methods 0.000 description 27
- 230000005593 dissociations Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 25
- 239000013078 crystal Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 230000003993 interaction Effects 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 21
- 230000035772 mutation Effects 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 230000002068 genetic effect Effects 0.000 description 20
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 19
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 19
- 241000282567 Macaca fascicularis Species 0.000 description 18
- 238000009825 accumulation Methods 0.000 description 18
- 230000004071 biological effect Effects 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 230000004481 post-translational protein modification Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 241000282693 Cercopithecidae Species 0.000 description 17
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 17
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 17
- 210000004408 hybridoma Anatomy 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 17
- 230000037361 pathway Effects 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 238000001262 western blot Methods 0.000 description 17
- 206010018910 Haemolysis Diseases 0.000 description 16
- 230000008859 change Effects 0.000 description 16
- 230000008588 hemolysis Effects 0.000 description 16
- -1 phosphoryl groups Chemical group 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 208000002780 macular degeneration Diseases 0.000 description 14
- 229940124597 therapeutic agent Drugs 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000007991 ACES buffer Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000562 conjugate Substances 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 238000000159 protein binding assay Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 10
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 10
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 10
- 102220645374 Sodium- and chloride-dependent GABA transporter 2_E48A_mutation Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940127121 immunoconjugate Drugs 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 9
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 9
- 206010064930 age-related macular degeneration Diseases 0.000 description 9
- 235000004279 alanine Nutrition 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 206010052779 Transplant rejections Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102220620620 Complement C5_S1310N_mutation Human genes 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 102200094449 rs17612 Human genes 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- 102220471012 Dual specificity mitogen-activated protein kinase kinase 6_K109A_mutation Human genes 0.000 description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 6
- 239000007987 MES buffer Substances 0.000 description 6
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012505 Superdex™ Substances 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 208000022401 dense deposit disease Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102220492486 Selenoprotein V_D51A_mutation Human genes 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 108010089414 Anaphylatoxins Proteins 0.000 description 4
- 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 208000005777 Lupus Nephritis Diseases 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000002612 cardiopulmonary effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 4
- 208000008795 neuromyelitis optica Diseases 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 208000008899 Habitual abortion Diseases 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 108010079723 Shiga Toxin Proteins 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000031978 negative regulation of complement activation Effects 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- DTLVBHCSSNJCMJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)NCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O DTLVBHCSSNJCMJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 206010001526 Air embolism Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000016323 C3 glomerulonephritis Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 2
- 108010028773 Complement C5 Proteins 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- 208000010837 Diabetic eye disease Diseases 0.000 description 2
- 208000013600 Diabetic vascular disease Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 2
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000034706 Graft dysfunction Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010069440 Henoch-Schonlein purpura nephritis Diseases 0.000 description 2
- 206010019860 Hereditary angioedema Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000027032 Renal vascular disease Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 230000009833 antibody interaction Effects 0.000 description 2
- 230000009831 antigen interaction Effects 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 108010032939 des-Arginine Complement C5a Proteins 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108090000062 ficolin Proteins 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 229950005692 larotaxel Drugs 0.000 description 2
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- GMDNUWQNDQDBNQ-UHFFFAOYSA-L magnesium;diformate Chemical compound [Mg+2].[O-]C=O.[O-]C=O GMDNUWQNDQDBNQ-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 231100000855 membranous nephropathy Toxicity 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000015670 renal artery disease Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 2
- 229950009016 tesetaxel Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 230000010773 Antigen Neutralization Effects 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 101710128063 Carbohydrate oxidase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 244000267640 Dendrobium capra Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- UDSFAEKRVUSQDD-UHFFFAOYSA-N Dimethyl adipate Chemical compound COC(=O)CCCCC(=O)OC UDSFAEKRVUSQDD-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000976823 Embernagra platensis Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024508 Ficolin-1 Human genes 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018901 Haemoglobinaemia Diseases 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 241001590997 Moolgarda engeli Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102220467128 Runt-related transcription factor 1_L13Y_mutation Human genes 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000234181 Syzygium samarangense Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 102220515664 Zinc finger protein Helios_S13D_mutation Human genes 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical class CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009300 dissolved air flotation Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940044700 hylenex Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108010086662 phytohemagglutinin-M Proteins 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108010004093 retinal S antigen peptide M Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102200020673 rs121912989 Human genes 0.000 description 1
- 102200141516 rs149079952 Human genes 0.000 description 1
- 102200015813 rs387906871 Human genes 0.000 description 1
- 102200000909 rs7905009 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The present invention provides anti-C5 antibodies and methods of use thereof. In some embodiments, the isolated anti-C5 antibodies of the invention bind to an epitope within the beta chain of C5 with greater affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding the anti-C5 antibodies of the invention. The invention also provides a host cell comprising a nucleic acid of the invention. The invention also provides a method of producing an antibody, the method comprising culturing a host cell of the invention to produce the antibody. The invention also provides a method of making an anti-C5 antibody, the method comprising immunizing an animal against a polypeptide comprising the MG1-MG2 domain of the β chain of C5. The anti-C5 antibodies of the invention may be used as medicaments.
Description
The application is a divisional application with the application date of 2017, 6 and 16 months and the Chinese application number of 201780036916.4, and the invention name of the application is 'anti-C5 antibody and a using method'.
Technical Field
The present invention relates to anti-C5 antibodies and methods of use thereof.
Background
The complement system plays a key role in the clearance of immune complexes and in the immune response to infectious agents, foreign antigens, virus-infected cells and tumor cells. There are about 25-30 complement proteins, which are found as a complex pool of plasma proteins and membrane cofactors. The complement components fulfill their immune defense functions by interacting in a complex series of enzymatic and membrane-bound events. The complement cascade produced results in the production of products with opsonin, immunoregulatory, and bacteriolytic functions.
At present, it is widely accepted that the complement system can be activated by three different pathways: the classical pathway, the lectin pathway and the alternative pathway. These pathways share many components, and although their initial steps differ, they focus on and share the same late complement components (C5 to C9) responsible for activating and destroying the target cells.
The classical pathway is usually activated by the formation of antigen-antibody complexes. Independently, the first step in the activation of the lectin pathway is the binding of specific lectins such as mannan-binding lectin (MBL), H-ficolin, M-ficolin, L-ficolin and C-type lectin CL-11. In contrast, the alternative pathway spontaneously undergoes low levels of turn activation, which can be readily amplified on foreign or other abnormal surfaces (bacteria, yeast, virus-infected cells, or damaged tissue). These pathways converge at a point where complement component C3 is cleaved by the active protease to produce C3a and C3b.
C3a is an anaphylatoxin. C3b binds bacteria and other cells, as well as certain viruses and immune complexes, and marks it as being removed from circulation (known as the role of opsonin). C3b also forms complexes with other components to form C5 convertases, which cleave C5 into C5a and C5b.
C5 is a 190kDa protein found in normal serum at about 80. Mu.g/ml (0.4. Mu.M). About 1.5-3% of the mass attributed to carbohydrates in C5 is glycosylated. Mature C5 is a disulfide-linked heterodimer of a 115kDa alpha chain and a 75kDa beta chain. C5 is synthesized as a 1676 amino acid single-chain precursor protein (pro-C5 precursor) (see, for example, PTL 1 and PTL 2). The pro-C5 precursor is cleaved to yield the beta chain as the amino-terminal fragment and the alpha chain as the carboxy-terminal fragment. The alpha and beta chain polypeptide fragments are linked to each other via disulfide bonds and constitute the mature C5 protein.
Mature C5 is cleaved into C5a and C5b fragments during activation of the complement pathway. C5a is cleaved from the C5 alpha chain by the C5 convertase, which is an amino-terminal fragment comprising the first 74 amino acids of the alpha chain. The remainder of mature C5 is fragment C5b, which contains the remaining alpha and beta chains linked by disulfide bonds. About 20% of the 11kDa molecular weight of C5a is attributed to carbohydrates.
C5a is another anaphylatoxin. C5b combines with C6, C7, C8 and C9 to form a membrane attack complex (MAC, C5b-9, the final complement complex (TCC) at the surface of the target cell). When a sufficient amount of MAC is inserted into the target cell membrane, a MAC pore is formed to mediate rapid osmotic lysis of the target cell.
As mentioned above, C3a and C5a are anaphylatoxins. It can trigger mast cell degranulation, which releases histamine and other inflammatory mediators, resulting in smooth muscle contraction, increased vascular permeability, leukocyte activation, and other inflammatory phenomena, including cell proliferation leading to hypercellularity. C5a also acts as a chemotactic peptide for attracting granulocytes such as neutrophils, eosinophils, basophils and monocytes to sites of complement activation.
The activity of C5a is regulated by the plasma enzyme carboxypeptidase N, which removes the carboxy-terminal arginine from C5a, thereby forming the C5a-des-Arg derivative. C5a-des-Arg shows only 1% of the allergic and polymorphonuclear chemotactic activities of unmodified C5 a.
The normal functioning complement system provides a powerful defense against infectious microorganisms, while inappropriate regulation or activation of complement is implicated in the pathogenesis of a variety of disorders including, for example, rheumatoid Arthritis (RA); lupus nephritis (lupus nephritis); ischemia-reperfusion injury (ischemia-reperfusion injury); paroxysmal Nocturnal Hemoglobinuria (PNH); atypical hemolytic uremic syndrome (aHUS); dense Deposit Disease (DDD); macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis (hemolysis), elevated liver enzymes (aged liver enzymes), and low platelet (HELLP) syndrome; thrombotic Thrombocytopenic Purpura (TTP); spontaneous abortion (sporaneous total loss); microvascular vasculitis (Pauci-immune vasculitis); epidermolysis bullosa (epidermolysis bullosa); recurrent abortion (recurrent total loss); multiple Sclerosis (MS); traumatic brain injury (traumatic brain injury); and damage caused by myocardial infarction (myocardiac injury), cardiopulmonary bypass (cardiopulmonary bypass), and hemodialysis (hemilysis) (see, e.g., NPL 1). Thus, inhibition of the excessive or uncontrolled complement activation cascade may provide clinical benefit to patients suffering from the disorder.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is an uncommon blood disorder in which red blood cells are damaged and thus destroyed more rapidly than normal red blood cells. Ext> PNHext> isext> dueext> toext> clonalext> amplificationext> ofext> hematopoieticext> stemext> cellsext> withext> aext> somaticext> mutationext> inext> theext> PIGext> -ext> Aext> (ext> glypicanext> Aext> typeext>)ext> geneext> locatedext> onext> theext> Xext> chromosomeext>.ext> Ext> mutationext> ofext> PIGext> -ext> aext> resultsext> inext> earlyext> blockingext> ofext> glycosylphosphatidylinositolext> (ext> gpiext>)ext> synthesisext>,ext> aext> moleculeext> requiredext> forext> manyext> proteinsext> toext> anchorext> toext> theext> cellext> surfaceext>.ext> Thus, PNH blood cells lack GPI-anchored proteins, including complement-regulatory proteins CD55 and CD59. Under normal conditions, these complement-regulatory proteins block the formation of MAC on the cell surface, thereby preventing erythrocyte lysis. In PNH, the absence of GPI-anchored proteins leads to complement-mediated hemolysis.
PNH is characterized by hemolytic anemia (reduced number of red blood cells), hemoglobinuria (hemoglobin present in urine, particularly evident after sleep), and hemoglobinemia (hemoglobin present in the blood stream). Individuals afflicted with PNH are known to have sudden onset, which is defined herein as the occurrence of dark urine. Hemolytic anemia is due to the intravascular destruction of red blood cells by complement components. Other known symptoms include speech impairment, fatigue, erectile dysfunction, thrombosis, and recurrent abdominal pain.
Eculizumab (Eculizumab) is a humanized monoclonal antibody against complement protein C5 and is the first approved therapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (see, e.g., NPL 2). Eculizumab inhibits C5 convertase cleavage of C5 into C5a and C5b, which prevents the generation of the final complement complex C5 b-9. Both C5a and C5b-9 lead to late complement-mediated events characterized as PNH and aHUS (see also, PTL 3, PTL 4, PTL 5 and PTL 6).
Several reports have described anti-C5 antibodies. For example, PTL 7 describes binding to the C5 alpha chain but not to C5a and block activation of C5, while PTL 8 describes anti-C5 monoclonal antibodies that inhibit C5a formation. On the other hand, PTL 9 describes an anti-C5 antibody that recognizes a proteolytic site of C5 convertase on the α chain of C5 and inhibits the conversion of C5 to C5a and C5 b. PTL 10 describes affinity constants of at least 1x10 7 M -1 The anti-C5 antibody of (1).
Antibodies (IgG) bind to neonatal Fc receptor (FcRn) and have long plasma retention times. Binding of IgG to FcRn is typically observed under acidic conditions (e.g., pH 6.0) and is barely observed under neutral conditions (e.g., pH 7.4). Typically, igG enters the cell non-specifically via endocytosis and returns to the cell surface by binding to the endosomal FcRn in the endosome under acidic conditions. IgG then dissociates from FcRn in plasma under neutral conditions. IgG that does not bind FcRn is broken down in lysosomes. When their FcRn binding capacity under acidic conditions is abrogated by introducing mutations into the Fc region of IgG, igG is not recycled from the endosome into the plasma, which results in significant impairment of plasma retention of IgG. Methods to enhance FcRn binding under acidic conditions have been reported in order to improve plasma retention of IgG. When FcRn binding under acidic conditions is increased by introducing amino acid substitutions to the Fc region of IgG, igG is more efficiently recycled from endosomes to plasma and thus shows increased plasma retention. Meanwhile, it has also been reported that IgG with enhanced FcRn binding under neutral conditions does not dissociate from FcRn under neutral conditions in plasma even when it returns to the cell surface via its binding to FcRn under acidic conditions in endosomes, and then its plasma retention remains unchanged, or worsens (see, for example, NPL 3 NPL 4.
Recently, antibodies that bind to antigens in a pH-dependent manner have been reported (see, for example, PTL 11 and PTL 12). These antibodies bind strongly to antigen under plasma neutral conditions and dissociate from antigen under endosomal acidic conditions. After dissociation from the antigen, the antibody becomes capable of binding the antigen again upon recycling to plasma via FcRn. Thus, a single antibody molecule can repeatedly bind to multiple antigen molecules. In general, the plasma retention of antigen is much shorter than that of antibodies with the FcRn-mediated recycling mechanism described above. Thus, when an antigen binds to an antibody, the antigen typically exhibits prolonged plasma retention, resulting in an increase in the plasma concentration of the antigen. On the other hand, it has been reported that the above antibody binding to an antigen in a pH-dependent manner more rapidly eliminates the antigen from plasma than a typical antibody because it dissociates from the antigen in vivo during an FcRn-mediated recycling process. PTL 13 also describes computer modeling analysis that shows that antibodies with pH-dependent binding to C5 can extend antigen knockdown (knockdown).
Reference list
Patent document
PTL 1: U.S. Pat. No. 6,355,245
PTL 2: U.S. Pat. No. 7,432,356
PTL 3:WO 2005/074607
PTL 4:WO 2007/106585
PTL 5:WO 2008/069889
PTL 6:WO 2010/054403
PTL 7:WO 95/29697
PTL 8:WO 02/30985
PTL 9:WO 2004/007553
PTL 10:WO 2010/015608
PTL 11:WO 2009/125825
PTL 12:WO 2011/122011
PTL 13:WO 2011/111007
Non-patent document
NPL 1: holers et al, immunol. Rev.223:300-316 (2008)
NPL 2: dmbtrijuk et al, the Oncoloist 13 (9): 993-1000 (2008)
NPL 3: yeung et al, J Immunol.182 (12): 7663-7671 (2009)
NPL 4: datta-Mannan et al, J biol. Chem.282 (3): 1709-1717 (2007)
NPL 5: dall' Acqua et al, J.Immunol.169 (9): 5171-5180 (2002)
Summary of The Invention
Technical problem
It is an object of the present invention to provide anti-C5 antibodies and methods of use thereof.
Means for solving the problems
The present invention provides anti-C5 antibodies and methods of use thereof.
In some embodiments, an isolated anti-C5 antibody of the invention binds to an epitope within the beta chain of C5. In some embodiments, an isolated anti-C5 antibody of the invention binds to an epitope within the MG1-MG2 domain of the β chain of C5. In some embodiments, an isolated anti-C5 antibody of the invention binds to an epitope within a fragment consisting of amino acids 33-124 of the beta chain of C5 (SEQ ID NO: 40). In some embodiments, an isolated anti-C5 antibody of the invention binds to an epitope within the beta chain of C5 (SEQ ID NO: 40) that comprises at least one fragment selected from the group consisting of: amino acids 47-57, 70-76, and 107-110. In some embodiments, an isolated anti-C5 antibody of the invention binds to an epitope within a fragment of the beta chain of C5 (SEQ ID NO: 40) that comprises at least one amino acid residue selected from the group consisting of: glu48, asp51, his70, his72, lys109, and His110 of SEQ ID NO 40. In further embodiments, the antibody binds C5 with higher affinity at neutral pH than at acidic pH. In another embodiment, the antibody binds C5 with greater affinity at pH7.4 than at pH 5.8. In another embodiment, the isolated anti-C5 antibody of the invention binds to the same epitope as an antibody described in table 2. In a further embodiment, the antibody binds the same epitope as an antibody described in table 2 with higher affinity at ph7.4 than at ph 5.8. In another embodiment, an anti-C5 antibody of the invention binds to the same epitope as an antibody described in table 7 or 8. In a further embodiment, the antibody binds the same epitope as an antibody described in table 7 or 8 with higher affinity at ph7.4 than at ph 5.8.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (b) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (c) the VH of SEQ ID NO:4 and the VL of SEQ ID NO: 14; (d) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (e) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (f) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (g) the VH of SEQ ID NO 9 and the VL of SEQ ID NO 19; (h) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; (i) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18; and (j) the VH of SEQ ID NO:10 and the VL of SEQ ID NO: 20. In further embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH. In another embodiment, the anti-C5 antibody binds C5 with greater affinity at pH7.4 than at pH 5.8.
In some embodiments, the isolated anti-C5 antibodies of the invention have a characteristic selected from the group consisting of: (a) The antibody contacts amino acids D51 and K109 of C5 (SEQ ID NO: 39); (b) The affinity of the antibody for C5 (SEQ ID NO: 39) is greater than the affinity of the antibody for the C5 mutant consisting of the E48A substitution of SEQ ID NO: 39; or (C) the antibody binds to C5 protein consisting of the amino acid sequence of SEQ ID NO:39 at pH7.4, but does not bind to C5 protein consisting of the amino acid sequence of SEQ ID NO:39 with a H72Y substitution at pH 7.4. In further embodiments, the antibody binds C5 with higher affinity at neutral pH than at acidic pH. In another embodiment, the antibody binds C5 with greater affinity at ph7.4 than at ph 5.8.
In some embodiments, an isolated anti-C5 antibody of the invention inhibits activation of C5. In some embodiments, an isolated anti-C5 antibody of the invention inhibits activation of C5 variant R885H. In some embodiments, the isolated anti-C5 antibody of the invention is a monoclonal antibody. In some embodiments, the isolated anti-C5 antibody of the invention is a human, humanized, or chimeric antibody. In some embodiments, an isolated anti-C5 antibody of the invention is an antibody fragment that binds C5. In some embodiments, the isolated anti-C5 antibody of the invention is a full length IgG1 or IgG4 antibody.
In some embodiments, an isolated anti-C5 antibody of the invention comprises (a) HVR-H3, said HVR-H3 comprising amino acid sequence DX 1 GYX 2 X 3 PTHAMX 4 X 5 Wherein X is 1 Is G or A, X 2 Is V, Q or D, X 3 Is T or Y, X 4 Is Y or H, X 5 Is L or Y (SEQ ID NO: 128), (b) HVR-L3, said HVR-L3 comprising amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131), and (c) HVR-H2, said HVR-H2 comprising amino acid sequence X 1 IX 2 TGSGAX 3 YX 4 AX 5 WX 6 KG, wherein X 1 Is C, A or G, X 2 Is Y or F, X 3 Is T, D or E, X 4 Is Y, K or Q, X 5 Is S, D or E, X 6 Is A or V (SEQ ID NO: 127).
In some embodiments, an isolated anti-C5 antibody of the invention comprises (a) HVR-H1, said HVR-H1 comprises SSYYX 1 X 2 Wherein X is 1 Is M or V, X 2 Is C or A (SEQ ID NO: 126), (b) HVR-H2, said HVR-H2 comprising an amino acid sequence
X 1 IX 2 TGSGAX 3 YX 4 AX 5 WX 6 KG, wherein X 1 Is C, A or G, X 2 Is Y or F, X 3 Is T, D or E, X 4 Is Y, K or Q, X 5 Is S, D or E, X 6 Is A or V (SEQ ID NO: 127), and (c) HVR-H3, said HVR-H3 comprising amino acid sequence DX 1 GYX 2 X 3 PTHAMX 4 X 5 Wherein X is 1 Is G or A, X 2 Is V, Q or D, X 3 Is T or Y, X 4 Is Y or H, X 5 Is L or Y (SEQ ID NO: 128). In additional embodiments, the antibody comprises (a) HVR-L1, wherein HVR-L1 comprises amino acid sequence X 1 ASQX 2 IX 3 SX 4 LA, wherein X 1 Is Q or R, X 2 Is N, Q or G, X 3 Is G or S, X 4 Is D, K or S (SEQ ID NO: 129); (b) HVR-L2, the HVR-L2 comprises the amino acid sequence GASX 1 X 2 X 3 S, wherein X 1 Is K, E or T, X 2 Is L or T, X 3 Is A, H, E or Q (SEQ ID NO: 130); and (c) HVR-L3, the HVR-L3 comprises amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131).
In some embodiments, an isolated anti-C5 antibody of the invention comprises (a) HVR-L1, said HVR-L1 comprises amino acid sequence X 1 ASQX 2 IX 3 SX 4 LA, wherein X 1 Is Q or R, X 2 Is N, Q or G, X 3 Is G or S, X 4 Is D, K or S (SEQ ID NO: 129); (b) HVR-L2, the HVR-L2 comprises the amino acid sequence GASX 1 X 2 X 3 S, wherein X 1 Is K, E or T, X 2 Is L or T, X 3 Is A, H, E or Q (SEQ ID NO: 130); and (c) HVR-L3, the HVR-L3 comprises amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131).
In some embodiments, an isolated anti-C5 antibody of the invention comprises a heavy chain variable domain framework FR1, said FR1 comprising the amino acid sequence of any one of SEQ ID NOS 132-134; FR2, said FR2 comprising an amino acid sequence of any one of SEQ ID NOs 135-136; FR3, said FR3 comprising the amino acid sequence of any one of SEQ ID NOS 137-139; and FR4, said FR4 comprising the amino acid sequence of any one of SEQ ID NOS 140-141. In some embodiments, an isolated anti-C5 antibody of the invention comprises a light chain variable domain framework FR1, said FR1 comprising the amino acid sequence of any one of SEQ ID NOS 142-143; FR2, said FR2 comprising the amino acid sequence of any one of SEQ ID NOs 144-145; FR3, said FR3 comprising the amino acid sequence of any one of SEQ ID NOS: 146-147; and FR4, said FR4 comprising the amino acid sequence of SEQ ID NO: 148.
In some embodiments, an isolated anti-C5 antibody of the invention comprises (a) a VH sequence having at least 95% sequence identity to any of the amino acid sequences SEQ ID NOs 10, 106-110; (b) A VL sequence having at least 95% sequence identity with any of the amino acid sequences SEQ ID NO 20, 111-113; or (c) the VH sequence of (a) and the VL sequence of (b). In further embodiments, the antibody comprises a VH sequence of any one of SEQ ID NOS 10, 106-110. In further embodiments, the antibody comprises the VL sequence of any one of SEQ ID NOS 20, 111-113.
The invention provides antibodies comprising a VH sequence of any one of SEQ ID NOs 10, 106-110 and a VL sequence of any one of SEQ ID NOs 20, 111-113.
The invention also provides isolated nucleic acids encoding the anti-C5 antibodies of the invention. The invention also provides a host cell comprising a nucleic acid of the invention. The invention also provides a method of producing an antibody, the method comprising culturing a host cell of the invention to produce the antibody.
The invention also provides methods of making anti-C5 antibodies. In some embodiments, the method includes immunizing an animal against a polypeptide comprising the MG1-MG2 domain of the C5 beta chain (SEQ ID NO: 43). In some embodiments, the method comprises immunizing an animal against a polypeptide comprising a region corresponding to amino acids at positions 33 to 124 of the beta chain of C5 (SEQ ID NO: 40). In some embodiments, the method includes immunizing an animal against a polypeptide comprising at least one fragment selected from amino acids 47-57, 70-76, and 107-110 of the C5 beta chain (SEQ ID NO: 40). In some embodiments, the method comprises immunizing an animal against a polypeptide comprising a fragment of the beta strand of C5 (SEQ ID NO: 40) comprising at least one amino acid selected from Glu48, asp51, his70, his72, lys109 and His 110.
The invention also provides a pharmaceutical formulation comprising an anti-C5 antibody of the invention and a pharmaceutically acceptable carrier.
The anti-C5 antibodies of the invention may be used as medicaments. The anti-C5 antibodies of the invention may be used to treat complement-mediated diseases or conditions involving excessive or uncontrolled C5 activation. The anti-C5 antibodies of the invention may be used to enhance the clearance of C5 from plasma.
The anti-C5 antibodies of the invention can be used for the preparation of a medicament. In some embodiments, the medicament is for treating a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In some embodiments, the medicament is for enhancing clearance of C5 from plasma.
The invention also provides methods of treating an individual having a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In some embodiments, the method comprises administering to the individual an effective amount of an anti-C5 antibody of the invention. The invention also provides methods of enhancing clearance of C5 from plasma in an individual. In some embodiments, the method comprises administering to the individual an effective amount of an anti-C5 antibody of the invention to enhance clearance of C5 from plasma.
Brief Description of Drawings
[ FIG. 1]
FIG. 1 shows the epitope box (binding) of anti-C5 antibody, as described in example 2.2. Antibodies classified in the same epitope box (bin) are boxed with bold lines.
[ FIG. 2A ]
FIG. 2A shows BIACORE (registered trademark) sensorgrams of anti-C5 antibody at pH7.4 (solid line) and pH5.8 (dotted line) for evaluation of pH-dependence, as described in example 3.2. CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, and CFA0599 are antibodies that are grouped into epitope C, as described in example 2.2.
[ FIG. 2B ]
FIG. 2B shows BIACORE (registered trademark) sensorgrams of anti-C5 antibody at pH7.4 (solid line) and pH5.8 (dotted line) for evaluation of pH-dependence, as described in example 3.2. CFA0666, CFA0672, and CFA0675 are antibodies grouped into epitope C, CFA0330 and CFA0341 are antibodies grouped into epitope B, as described in example 2.2. 305LO5 is a humanized antibody to CFA0305, as described in example 2.3.
[ FIG. 3]
FIG. 3 shows a Western blot analysis for C5 β -strand derived fragments fused to a GST-tag (amino acids 19-180, 161-340, 321-500, and 481-660 of SEQ ID NO: 40), as described in example 4.1. CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675 are antibodies grouped into epitope C. anti-GST antibody is a positive control. The position of the GST-fused C5 fragment (46-49 kDa) is marked by an arrow.
[ FIG. 4]
FIG. 4 shows BIACORE (registered trademark) profiles of anti-C5 antibodies to the MG1-MG2 domains of the C5 β -chain, as described in example 4.3. The upper panel shows the results for CFA0305 (solid line), CFA0307 (dotted line), CFA0366 (dotted line), and eculizumab (dotted line). The middle panel shows the results for CFA0501 (solid line), CFA0599 (dashed line), CFA0538 (dotted line), and eculizumab (dotted line). The lower panel shows the results for CFA0666 (solid line), CFA0672 (dashed line), CFA0675 (dotted line), and eculizumab (dotted line). CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675 are antibodies grouped into epitope C. Eculizumab is a control anti-C5 antibody.
[ FIG. 5A ]
FIG. 5A shows a Western blot analysis of peptide fragments derived from MG1-MG2 domains fused to a GST tag (amino acids 33-124, 45-124, 52-124, 33-111, 33-108, and 45-111 of SEQ ID NO: 40), as described in example 4.4. An anti-GST antibody was used as the antibody for the reaction. The position of the GST-fused C5 fragment (35-37 kDa) is marked by an arrow.
[ FIG. 5B ]
FIG. 5B shows a Western blot analysis of peptide fragments derived from MG1-MG2 domains fused to a GST-tag (amino acids 33-124, 45-124, 52-124, 33-111, 33-108, and 45-111 of SEQ ID NO: 40), as described in example 4.4. CFA0305 was used as antibody for the reaction.
[ FIG. 5C ]
Figure 5C summarizes the binding reaction of anti-C5 antibodies to C5 β -chain derived fragments, as described in example 4.4. Fragments binding to anti-C5 antibodies (CFA 0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA 0675) grouped into epitope C are shown in grey and fragments not binding thereto are shown in white.
[ FIG. 6]
Figure 6 shows western blot analysis for C5-point mutants in which E48, D51, and K109 of the β -strand were substituted with alanine (E48A, D51A, and K109A, respectively), as described in example 4.5. In the left panel, eculizumab (anti-C5 antibody, α -chain binder) was used as the antibody for reaction, and the position of the α -chain of C5 (about 113 kDa) is marked with an arrow. In the right panel, CFA0305 (grouped into epitope C, beta-chain binder) was used as antibody for the reaction, and the position of the beta-chain of C5 (about 74 kDa) is marked with an arrow.
[ FIG. 7]
FIG. 7 shows BIACORE (registered trademark) sensorgrams showing the interaction of eculizumab-F760G 4 (top panel) or 305LO5 (bottom panel) with the C5 mutant, as described in example 4.6. Sensorgrams were obtained by injecting C5-wt (thick solid curve), C5-E48A (short dashed curve), C5-D51A (long dashed curve), and C5-K109A (thin solid curve), respectively, onto a sensor surface immobilized with Ekulizumab-F760G 4 or 305LO 5. Eculizumab is a control anti-C5 antibody. 305LO5 is a CFA0305 humanized antibody (grouped into epitope C) as described in example 2.3.
[ FIG. 8]
Fig. 8 shows BIACORE (registered trademark) sensorgrams showing interaction of 305LO5 with C5 His mutant for evaluation of pH-dependence, as described in example 4.7. The sensorgrams were obtained by injecting C5-wt (bold solid curve), C5-H70Y (long dashed curve), C5-H72Y (short dashed curve), C5-H110Y (dotted curve), and C5-H70Y + H110Y (thin solid curve), respectively, onto a sensor surface immobilized with 305LO 5. The antibody/antigen complex was allowed to dissociate at pH7.4, followed by further dissociation (indicated by arrows) at pH5.8 to assess pH-dependent interactions.
[ FIG. 9A ]
Figure 9A shows inhibition of liposome lysis by complement activation of anti-C5 antibody, as described in example 5.1. Results are shown for CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675 grouped into epitope C, as described in example 2.2.
[ FIG. 9B ]
Figure 9B shows inhibition of liposome lysis by complement activation of anti-C5 antibody, as described in example 5.1. The results for antibodies CFA0330 and CFA0341 grouped into epitope B are shown, as described in example 2.2.
[ FIG. 10A ]
Figure 10A shows inhibition of C5a production by anti-C5 antibodies, as described in example 5.2. The C5a concentration was quantified in the supernatant obtained during the liposome lysis assay depicted in fig. 9A.
[ FIG. 10B ]
Figure 10B shows inhibition of C5a production by anti-C5 antibodies, as described in example 5.2. The C5a concentration was quantified in the supernatant obtained during the liposome lysis assay depicted in fig. 9B.
[ FIG. 11]
FIG. 11 shows inhibition of hemolysis by complement activation of anti-C5 antibodies, as described in example 5.3. Complement is activated via the classical pathway.
[ FIG. 12]
FIG. 12 shows inhibition of hemolysis by complement activation of anti-C5 antibodies, as described in example 5.4. Complement is activated via the alternative pathway.
[ FIG. 13]
Figure 13 shows the time course of plasma human C5 concentration after intravenous administration of human C5 alone or human C5 with anti-human C5 antibody in mice evaluated for C5 clearance, as described in example 6.2. CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675 are antibodies grouped into epitope C, and CFA0330 and CFA0341 are antibodies grouped into epitope B, as described in example 2.2.
[ FIG. 14]
Figure 14 shows the time course of plasma anti-human C5 antibody concentrations following intravenous administration of human C5 alone and anti-human C5 antibody in mice evaluated for antibody pharmacokinetics, as described in example 6.3. CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675 are antibodies grouped into epitope C, and CFA0330 and CFA0341 are antibodies grouped into epitope B, as described in example 2.2.
[ FIG. 15]
FIG. 15 shows the inhibition of liposome lysis by complement activation of anti-C5 antibody, as described in example 9.1. Results for antibodies 305LO15-SG422, 305LO16-SG422, 305LO18-SG422, 305LO19-SG422, 305LO20-SG422, and 305LO20-SG115 are shown.
[ FIG. 16]
FIG. 16 shows the inhibition of liposome lysis by complement activation of anti-C5 antibody, as described in example 9.1. The results for antibodies 305LO15-SG115 and 305LO23-SG429 are shown.
[ FIG. 17]
Figure 17 shows inhibition of liposome lysis by complement activation of anti-C5 antibody, as described in example 9.1. Results for antibodies 305LO22-SG115, 305LO22-SG422, 305LO23-SG115, and 305LO23-SG422 are shown.
[ FIG. 18]
Figure 18 shows inhibition of C5a production by anti-C5 antibodies, as described in example 9.2. The C5a concentration was quantified in the supernatant obtained during the liposome lysis assay depicted in figure 15.
[ FIG. 19]
Figure 19 shows inhibition of C5a production by anti-C5 antibodies, as described in example 9.2. The C5a concentration was quantified in the supernatant obtained during the liposome lysis assay depicted in figure 16.
[ FIG. 20]
Figure 20 shows inhibition of complement activity in monkey plasma by anti-C5 antibodies, as described in example 9.3. anti-C5 antibody was administered to cynomolgus monkeys (cynomolgus monkey) and the complement activity in monkey plasma was measured in a hemolytic assay.
[ FIG. 21]
Fig. 21 shows inhibition of biological activity by wild-type C5 (WT) and C5 variants (V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N, and E1437D) of anti-C5 antibody (eculizumab), as described in example 9.4.
[ FIG. 22]
Fig. 22 shows inhibition of biological activity by wild-type C5 (WT) and C5 variants (V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N, and E1437D) of anti-C5 antibody (305 variant), as described in example 9.4.
[ FIG. 23]
Figure 23 shows inhibition of liposome lysis by complement activation of anti-C5 antibody (BNJ 441 and 305 variants), as described in example 9.5.
[ FIG. 24]
Figure 24 shows the time course of plasma cynomolgus C5 concentration after intravenous administration of anti-human C5 antibody in cynomolgus monkeys assessing C5 clearance, as described in example 10.2.
[ FIG. 25]
Figure 25 shows the time course of plasma anti-human C5 antibody concentration after intravenous administration of anti-human C5 antibody in cynomolgus monkeys assessing antibody pharmacokinetics, as described in example 10.3.
[ FIG. 26]
Fig. 26A and 26B show the crystal structure of 305Fab binding to the human C5 (hC 5) -MG1 domain, as described in example 11.6. Fig. 26A shows an asymmetric cell. MG1 is shown in surface representation and 305Fab is shown as a band (dark grey: heavy chain, light grey: light chain). FIG. 26B shows the overlapping molecules 1 and 2 (dark gray: molecule 1, light gray: molecule 2).
[ FIG. 27A ]
Figure 27A shows the epitope of the 305Fab contact region on the MG1 domain, as described in example 11.6. FIG. 27A shows epitope localization in the MG1 amino acid sequence (dark gray: proximity less than 3.0 angstroms, light gray: proximity less than 4.5 angstroms).
[ FIG. 27B ]
Figure 27B shows the epitope of the 305Fab contact region on the MG1 domain as described in example 11.6. FIG. 27B shows epitope localization in crystal structure (dark gray spheres: proximity less than 3.0 angstroms, light gray rods: proximity less than 4.5 angstroms).
[ FIG. 28A ]
Figure 28A shows a close-up view of the interaction of E48, D51 and K109 (stick representation) with 305Fab (surface representation), as described in example 11.7.
[ FIG. 28B ]
Figure 28B shows the interaction between E48 and its environment (dark grey dotted line: hydrogen bonding with Fab, light grey dotted line: water mediated hydrogen bonding) as described in example 11.7.
[ FIG. 28C ]
FIG. 28C shows the interaction between D51 and its environment (dark grey dotted line: hydrogen bonding with Fab), as described in example 11.7.
[ FIG. 28D ]
FIG. 28D shows the interaction between K109 and its environment (dark grey dotted line: hydrogen bonds to Fab, light grey dotted line: salt bridge to H-CDR3_ D95) as described in example 11.7.
[ FIG. 29A ]
Fig. 29A shows a close-up view of the interaction of H70, H72 and H110 (stick representation) with 305Fab (surface representation), oriented the same as fig. 28A, as described in example 11.8.
[ FIG. 29B ]
Fig. 29B shows the interaction between H70 and its environment, as described in example 11.8. The histidine residues are indicated in bar and net list representations. Hydrogen bonds are indicated by dotted lines.
[ FIG. 29C ]
Fig. 29C shows the interaction between H72 and its environment, as described in example 11.8. The histidine residues are indicated in bar and net list representations. Hydrogen bonds are indicated by dotted lines.
[ FIG. 29D ]
Fig. 29D shows the interaction between H110 and its environment, as described in example 11.8. The histidine residues are indicated in stick and net notation. The distance between H110 and H-CDR3_ H100c is shown in dotted lines.
Detailed description of the preferred embodiments
The techniques and methods described or referenced herein are generally well understood and routinely used by those skilled in the art using conventional methodologies, such as, for example, the widely used method described in Sambrook et al, molecular Cloning, A Laboratory Manual 3 rd edition (2001) Cold Spring Harbor Laboratory Press, cold Spring Harbor, N.Y.; current Protocols in Molecular Biology (F.M. Ausubel et al, eds., (2003)); series Methods in Enzymology (Academic Press, inc.: PCR 2A Practical Approach (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freekney, ed. (1987)); oligonucleotide Synthesis (m.j. gate, ed., 1984); methods in Molecular Biology, human Press; cell Biology A Laboratory Notebook (J.E.Cellis, ed., 1998) Academic Press; animal Cell Culture (r.i. freshney), ed., 1987); introduction to Cell and Tissue Culture (J.P.Mather and P.E.Roberts, 1998) Plenum Press; cell and Tissue Culture Laboratory Procedures (A.Doyle, J.B.Griffiths, and D.G.Newell, eds., 1993-8) J.Wiley & Sons; handbook of Experimental Immunology (d.m.weir and c.c.blackwell, eds.); gene Transfer Vectors for mammlian Cells (j.m. miller and m.p. calos, eds., 1987); PCR The Polymerase Chain Reaction, (Mullis et al, eds., 1994); current Protocols in Immunology (J.E.Coligan et al, eds., 1991); short Protocols in Molecular Biology (Wiley & Sons, 1999); immunobiology (c.a. Janeway and p.travers, 1997); antibodies (p.finch, 1997); antibodies: A Practical Approach (D.Catty., ed., IRL Press, 1988-1989); monoclonal Antibodies, APracial Approach (P.shepherd and C.dean, eds., oxford University Press, 2000); a Laboratory Manual (E.Harlow and D.Lane Cold Spring Harbor Laboratory Press, 1999); the Antibodies (m.zanetti and j.d.capra, eds., harwood Academic Publishers, 1995); and Cancer: principles and Practice of Oncology (V.T.Devita et al, eds., J.B.Lippincott Company, 1993).
I. Definition of
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al, dictionary of Microbiology and Molecular Biology 2nd ed, J.Wiley & Sons (New York, N.Y.1994) and March, advanced Organic Chemistry Reactions, mechanics and Structure 4th ed, john Wiley & Sons (New York, N.Y.1992) provide those skilled in the art with a general guidance for many of the terms used in this application. All documents, including patent applications and publications, cited herein are hereby incorporated by reference in their entirety.
For purposes of interpreting this application, the following definitions will apply and where appropriate, terms used in the singular will also include the plural and vice versa. It is to be understood that the technology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. In the event that any of the definitions set forth below conflict with any document incorporated herein by reference, the definitions set forth below control.
An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence variations. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the sequence of the VL acceptor human framework is identical to a VL human immunoglobulin framework sequence or a human consensus framework sequence.
"affinity" refers to the sum of the forces of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to an intrinsic binding affinity that reflects a 1. The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by conventional methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
An "affinity matured" antibody is one that has one or more alterations in one or more hypervariable regions (HVRs) as compared to a parent antibody not having such alterations that result in an increase in the affinity of the antibody for an antigen.
The terms "anti-C5 antibody" and "antibody that binds to C5" refer to an antibody that is capable of binding to C5 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent for targeting C5. In one embodiment, the extent of binding of an anti-C5 antibody to an unrelated, non-C5 protein is less than about 10% of the binding of the antibody to C5, as measured, for example, by Radioimmunoassay (RIA). In certain embodiments, the dissociation constant (Kd) of an antibody that binds C5 is: less than 1 μ M, less than 100nM, less than 10nM, 1nM or Lower, less than 0.1nM, less than 0.01nM, or less than 0.001nM (e.g., 10 nM) -8 M or less, e.g. 10 -8 M to 10 -13 M, e.g. 10 -9 M to 10 -13 M). In certain embodiments, the anti-C5 antibody binds to an epitope of C5 that is conserved between C5's derived from different species.
The term "antibody" is used herein in the broadest sense and includes a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of the intact antibody that binds to an antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, fv, fab, fab ', fab ' -SH, F (ab ') 2 (ii) a A diabody; a linear antibody; single chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks the binding of the reference antibody to its antigen in a competition assay and/or, conversely, blocks the binding of the antibody to its antigen in a competition assay. Exemplary competition assays are provided herein.
The term "chimeric" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
The "class" of an antibody refers to the type of constant domain or constant region that the heavy chain has. There are mainly five classes of antibodies: igA, igD, igE, igG, and IgM, and some of these may be further divided into subclasses (allotypes), e.g., igG 1 ,IgG 2 ,IgG 3 ,IgG 4 ,IgA 1 And IgA, and 2 . The heavy chain constant domains corresponding to different types of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
As used herein, the term "cytotoxic agent" refers to inhibitionOr substances that prevent cell function and/or cause cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., at) 211 ,I 131 ,I 125 ,Y 90 ,Re 186 ,Re 188 ,Sm 153 ,Bi 212 ,P 32 ,Pb 212 And radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate (methotrexate), doxorubicin (adriamycin), vinca alkaloids (vinca alkoids) (vincristine), vinblastine (vinblastine), etoposide (etoposide)), doxorubicin (doxorubicin), melphalan (melphalan), mitomycin C (mitomycin C), chlorambucil (chlorembucil), daunorubicin (daunorubicin), or other chimerics); a growth inhibitor; enzymes and fragments thereof such as nucleic acid hydrolases; an antibiotic; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and various antitumor agents or anticancer agents disclosed below.
"Effector function" refers to those biological activities attributable to the Fc region of an antibody that vary with antibody allotype. Examples of antibody effector functions include: c1q binding and Complement Dependent Cytotoxicity (CDC); fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptors); and B cell activation.
An "effective amount" of an agent (e.g., a pharmaceutical formulation) is an amount, dosage and time, effective to achieve the desired therapeutic or prophylactic result.
The term "epitope" includes any determinant capable of being bound by an antibody. An epitope is the region of an antigen that is bound by an antibody targeted to the antigen and includes specific amino acids in direct contact with the antibody. Epitopic determinants may include chemically active surface clusters of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and may have specific three-dimensional structural characteristics, and/or specific charge characteristics. Generally, an antibody specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and/or macromolecules.
Herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxy-terminus of the heavy chain. However, the C-terminal lysine (Lys 447) of the Fc region may or may not be present. Unless otherwise indicated herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, which is also referred to as the EU index, as defined in Kabat et al, sequences of Proteins of Immunological Interest,5th Ed.public Health service, national Institutes of Health, bethesda, MD, 1991.
"framework" or "FR" refers to variable domain residues that are different from the hypervariable region (HVR) residues. The FRs of a variable domain typically consist of four FR domains: FR1, FR2, FR3 and FR4. Thus, in VH (or VL) the HVR and FR sequences typically occur in the following order: FR1-H1 (L1) -FR2-H2 (L2) -FR3-H3 (L3) -FR4.
The terms "full length antibody", "intact antibody" and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain containing an Fc region as defined herein.
The terms "host cell," "host cell line," and "host cell culture" are used interchangeably to refer to a cell into which an exogenous nucleic acid is introduced, including the progeny of such a cell. Host cells include "transformants" and "transformed cells," which include transformed primary cells and progeny derived therefrom (regardless of the number of passages). The nucleic acid content of the progeny may not be identical to the parent cell and may contain mutations. Included herein are mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell.
A "human antibody" is an antibody having an amino acid sequence corresponding to that of an antibody produced by a human or human cell or derived from an antibody of non-human origin using a human antibody repertoire or other human antibody coding sequence. This definition of human antibodies specifically excludes humanized antibodies comprising non-human antigen binding residues.
A "human consensus framework" is a framework that represents the most common amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subset of variable domain sequences. Typically, the subset of Sequences is a subset as in Kabat et al, sequences of Proteins of Immunological Interest, 5 th edition, NIH publication 91-3242, bethesda MD (1991), volumes 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I as in Kabat et al, supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al above.
A "humanized" antibody is a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one (and typically, two) variable domain, wherein all or substantially all of the HVRs (e.g., CDRs) correspond to HVRs of a non-human antibody, and all or substantially all of the FRs correspond to FRs of a human antibody. The humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. "humanized forms" of antibodies, e.g., non-human antibodies, refer to antibodies that have been humanized.
The term "hypervariable region" or "HVR" as used herein refers to the regions of an antibody variable domain which are hypervariable in sequence ("complementarity determining regions" or "CDRs") and/or form structurally defined loops ("hypervariable loops") and/or contain residues which contact antigen ("antigen contacts"). Typically, an antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs herein include: (a) The hypervariable loops which occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia, J.mol.biol.196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al, sequences of Proteins of Immunological Interest,5th Ed. Public Health service, NIH, bethesda, MD (1991)); (c) Antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al, J.mol.biol.262:732-745 (1996)); and (d) combinations of (a), (b), and/or (c) comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
Unless otherwise indicated, HVR residues and other residues in the variable domains (e.g., FR residues) are numbered according to Kabat et al, supra, herein.
An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules including, but not limited to, cytotoxic agents.
An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
An "isolated" antibody is one that has been separated from components of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods. For a review of methods used to assess antibody purity, see, e.g., flatman et al, j.chromager.b 848 (2007).
An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule that is contained in a cell that normally contains the nucleic acid molecule, but which is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
An "isolated nucleic acid encoding an anti-C5 antibody" refers to one or more nucleic acid molecules encoding the heavy and light chains of an antibody (or fragments thereof), including such nucleic acid molecules in a single vector or in separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or produced during the manufacture of monoclonal antibody preparations, such variants typically being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the phrase "monoclonal" indicates that the nature of the antibody is obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods that utilize transgenic animals containing all or part of a human immunoglobulin locus, such methods being described herein, as well as other exemplary methods for preparing monoclonal antibodies.
By "naked antibody" is meant an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or a radiolabel. Naked antibodies may be present in pharmaceutical formulations.
"native antibody" refers to a naturally occurring immunoglobulin molecule having a variety of structures. For example, a native IgG antibody is a heterologous tetraglycan protein of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains bonded by disulfide bonds. From N-terminus to C-terminus, each heavy chain has a variable region (VH), also known as a variable heavy or heavy chain variable domain, followed by three constant domains (CH 1, CH2 and CH 3). Similarly, from N-terminus to C-terminus, each light chain has a variable region (VL), also referred to as a variable light chain domain or light chain variable domain, followed by a light chain Constant (CL) domain. The light chain of an antibody can be assigned to one of two types, called kappa (kappa) and lambda (lambda), based on the amino acid sequence of its constant domain.
The term "package insert" is used to refer to instructions for use, typically contained in commercial packaging for a therapeutic product, that contain an indication, use, dosage, administration, combination therapy, contraindications and/or warnings of use for such therapeutic product.
"percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with amino acid residues in the reference polypeptide sequence after the sequences are aligned and gaps (gaps) introduced, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignments to determine percent amino acid sequence identity can be accomplished in a variety of ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can determine suitable parameters for aligning the sequences, including any algorithms necessary to achieve maximum alignment over the full length of the sequences being compared. The author of the ALIGN-2 sequence comparison computer program was Genentech, inc, and the source code has been submitted with the user file to the us copyright office, washington d.c.,20559, which is registered with us copyright registration number TXU 510087. However, for purposes herein, the use of the sequence comparison computer program ALIGN-2 results in% amino acid sequence identity values. The ALIGN-2 program is publicly available from Genentech, inc., south San Francisco, california, or the program may be compiled from source code. The ALIGN-2 program should be compiled for use with a UNIX operating system, including the digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and need not be changed.
In the case where ALIGN-2 is used for amino acid sequence comparison, the% amino acid sequence identity of a given amino acid sequence a to or relative to a given amino acid sequence B (which may alternatively be expressed as a given amino acid sequence a having or comprising a particular% amino acid sequence identity to or relative to a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y; wherein X is the number of amino acid residues scored as identical matches by sequence alignment program ALIGN-2 in the program alignment of A and B, and Y is the total number of amino acid residues in B. It is understood that when the length of amino acid sequence a is not equal to the length of amino acid sequence B, the% amino acid sequence identity of a to B will not be equal to the% amino acid sequence identity of B to a. Unless otherwise specifically indicated, all% amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
The term "pharmaceutical formulation" refers to a formulation having a form that allows the biological activity of the active ingredient contained therein to be effective, and which is free of other components having unacceptable toxicity to the subject to which the formulation is to be administered.
By "pharmaceutically acceptable carrier" is meant an ingredient of a pharmaceutical formulation other than the active ingredient that is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
The term "C5" as used herein includes any native C5 from any vertebrate source, including mammals such as primates (e.g., humans and monkeys) and rodents (e.g., mice and rats). Unless otherwise indicated, the term "C5" refers to the human C5 protein having the amino acid sequence shown in SEQ ID NO:39 and containing the beta chain sequence shown in SEQ ID NO: 40. The term includes "full-length" unprocessed C5 as well as any form of C5 that results from processing in a cell. The term also includes naturally occurring variants of C5, e.g., splice variants or allelic variants. The amino acid sequence of exemplary human C5 is shown in SEQ ID NO:39 ("wild-type" or "WT" C5). The amino acid sequence of an exemplary beta chain of human C5 is shown in SEQ ID NO 40. The amino acid sequences of exemplary MG1, MG2 and MG1-MG2 domains of the beta chain of human C5 are shown in SEQ ID NOS: 41, 42 and 43, respectively. Exemplary cynomolgus monkey and murine C5 amino acid sequences are shown in SEQ ID NO:44 and 105, respectively. 39, 40, 43, 44, and 105 correspond to a signal sequence that is removed during processing in a cell and is therefore not found in the corresponding exemplary amino acid sequences.
As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to a clinical intervention that attempts to alter the natural process of the treated individual, and may be performed for prophylaxis or during the clinical course of disease. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, eliminating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and eliminating or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the progression of the disease or to slow the progression of the disease.
The term "variable region" or "variable domain" refers to a domain of an antibody heavy or light chain that is involved in antigen binding of the antibody. The heavy and light chain variable domains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved Framework Regions (FR) and three hypervariable regions (HVRs). (see, e.g., kindt et al, kuby Immunology,6 th ed.,W.H.Freeman&Co, page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen binding specificity. Furthermore, antibodies that bind a particular antigen can be isolated by screening libraries of complementary VL or VH domains using VH or VL domains, respectively, from antibodies that bind the antigen. See, e.g., portolano et al, J.Immunol.150:880-887 (1993); clarkson et al, nature 352 (1991).
As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors which are self-replicating nucleic acid structures as well as vectors which are incorporated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of a nucleic acid to which they are operatively linked. Such vectors are referred to herein as "expression vectors".
Compositions and methods
In one aspect, the invention is based, in part, on anti-C5 antibodies and uses thereof. In certain embodiments, antibodies that bind C5 are provided. The antibodies of the invention are useful, for example, in the diagnosis or treatment of complement-mediated diseases or disorders involving excessive or uncontrolled C5 activation.
A. Exemplary anti-C5 antibodies
In one aspect, the invention provides an isolated antibody that binds C5. In certain embodiments, an anti-C5 antibody of the invention binds to an epitope within the beta chain of C5. In certain embodiments, the anti-C5 antibody binds to an epitope within the MG1-MG2 domain of the β chain of C5. In certain embodiments, the anti-C5 antibody binds to an epitope within a fragment consisting of amino acids 19-180 of the beta chain of C5. In certain embodiments, the anti-C5 antibody binds to an epitope within the MG1 domain of the beta chain of C5 (amino acids 20-124 of SEQ ID NO:40 (SEQ ID NO: 41)). In certain embodiments, the anti-C5 antibody binds to an epitope within a fragment consisting of amino acids 33-124 of the beta chain of C5 (SEQ ID NO: 40). In another embodiment, the antibody does not bind to a fragment shorter than a fragment consisting of amino acids 33-124 of the beta chain of C5, e.g., a fragment consisting of amino acids 45-124, 52-124, 33-111, 33-108, or 45-111 of the beta chain of C5 (SEQ ID NO: 40).
In another aspect, the invention provides anti-C5 antibodies that exhibit pH-dependent binding properties. As used herein, the expression "pH-dependent binding" means that the antibody "shows reduced binding to C5 at acidic pH compared to its binding at neutral pH" (for the present disclosure, both expressions may be used interchangeably). For example, an antibody that "has pH-dependent binding properties" includes an antibody that binds C5 with a higher affinity at neutral pH than at acidic pH. In certain embodiments, the antibodies of the invention bind C5 with an affinity at neutral pH that is at least 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than at acidic pH. In some embodiments, the antibody binds C5 with higher affinity at ph7.4 than at ph 5.8. In further embodiments, the antibody binds C5 with an affinity at ph7.4 that is at least 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than at ph 5.8.
For the purposes of this disclosure, the "affinity" of an antibody for C5 is expressed as the KD of the antibody. The KD of an antibody refers to the equilibrium dissociation constant of an antibody-antigen interaction. The greater the KD value for an antibody binding to its antigen, the weaker its binding affinity for that particular antigen. Thus, as used herein, the expression "higher affinity at neutral pH than at acidic pH" (or equivalently the expression "pH-dependent) Binding ") means that the KD for antibody binding to C5 is higher at acidic pH than at neutral pH. For example, in the context of the present invention, an antibody is considered to bind C5 with a higher affinity at neutral pH than at acidic pH if the KD with which the antibody binds C5 is at least 2 times higher at acidic pH than at neutral pH. Thus, the invention includes antibodies that bind C5 at acidic pH with a KD that is at least 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than the KD for the antibody to bind C5 at neutral pH. In another embodiment, the antibody may have a KD value of 10 at neutral pH -7 M,10 -8 M,10 -9 M,10 -10 M,10 -11 M,10 -12 M is less than or equal to M. In another embodiment, the antibody may have a KD value of 10 at acidic pH -9 M,10 -8 M,10 -7 M,10 -6 M is more than M.
In a further embodiment, an antibody is considered to bind C5 with a higher affinity at neutral pH than at acidic pH if the KD for the antibody to bind C5 at pH5.8 is at least 2-fold higher than the KD for the antibody to bind C5 at pH 7.4. In some embodiments, an antibody is provided that binds C5 with a KD at ph5.8 that is at least 3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than the KD for the antibody to bind C5 at ph 7.4. In another embodiment, the antibody may have a KD value of 10 at pH7.4 -7 M,10 -8 M,10 -9 M,10 -10 M,10 -11 M,10 -12 M is less than or equal to M. In another embodiment, the antibody may have a KD value of 10 at pH5.8 -9 M,10 -8 M,10 -7 M,10 -6 M or greater.
The binding properties of an antibody to a particular antigen can also be expressed as kd for the antibody. Kd of an antibody refers to the dissociation rate constant of an antibody with respect to a particular antigen and is in the reciprocal of a unit second (i.e., sec) -1 ) And (4) showing. An increase in kd indicates that the antibody binds weakly to its antigen. The invention therefore includes antibodies directed againstThe kd value of the body at acidic pH in combination with C5 is higher than at neutral pH. The invention includes antibodies that bind C5 at acidic pH with a kd that is at least 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than the kd that the antibody binds C5 at neutral pH. In another embodiment, the antibody may have a kd value of 10 at neutral pH - 2 1/s,10 -3 1/s,10 -4 1/s,10 -5 1/s,10 -6 1/s or less. In another embodiment, the antibody may have a kd value of 10 at acidic pH -3 1/s,10 -2 1/s,10 -1 More than 1/s. The invention also includes antibodies that bind C5 at pH5.8 with a higher kd value than at pH 7.4. The invention includes antibodies that bind C5 at ph5.8 with a kd that is at least 3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 times higher than the kd that the antibody binds C5 at ph 7.4. In another embodiment, the antibody may have a kd value of 10 at pH7.4 -2 1/s,10 -3 1/s,10 -4 1/s,10 -5 1/s,10 -6 1/s or less. In another embodiment, the antibody may have a kd value of 10 at pH5.8 -3 1/s,10 -2 1/s,10 -1 1/s or more.
In certain instances, "binding to C5 at acidic pH is reduced compared to its binding at neutral pH" is expressed as the ratio of the KD value for an antibody to bind to C5 at acidic pH to the KD value for an antibody to bind to C5 at neutral pH (or vice versa). For example, for the present invention, an antibody can be considered to exhibit "reduced binding to C5 at acidic pH compared to its binding at neutral pH" if the antibody exhibits an acidic/neutral KD ratio of 2 or greater. In certain exemplary embodiments, the antibodies of the invention have a pH5.8/pH7.4KD ratio of 2 or greater. In certain exemplary embodiments, the antibodies of the invention can have an acidic/neutral KD ratio of 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or greater. In another embodimentIn embodiments, the antibody can have a KD value of 10 at neutral pH -7 M,10 -8 M,10 -9 M,10 - 10 M,10 -11 M,10 -12 M is less than or equal to M. In another embodiment, the antibody may have a KD value of 10 at acidic pH -9 M,10 -8 M,10 -7 M,10 -6 M is more than M. In other cases, for the present invention, an antibody can be considered to exhibit "binding to C5 at acidic pH is reduced compared to its binding at neutral pH" if the antibody exhibits a pH5.8/pH7.4KD ratio of 2 or greater. In certain exemplary embodiments, the antibodies of the invention can have a ph5.8/ph7.4kd ratio of 3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In another embodiment, the antibody may have a KD value of 10 at pH7.4 -7 M,10 -8 M,10 -9 M,10 -10 M,10 -11 M,10 -12 M is less than or equal to M. In another embodiment, the antibody may have a KD value of 10 at pH5.8 -9 M,10 -8 M,10 -7 M,10 -6 M is more than M.
In certain instances, "binding to C5 at acidic pH is reduced compared to its binding at neutral pH" is expressed as the ratio of the kd value at which the antibody binds C5 at acidic pH to the kd value at which the antibody binds C5 at neutral pH (or vice versa). For example, for the present invention, an antibody may be considered to exhibit "reduced binding to C5 at acidic pH compared to its binding at neutral pH" if the antibody exhibits an acidic/neutral kd ratio of 2 or greater. In certain exemplary embodiments, the antibodies of the invention have a pH5.8/pH7.4 kd ratio of 2 or greater. In certain exemplary embodiments, the antibodies of the invention can have an acidic/neutral kd ratio of 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or greater. In further exemplary embodiments, the antibodies of the invention can have a ph5.8/ph7.4 kd ratio of 2,3,5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 400, 1000, 10000 or more. In addition toIn one embodiment, the antibody may have a kd value of 10 at neutral pH -2 1/s,10 -3 1/s,10 -4 1/s,10 - 5 1/s,10 -6 1/s or less. In another embodiment, the kd value of the antibody at pH 7.4 may be 10 -2 1/s,10 -3 1/s,10 - 4 1/s,10 -5 1/s,10 -6 1/s or less. In another embodiment, the antibody may have a kd value of 10 at acidic pH -3 1/s,10 -2 1/s,10 -1 1/s or more. In another embodiment, the antibody may have a kd value of 10 at pH5.8 -3 1/s,10 - 2 1/s,10 -1 1/s or more.
As used herein, the expression "acidic pH" refers to a pH of 4.0 to 6.5. The expression "acidic pH" includes pH values of any of 4.0,4.1,4.2,4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,5.1,5.2,5.3,5.4,5.5,5.6,5.7,5.8,5.9,6.0,6.1,6.2,6.3,6.4, and 6.5. In a particular aspect, the "acidic pH" is 5.8.
As used herein, the expression "neutral pH" refers to a pH of 6.7 to about 10.0. The expression "neutral pH" includes pH values of any of 6.7,6.8,6.9,7.0,7.1,7.2,7.3,7.4,7.5,7.6,7.7,7.8,7.9,8.0,8.1,8.2,8.3,8.4,8.5,8.6,8.7,8.8,8.9,9.0,9.1,9.2,9.3,9.4,9.5,9.6,9.7,9.8,9.9 and 10.0. In a particular aspect, the "neutral pH" is 7.4.
As expressed herein, KD values as well as KD values can be determined using surface plasmon resonance based biosensors to characterize antibody-antigen interactions. (see, e.g., example 3 herein). The KD and KD values can be determined at 25 ℃ or 37 ℃.
In certain embodiments, an anti-C5 antibody of the invention binds to an epitope consisting of the beta intrachain MG1 domain of C5 (SEQ ID NO: 41). In certain embodiments, the anti-C5 antibodies of the invention bind to an epitope within the beta chain of C5 (SEQ ID NO: 40) that comprises at least one fragment selected from the group consisting of: amino acids 47-57, 70-76, and 107-110. In certain embodiments, an anti-C5 antibody of the invention binds to an epitope within a fragment of the beta chain of C5 (SEQ ID NO: 40) that comprises at least one amino acid selected from the group consisting of: thr47, glu48, ala49, phe50, asp51, ala52, thr53, lys57, his70, val71, his72, ser74, glu76, val107, ser108, lys109, and His110. In certain embodiments, the anti-C5 antibodies of the invention bind to an epitope within a fragment of the beta chain of C5 (SEQ ID NO: 40) that comprises at least one amino acid selected from the group consisting of: glu48, asp51, his70, his72, lys109, and His110. In certain embodiments, an anti-C5 antibody of the invention binds to a C5 mutant with reduced binding to wild-type C5 compared to its binding to the mutant, wherein the C5 mutant has at least one amino acid substitution at a position selected from the group consisting of: glu48, asp51, his72, and Lys109. In another embodiment, the anti-C5 antibody of the invention has reduced pH-dependent binding to wild-type C5 compared to the pH-dependent binding of a C5 mutant, wherein the C5 mutant has at least one amino acid substitution at a position selected from the group consisting of: his70, his72, and His110. In another embodiment, in the C5 mutant, the amino acid at the position selected from Glu48, asp51 and Lys109 is substituted with alanine, and the amino acid at the position selected from His70, his72 and His110 is substituted with tyrosine.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (b) the VH of SEQ ID NO:22 and the VL of SEQ ID NO: 26; (c) the VH of SEQ ID NO:21 and the VL of SEQ ID NO: 25; (d) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (e) the VH of SEQ ID NO:4 and the VL of SEQ ID NO: 14; (f) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (g) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (h) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (i) the VH of SEQ ID NO:9 and the VL of SEQ ID NO: 19; (j) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; (k) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18; (l) the VH of SEQ ID NO:23 and the VL of SEQ ID NO: 27; and (m) the VH of SEQ ID NO:10 and the VL of SEQ ID NO: 20.
In certain embodiments, an anti-C5 antibody of the invention binds to C5 and contacts amino acid Asp51 (D51) of SEQ ID NO: 39. In another embodiment, an anti-C5 antibody of the invention binds to C5 and contacts amino acid Lys109 (K109) of SEQ ID NO: 39. In another embodiment, an anti-C5 antibody of the invention binds to C5 and contacts amino acid Asp51 (D51) and amino acid Lys109 (K109) of SEQ ID NO: 39.
In certain embodiments, the anti-C5 antibodies of the invention bind to a C5 mutant with reduced binding to wild-type C5 compared to the binding of the C5 mutant, wherein the C5 mutant has the Glu48Ala (E48A) substitution of SEQ ID NO: 39. In another embodiment, the anti-C5 antibody of the invention has reduced pH-dependent binding to wild-type C5 compared to the pH-dependent binding of a C5 mutant, wherein the C5 mutant has the Glu48Ala (E48A) substitution of SEQ ID NO: 39.
In another embodiment, the anti-C5 antibody binds to a C5 protein consisting of the amino acid sequence of SEQ ID NO:39, but does not bind to a C5 protein consisting of the amino acid sequence of SEQ ID NO:39 having a H72Y substitution, wherein the C5 protein and the C5 protein having a H72Y substitution are prepared and screened under the same conditions. In another embodiment, the anti-C5 antibody binds to the C5 protein consisting of the amino acid sequence of SEQ ID NO:39 at pH7.4, but does not bind to the C5 protein having the H72Y substitution at pH 7.4.
Without being bound to a particular theory, it is expected that the binding of the anti-C5 antibody to C5 is reduced (or almost lost) when one amino acid residue on C5 is substituted for another, which means that the amino acid residue on C5 is critical for the interaction between the anti-C5 antibody and C5, and the antibody can recognize an epitope around the amino acid residue on C5.
In the present invention, it has been found that a group of anti-C5 antibodies that compete with each other or bind to the same epitope can exhibit pH-dependent binding characteristics. Among amino acids, histidine with pKa values of about 6.0 to 6.5 may have different proton dissociation states between neutral and acidic pH. Thus, histidine residues on C5 can aid in pH-dependent interactions between anti-C5 antibodies and C5. Without being bound to a particular theory, it is expected that anti-C5 antibodies can recognize conformational structures near histidine residues on C5, which can vary depending on pH. This expectation may be consistent with the experimental results described below: when the histidine residue on C5 is replaced with another amino acid, the pH-dependence of the anti-C5 antibody is reduced (or nearly lost) (i.e., at neutral pH, an anti-C5 antibody with pH-dependent binding characteristics binds to histidine mutants of C5 with similar affinity as wild-type C5, while at acidic pH, the same antibody binds to histidine mutants of C5 with higher affinity than wild-type C5).
In certain embodiments, an anti-C5 antibody of the invention binds C5 from more than one species. In further embodiments, the anti-C5 antibody binds to C5 from both human and non-human animals. In additional embodiments, the anti-C5 antibody binds C5 from human and monkey (e.g., cynomolgus monkey, rhesus monkey, marmoset monkey, chimpanzee, or baboon).
In one aspect, the invention provides anti-C5 antibodies that inhibit activation of C5. In certain embodiments, an anti-C5 antibody is provided that prevents C5 cleavage to form C5a and C5b, thus preventing development of C5 a-associated anaphylatoxin activity, and preventing C5b-9 Membrane Attack Complex (MAC) assembly associated with C5 b. In certain embodiments, anti-C5 antibodies are provided that block the conversion of C5 to C5a and C5b by C5 convertase. In certain embodiments, anti-C5 antibodies are provided that prevent access of C5 convertase to the cleavage site on C5. In certain embodiments, anti-C5 antibodies are provided that block hemolytic activity caused by activation of C5. In additional embodiments, the anti-C5 antibodies of the invention inhibit activation of C5 via the classical pathway and/or the alternative pathway.
In one aspect, the invention provides anti-C5 antibodies that inhibit activation of a C5 variant. C5 variants refer to genetic variants of C5 due to genetic changes such as mutations, polymorphisms or allelic changes. Genetic changes may include deletions, substitutions or insertions of one or more nucleotides. The C5 variant may comprise one or more genetic changes in C5. In certain embodiments, the C5 variant has similar biological activity as wild-type C5. Such C5 variants may comprise at least one alteration selected from the group consisting of: V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N, and E1437D. Herein, for example, R885H represents a genetic change wherein the arginine at position 885 is replaced with histidine. In certain embodiments, the anti-C5 antibodies of the invention inhibit activation of both wild-type C5 and at least one C5 variant selected from the group consisting of V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N, and E1437D.
In one aspect, the invention provides an anti-C5 antibody comprising at least one, two, three, four, five or six hypervariable regions (HVRs) selected from: (a) HVR-H1, the HVR-H1 comprises an amino acid sequence of any one of SEQ ID NOS 45-54; (b) HVR-H2, said HVR-H2 comprises an amino acid sequence of any one of SEQ ID NOs: 55-64; (c) HVR-H3, the HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS 65-74; (d) HVR-L1, said HVR-L1 comprises an amino acid sequence of any one of SEQ ID NOs 75-84; (e) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS: 85-94; and (f) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS 95-104.
In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from: (a) HVR-H1, the HVR-H1 comprises an amino acid sequence of any one of SEQ ID NOS 45-54; (b) HVR-H2, said HVR-H2 comprises an amino acid sequence of any one of SEQ ID NOs: 55-64; and (c) HVR-H3, said HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65-74. In one embodiment, the antibody comprises HVR-H3, wherein HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS 65-74. In another embodiment, the antibody comprises HVR-H3 and HVR-L3, wherein HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65-74 and HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95-104. In another embodiment, said antibody comprises HVR-H3, HVR-L3 and HVR-H2, wherein said HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65-74, said HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95-104, and said HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOS: 55-64. In another embodiment, the antibody comprises (a) an HVR-H1, wherein the HVR-H1 comprises the amino acid sequence of any one of SEQ ID NOS 45-54; (b) HVR-H2, said HVR-H2 comprises an amino acid sequence of any one of SEQ ID NOs: 55-64; and (c) HVR-H3, the HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65-74.
In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from: (a) HVR-L1, said HVR-L1 comprises an amino acid sequence of any one of SEQ ID NOs 75-84; (b) HVR-L2, said HVR-L2 comprises an amino acid sequence of any one of SEQ ID NOs 85-94; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS 95-104. In one embodiment, the antibody comprises (a) HVR-L1, wherein HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOS: 75-84; (b) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS: 85-94; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS 95-104.
In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from: (ii) an HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOS: 45-54, (ii) an HVR-H2, said HVR-H2 comprising the amino acid sequence of any one of SEQ ID NOS: 55-64, and (iii) an HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOS: 65-74; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from: (i) HVR-L1, said HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOS: 75-84, (ii) HVR-L2, said HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS: 85-94, and (c) HVR-L3, said HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95-104.
In another aspect, the invention provides an antibody comprising: (a) HVR-H1, the HVR-H1 comprises an amino acid sequence of any one of SEQ ID NOS 45-54; (b) HVR-H2, the HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOS: 55-64; (c) HVR-H3, said HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65-74; (d) HVR-L1, the HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOS 75-84; (e) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS: 85-94; and (f) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS 95-104.
In one aspect, the invention provides an anti-C5 antibody comprising at least one, two, three, four, five or six HVRs selected from: (a) HVR-H1, the HVR-H1 comprises the amino acid sequence of any one of SEQ ID NOs 45, 54, 117, 126; (b) HVR-H2, said HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127; (c) HVR-H3, said HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOs 65, 74, 121, 128; (d) HVR-L1, the HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOs 75, 84, 122, 129; (e) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOs 85, 94, 123-124, 130; and (f) HVR-L3, said HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131.
In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH HVR sequences selected from: (a) HVR-H1, the HVR-H1 comprises the amino acid sequence of any one of SEQ ID NOs 45, 54, 117, 126; (b) HVR-H2, said HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127; and (c) HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOS: 65, 74, 121, 128. In one embodiment, the antibody comprises HVR-H3, wherein HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65, 74, 121, 128. In another embodiment, the antibody comprises HVR-H3 and HVR-L3, wherein HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65, 74, 121, 128, and HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131. In another embodiment, the antibody comprises HVR-H3, HVR-L3 and HVR-H2, wherein HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS: 65, 74, 121, 128, HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131, and HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOS: 55, 64, 118-120, 127. In another embodiment, the antibody comprises (a) an HVR-H1, wherein the HVR-H1 comprises the amino acid sequence of any one of SEQ ID NOS: 45, 54, 117, 126; (b) HVR-H2, the HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127; and (c) HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOS: 65, 74, 121, 128.
In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL HVR sequences selected from: (a) HVR-L1, the HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOs 75, 84, 122, 129; (b) HVR-L2, said HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOs: 85, 94, 123-124, 130; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131. In one embodiment, the antibody comprises (a) HVR-L1, wherein HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOS: 75, 84, 122, 129; (b) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOs 85, 94, 123-124, 130; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131.
In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH HVR sequences selected from: (ii) an HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOs 45, 54, 117, 126, (ii) an HVR-H2, said HVR-H2 comprising the amino acid sequence of any one of SEQ ID NOs 55, 64, 118-120, 127, and (iii) an HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOs 65, 74, 121, 128; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from: (i) HVR-L1, said HVR-L1 comprises the amino acid sequence of any of SEQ ID NOS: 75, 84, 122, 129, (ii) HVR-L2, said HVR-L2 comprises the amino acid sequence of any of SEQ ID NOS: 85, 94, 123-124, 130, and (c) HVR-L3, said HVR-L3 comprises the amino acid sequence of any of SEQ ID NOS: 95, 104, 125, 131.
In another aspect, the invention provides an antibody comprising (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOS: 45, 54, 117, 126; (b) HVR-H2, the HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127; (c) HVR-H3, the HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOs 65, 74, 121, 128; (d) HVR-L1, the HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOs 75, 84, 122, 129; (e) HVR-L2, the HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOs 85, 94, 123-124, 130; and (f) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131.
In certain embodiments, any one or more amino acids in an anti-C5 antibody as provided above are substituted at the following HVR positions: (a) In HVR-H1 (SEQ ID NO: 45), at positions 5 and 6; (b) In HVR-H2 (SEQ ID NO: 55), at positions 1,3,9, 11, 13 and 15; (c) In HVR-H3 (SEQ ID NO: 65), at positions 2,5,6, 12 and 13; (d) In HVR-L1 (SEQ ID NO: 75), at positions 1,5,7 and 9; (e) In HVR-L2 (SEQ ID NO: 85), at positions 4,5 and 6; and (f) in HVR-L3 (SEQ ID NO: 95), at positions 2,4 and 12.
In certain embodiments, the substitutions are conservative substitutions, as described herein. In certain embodiments, any one or more of the following substitutions may be made in any combination: (a) in HVR-H1 (SEQ ID NO: 45), M5V or C6A; (b) In HVR-H2 (SEQ ID NO: 55), C1A or G, Y3F, T9D or E, Y11K or Q, S13D or E, or A15V; (c) In HVR-H3 (SEQ ID NO: 65), G2A, V5Q or D, T6Y, Y12H, or L13Y; (d) In HVR-L1 (SEQ ID NO: 75), Q1R, N5Q or G, G7S, D9K or S; (e) In HVR-L2 (SEQ ID NO: 85), K4T or E, L5T, or A6H, A6E, or A6Q; (f) In HVR-L3 (SEQ ID NO: 95), C2S, C2N, or C2T, F4K; or A12T or A12H.
All possible combinations of the above substitutions are encompassed by the consensus sequences SEQ ID NO:126, 127, 128, 129, 130 and 131 of HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3, respectively.
In any of the above embodiments, the anti-C5 antibody is humanized. In one embodiment, the anti-C5 antibody comprises an HVR of any of the above embodiments, and further comprises an acceptor human framework, e.g., a human immunoglobulin framework or a human consensus framework. In another embodiment, an anti-C5 antibody comprises a HVR of any of the embodiments above, and further comprises a VH or VL comprising FR sequences, wherein the FR sequences are as follows. For the heavy chain variable domain, FR1 comprises the amino acid sequence of any one of SEQ ID NOS 132-134, FR2 comprises the amino acid sequence of any one of SEQ ID NOS 135-136, FR3 comprises the amino acid sequence of any one of SEQ ID NOS 137-139, and FR4 comprises the amino acid sequence of any one of SEQ ID NOS 140-141. For the light chain variable domain, FR1 comprises the amino acid sequence of any one of SEQ ID NOS 142-143, FR2 comprises the amino acid sequence of any one of SEQ ID NOS 144-145, FR3 comprises the amino acid sequence of any one of SEQ ID NOS 146-147 and FR4 comprises the amino acid sequence of SEQ ID NO 148.
In another aspect, the anti-C5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of any one of SEQ ID NOS: 1-10. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted and/or deleted in any of SEQ ID NOs 1-10. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises a VH sequence of any one of SEQ ID NOs 1-10, including post-translational modifications of said sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOS: 45-54, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence of any one of SEQ ID NOS: 55-64, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOS: 65-74.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of any one of SEQ ID NOS: 11-20. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted and/or deleted in any of SEQ ID NOs 11-20. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises a VL sequence in any of SEQ ID NOS: 11-20, including post-translational modifications of said sequence. In particular embodiments, the VL comprises one, two or three HVRs selected from: (a) HVR-L1, the HVR-L1 comprises the amino acid sequence of any one of SEQ ID NOS 75-84; (b) HVR-L2, said HVR-L2 comprises an amino acid sequence of any one of SEQ ID NOs 85-94; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS 95-104.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH in any one of the embodiments provided above and a VL in any one of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of any one of SEQ ID NOs: 1-10 and any one of SEQ ID NOs: 11-20, respectively, including post-translational modifications of the sequences.
In another aspect, the anti-C5 antibody comprises a heavy chain variable domain (VH) sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of any of SEQ ID NOS 10, 106-110. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in any of SEQ ID NOs 10, 106-110 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises a VH sequence of any one of SEQ ID NOS 10, 106-110, including post-translational modifications of said sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOs: 45, 54, 117, 126, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOs: 65, 74, 121, 128.
In another aspect, the anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of any of SEQ ID NOS 10, 106-110. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in any of SEQ ID NOs 10, 106-110 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises a VH sequence of any one of SEQ ID NOs 10, 106-110, including post-translational modifications of said sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising the amino acid sequence of any one of SEQ ID NOs: 45, 54, 117, 126, (b) HVR-H2, said HVR-H2 comprising the amino acid sequence of any one of SEQ ID NOs: 55, 64, 118-120, 127, and (c) HVR-H3, said HVR-H3 comprising the amino acid sequence of any one of SEQ ID NOs: 65, 74, 121, 128.
In another aspect, the anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO 10. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 10. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 10 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence in SEQ ID NO 10, including post-translational modifications of the sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:54, (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:64, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:74.
In another aspect, the anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO 106. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 106. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 106 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence of SEQ ID NO 106, including post-translational modifications of the sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:117, (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:118, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:121.
In another aspect, the anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:107. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 107. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 107 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence of SEQ ID NO:107, including post-translational modifications of the sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:117 (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:119, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:121.
In another aspect, the anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:108. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 108. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 108 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence of SEQ ID NO:108, including post-translational modifications of said sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:117 (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:118, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:121.
In another aspect, an anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO:109. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 109. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO:109 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence of SEQ ID NO:109, including post-translational modifications of the sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:117 (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:118, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:121.
In another aspect, an anti-C5 antibody comprises a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID No. 110. In certain embodiments, the VH sequence is the amino acid sequence SEQ ID NO 110. In certain embodiments, a VH sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 110 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VH sequence in SEQ ID NO:110, including post-translational modifications of the sequence. In particular embodiments, the VH comprises one, two or three HVRs selected from: (a) HVR-H1, said HVR-H1 comprising amino acid sequence SEQ ID NO:117 (b) HVR-H2, said HVR-H2 comprising amino acid sequence SEQ ID NO:120, and (c) HVR-H3, said HVR-H3 comprising amino acid sequence SEQ ID NO:121.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to the amino acid sequence of any of SEQ ID NOS 20, 111-113. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in any of SEQ ID NO 20, 111-113 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises a VL sequence of any one of SEQ ID NO 20, 111-113, including post-translational modifications of said sequence. In particular embodiments, a VL comprises one, two, or three HVRs selected from (a) HVR-L1 comprising the amino acid sequence of any one of SEQ ID NOS: 75, 84, 122, 129; (b) HVR-L2, said HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOs: 85, 94, 123-124, 130; and (c) HVR-L3, the HVR-L3 comprises the amino acid sequence of any one of SEQ ID NOS: 95, 104, 125, 131.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VL having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO:20. In certain embodiments, the VL sequence is the amino acid sequence SEQ ID NO 20. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 20 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VL sequence of SEQ ID NO:20, including post-translational modifications of the sequence. In particular embodiments, the VL comprises one, two or three HVRs selected from (a) HVR-L1, said HVR-L1 comprises the amino acid sequence SEQ ID NO:84; (b) HVR-L2, said HVR-L2 comprises amino acid sequence SEQ ID NO 94; and (c) HVR-L3, said HVR-L3 comprises amino acid sequence SEQ ID NO:104.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VL having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO 111. In certain embodiments, the VL sequence is the amino acid sequence SEQ ID NO 111. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 111 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VL sequence of SEQ ID NO 111, including post-translational modifications of the sequence. In particular embodiments, the VL comprises one, two, or three HVRs selected from (a) HVR-L1, said HVR-L1 comprises amino acid sequence SEQ ID NO:122; (b) HVR-L2, the HVR-L2 comprises amino acid sequence SEQ ID NO 123; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VL having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID NO:112. In certain embodiments, the VL sequence is the amino acid sequence SEQ ID NO 112. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO:112 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VL sequence of SEQ ID NO:112, including post-translational modifications of the sequence. In particular embodiments, a VL comprises one, two, or three HVRs selected from (a) HVR-L1, said HVR-L1 comprises amino acid sequence SEQ ID NO:122; (b) HVR-L2, said HVR-L2 comprises amino acid sequence SEQ ID NO 123; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VL having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%,99%, or 100% sequence identity to amino acid sequence SEQ ID No. 113. In certain embodiments, the VL sequence is the amino acid sequence SEQ ID NO 113. In certain embodiments, a VL sequence having at least 90%,91%,92%,93%,94%,95%,96%,97%,98%, or 99% identity comprises a substitution (e.g., a conservative substitution), insertion, or deletion relative to a reference sequence, but an anti-C5 antibody comprising the sequence retains the ability to bind C5. In certain embodiments, a total of 1 to 10 amino acids in SEQ ID NO 113 are substituted, inserted and/or deleted. In certain embodiments, the substitution, insertion, or deletion occurs in a region outside of the HVR (i.e., in the FR). Optionally, the anti-C5 antibody comprises the VL sequence of SEQ ID NO. 113, including post-translational modifications of the sequence. In particular embodiments, a VL comprises one, two, or three HVRs selected from (a) HVR-L1, said HVR-L1 comprises amino acid sequence SEQ ID NO:122; (b) HVR-L2, said HVR-L2 comprises amino acid sequence SEQ ID NO:124; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH in any one of the embodiments provided above and a VL in any one of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of any of SEQ ID NOS: 10, 106-110 and any of SEQ ID NOS: 20, 111-113, respectively, including post-translational modifications of said sequences. In one embodiment, the antibody comprises the VH sequence of SEQ ID NO. 10 and the VL sequence of SEQ ID NO. 20. In one embodiment, the antibody comprises the VH sequence of SEQ ID NO 106 and the VL sequence of SEQ ID NO 111. In another embodiment, the antibody comprises the VH sequence of SEQ ID NO. 107 and the VL sequence of SEQ ID NO. 111. In additional embodiments, the antibody comprises the VH sequence of SEQ ID NO:108 and the VL sequence of SEQ ID NO: 111. In another embodiment, the antibody comprises the VH sequence of SEQ ID NO:109 and the VL sequence of SEQ ID NO: 111. In another embodiment, the antibody comprises the VH sequence of SEQ ID NO:109 and the VL sequence of SEQ ID NO: 112. In another embodiment, the antibody comprises the VH sequence of SEQ ID NO:109 and the VL sequence of SEQ ID NO: 113. In another embodiment, the antibody comprises the VH sequence of SEQ ID NO. 110 and the VL sequence of SEQ ID NO. 113.
In one aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH sequence comprising: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence SEQ ID NO:54, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence SEQ ID NO:64, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence SEQ ID NO:74, and a VL sequence comprising: (a) HVR-L1, the HVR-L1 comprises amino acid sequence SEQ ID NO:84; (b) HVR-L2, the HVR-L2 comprises amino acid sequence SEQ ID NO 94; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:104.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH sequence comprising: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence SEQ ID NO:117, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence SEQ ID NO:118, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence SEQ ID NO:121, and a VL sequence comprising: (a) HVR-L1, the HVR-L1 comprises amino acid sequence SEQ ID NO 122; (b) HVR-L2, said HVR-L2 comprises amino acid sequence SEQ ID NO 123; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH sequence comprising: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence SEQ ID NO:117, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence SEQ ID NO:119, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence SEQ ID NO:121, and a VL sequence comprising: (a) HVR-L1, said HVR-L1 comprises amino acid sequence SEQ ID NO 122; (b) HVR-L2, the HVR-L2 comprises amino acid sequence SEQ ID NO 123; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH sequence comprising: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence SEQ ID NO:117, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence SEQ ID NO:118, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence SEQ ID NO:121, and a VL sequence comprising: (a) HVR-L1, the HVR-L1 comprises amino acid sequence SEQ ID NO 122; (b) HVR-L2, the HVR-L2 comprises amino acid sequence SEQ ID NO:124; and (c) HVR-L3, the HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In another aspect, an anti-C5 antibody is provided, wherein the antibody comprises a VH sequence comprising: (a) an HVR-H1, said HVR-H1 comprising the amino acid sequence SEQ ID NO:117, (b) an HVR-H2, said HVR-H2 comprising the amino acid sequence SEQ ID NO:120, and (c) an HVR-H3, said HVR-H3 comprising the amino acid sequence SEQ ID NO:121, and a VL sequence comprising: (a) HVR-L1, said HVR-L1 comprises amino acid sequence SEQ ID NO 122; (b) HVR-L2, said HVR-L2 comprises amino acid sequence SEQ ID NO:124; and (c) HVR-L3, said HVR-L3 comprises amino acid sequence SEQ ID NO:125.
In certain embodiments, an anti-C5 antibody of the invention comprises a VH in any one of the embodiments provided above and a heavy chain constant region comprising the amino acid sequence of any one of SEQ ID NOs 33, 34, 35, 114, 115, and 116. In certain embodiments, an anti-C5 antibody of the invention comprises a VL of any of the embodiments provided above and a light chain constant region comprising the amino acid sequence of any of SEQ ID NOs 36, 37, and 38.
In another aspect, the invention provides antibodies that bind to the same epitope as an anti-C5 antibody provided herein. For example, in certain embodiments, antibodies are provided that bind to the same epitope as the antibodies described in table 2. As demonstrated by the working examples below, all anti-C5 antibodies described in table 2 were grouped into the same epitope box of C5 and showed pH-dependent binding characteristics.
In further aspects, the invention provides antibodies that bind to the same epitope as the antibodies provided herein. In a further aspect, the invention provides an antibody that binds to the same epitope as an antibody described in table 7 or 8. In certain embodiments, antibodies are provided that bind to an epitope within a fragment consisting of amino acids 33-124 of the beta chain of C5 (SEQ ID NO: 40). In certain embodiments, antibodies are provided that bind to an epitope within the beta chain of C5 (SEQ ID NO: 40) that comprises at least one fragment selected from the group consisting of: amino acids 47-57, 70-76, and 107-110. In certain embodiments, antibodies are provided that bind to an epitope within a fragment of the beta chain of C5 (SEQ ID NO: 40) that comprises at least one amino acid selected from the group consisting of: thr47, glu48, ala49, phe50, asp51, ala52, thr53, lys57, his70, val71, his72, ser74, glu76, val107, ser108, lys109, and His110. In another embodiment, the epitope of the anti-C5 antibody of the invention is a conformational epitope.
In another aspect of the invention, an anti-C5 antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, the anti-C5 antibody is an antibody fragment, e.g., fv, fab, fab ', scFv, diabody, or F (ab') 2 And (3) fragment. In another embodiment, the antibody is a full length antibody, e.g., a complete IgG1 or IgG4 antibody or other antibody class or isotype as defined herein.
In another aspect, an anti-C5 antibody according to any of the above embodiments may bind any of the features described in sections 1-7 below (alone or in combination).
1. Affinity of antibody
In certain embodiments, the antibodies provided herein have a dissociation constant (Kd) of: less than 1 μ M, less than 100nM, less than 10nM, less than 1nM, less than 0.1nM, less than 0.01nM or less than 0.001nM (e.g., 10 nM) -8 M or less, e.g. 10 - 8 M to 10 -13 M, e.g. 10 -9 M to 10 -13 M)。
In one embodiment, kd is measured by a radiolabeled antigen binding assay (RIA). In one embodiment, the RIA is performed using a Fab form of the antibody of interest and its antigen. For example, solution binding affinity of Fab to antigen is measured by: (iii) with minimum concentration in the presence of a titration series of unlabelled antigen 125 I) The labeled antigen equilibrates the Fab, and the bound antigen is then captured with an anti-Fab antibody coated plate (see, e.g., chen et al, J.Mol.biol.293:865-881 (1999)). To determine the assay conditions, MICRO was usedTITER (registered trademark) multi-well plates (Thermo Scientific) were coated overnight with 5. Mu.g/ml of capture anti-Fab antibody (Cappel Labs) in 50mM sodium carbonate (pH 9.6) and then blocked with 2% (w/v) fetal bovine serum albumin in PBS at room temperature (about 23 ℃) for two to five hours. In a non-adsorbing plate (Nunc # 269620), 100pM or 26pM [ alpha ] amino acid was prepared 125 I]Mixing of antigen with serial dilutions of Fab of interest (e.g.in accordance with the evaluation of anti-VEGF antibodies, fab-12, in Presta et al, cancer Res.57:4593-4599 (1997)). Then incubating the target Fab overnight; however, incubation may be continued for a longer period of time (e.g., about 65 hours) to ensure that equilibrium is achieved. Thereafter, the mixture is transferred to a capture plate for incubation at room temperature (e.g., for one hour). The solution was then removed and the plate was washed eight times with 0.1% polysorbate 20 (TWEEN-20 (registered trademark)) in PBS. When the plates had dried, 150. Mu.l/well of scintillator (MICROSCINT-20) was added TM (ii) a Packard) and place the plate on TOPCOUNT TM Count on a gamma counter (Packard) for ten minutes. The concentration of each Fab that resulted in less than or equal to 20% of maximal binding was selected for competitive binding assays.
According to another embodiment, kd is measured using BIACORE (registered trademark) surface plasmon resonance assay. For example, measurement using BIACORE (registered trademark) -2000 or BIACORE (registered trademark) -3000 (BIACORE (registered trademark), inc., piscataway, NJ) was performed at 25 ℃ using an immobilized antigen CM5 chip at-10 Response Units (RU). In one embodiment, the carboxymethylated dextran biosensor chip (CM 5, BIACORE (registered trademark), inc.) is activated with N-ethyl-N '- (3-dimethylaminopropyl) -carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the provider's instructions. Antigen was diluted to 5 μ g/ml (. About.0.2. Mu.M) with 10mM sodium acetate pH4.8 before injection at a flow rate of 5 μ l/min to achieve approximately 10 Response Units (RU) of conjugated protein. After injection of the antigen, 1M ethanolamine was injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions (0.78 nM to 500 nM) of Fab were injected at 25 ℃ with 0.05% polysorbate 20 (TWEEN-20) at a flow rate of about 25. Mu.l/min TM ) Surfactant in PBS (PBST). Simple one-to-one (one) to use-to-one) Langmuir (Langmuir) binding model (BIACORE (registered trademark) Evaluation Software version 3.2) the binding rate (k) was calculated by simultaneous fitting of the binding and dissociation sensorgrams on ) And dissociation Rate (k) off ). As k is off /k on The ratio of (d) to (d) is calculated as the equilibrium dissociation constant (Kd). See, e.g., chen et al, J.mol.biol.293:865-881 (1999). If the binding rate measured by the above surface plasmon resonance assay exceeds 10 6 M -1 s -1 The binding rate can then be determined by: such as in spectrometers such as the spectrophotometer (Aviv Instruments) equipped with a stop-flow or 8000-series SLM-AMINCO with stir chamber TM Measured in a spectrophotometer (ThermoSpectronic), using a fluorescence quenching technique (excitation =295nM; emission =340nm, 1691m band pass) that measures the increase or decrease in fluorescence emission intensity of 20nM anti-antigen antibody (Fab form) in the presence of increasing concentrations of antigen, at 25 ℃, in PBS, pH 7.2.
2. Antibody fragments
In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, fab ', fab ' -SH, F (ab ') 2 Fv and scFv fragments, as well as other fragments described below. For a review of specific antibody fragments, see Hudson et al nat. Med.9:129-134 (2003). For reviews on scFv fragments see, e.g., pluckthun, the Pharmacology of Monoclonal Antibodies, vol.113, edited by Rosenburg and Moore, (Springer-Verlag, new York), pp.269-315 (1994); see also, WO 93/16185; and U.S. Pat. nos. 5,571,894 and 5,587,458. For Fab and F (ab') containing salvage receptor binding epitope residues and having increased half-life in vivo 2 See U.S. Pat. No. 5,869,046 for a discussion of fragments.
Diabodies are antibody fragments with two antigen-binding sites, which may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; hudson et al, nat. Med.9:129-134 (2003); and Hollinger et al, proc.Natl.Acad.Sci.USA 90. Tri-and tetrabasic antibodies are also described in Hudson et al, nat. Med.9:129-134 (2003).
A single domain antibody is an antibody fragment comprising all or part of a heavy chain variable domain or all or part of a light chain variable domain of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, inc., waltham, mass.; see, e.g., U.S. Pat. No. 6,248,516).
Antibody fragments can be prepared by a variety of techniques including, but not limited to, proteolytic digestion of intact antibodies and preparation by recombinant host cells (e.g., e.coli or phage), as described herein.
3. Chimeric and humanized antibodies
In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in U.S. Pat. nos. 4,816,567; and Morrison et al, proc. Natl. Acad. Sci. USA81:6851-6855 (1984)). In one example, a chimeric antibody comprises non-human variable regions (e.g., variable regions derived from mouse, rat, hamster, rabbit, or non-human primate, such as monkey) and human constant regions. In further examples, a chimeric antibody is a "type-switch" antibody, wherein the type or subclass has been altered by the type or subclass of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
In certain embodiments, the chimeric antibody is a humanized antibody. Typically, non-human antibodies are humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parent non-human antibody. Typically, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs (or portions thereof), are derived from a non-human antibody and FRs (or portions thereof) are derived from a human antibody sequence. The humanized antibody optionally further comprises at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., an antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
Humanized antibodies and methods for their preparation are reviewed, for example, in Almagro and Fransson, front.biosci.13:1619-1633 (2008), and are further described, for example, in Riechmann et al, nature 332; queen et al, proc.nat' l Acad.Sci.USA 86; U.S. Pat. nos. 5,821,337,7,527,791,6,982,321 and 7,087,409; kashmiri et al, methods 36 (2005) (specificity determining region (SDR) grafting is described); padlan, mol.Immunol.28:489-498 (1991) (describing "resurfacing"); dall' Acqua et al, methods 36 (2005) (describing "FR shuffling"); and Osbourn et al, methods 36 (2005) and Klimka et al, br.J. cancer, 83.
Human framework regions that may be used for humanization include, but are not limited to: framework regions selected using the "best-fit" method (see, e.g., sims et al J.Immunol.151:2296 (1993)); framework regions derived from consensus sequences of human antibodies having particular subsets of light or heavy chain variable regions (see, e.g., carter et al, proc. Natl. Acad. Sci. USA 89 4285 (1992); and Presta et al J. Immunol.151:2623 (1993)); human mature (somatomerism) framework regions or human germline framework regions (see, e.g., almagro and Fransson, front.biosci.13:1619-1633 (2008)); and framework regions derived from FR library screening (see, e.g., baca et al, J.biol. Chem.272:10678-10684 (1997) and Rosok et al, J.biol. Chem.271:22611-22618 (1996)).
4. Human antibodies
In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be made using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, curr. Opin. Pharma.5:368-74 (2001) and Lonberg, curr. Opin. Immunol.20:450-459 (2008).
Human antibodies can be prepared by administering an immunogen to a transgenic animal that has been modified to produce a fully human antibody or a fully antibody with human variable regions in response to antigen challenge. Such animals typically contain all or part of a human immunoglobulin locus, which replaces an endogenous immunoglobulin locus, or which is present outside the chromosome or randomly integrated into the chromosome of the animal. In such transgenic mice, the endogenous immunoglobulin loci have typically been inactivated. Method for obtaining human antibodies from transgenic animals For a review see Lonberg, nat. Biotech.23:1117-1125 (2005). See also, for example, U.S. Pat. Nos. 6,075,181 and 6,150,584, which describe XeNOMOUSE TM A technique; U.S. Pat. No. 5,770,429, which describes HUMAB (registered trademark) technology; U.S. Pat. No. 7,041,870, which describes K-M MOUSE (registered trademark) technology, and U.S. patent application publication No. US 2007/0061900, which describes VELOCIMOUSE (registered trademark) technology. The human variable regions from intact antibodies produced by such animals may be further modified, for example, by combination with different human constant regions.
Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human hybrid myeloma cell lines for use in the preparation of human monoclonal antibodies have been described. (see, e.g., kozbor J.Immunol.,133, 3001 (1984); brodeur et al, monoclonal Antibody Production Techniques and Applications, pp.51-63 (Dekker, inc., new York, 1987); and Boerner et al, J.Immunol.147:86 (1991)). Human antibodies prepared via human B-cell hybridoma technology are also described in Li et al, proc.natl.acad.sci.usa 103. Additional methods include those described in, for example, U.S. Pat. No. 7,189,826 (describing the preparation of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, xiandai Mianyixue 26 (4): 265-268 (2006) (describing human-human hybridomas). The human hybridoma technique (Trioma technique) is also described in Vollmers, histology and Histopathology 20 (3): 927-937 (2005) and Vollmers, methods and Findgings in Experimental and Clinical Pharmacology 27 (3): 185-191 (2005).
Human antibodies can also be produced by isolating Fv clone variable domain sequences selected from a human phage display library. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.
5. Antibodies derived from libraries
Antibodies of the invention can be isolated by screening combinatorial libraries of antibodies having a desired activity or activities. For example, various methods are known in the art for generating phage display libraries and screening the libraries for antibodies having desired binding properties. Such Methods are reviewed, for example, in Hoogenboom et al, methods in Molecular Biology 178, 1-37 (O' Brien et al, ed., human Press, totowa, NJ, 2001) and are further described, for example, in McCafferty et al, nature 348; clackson et al, nature 352; marks et al, J.mol.biol.222:581-597 (1992); marks, meth.mol.biol.,248, 161-175 (Lo, ed., human Press, totowa, NJ, 2003); sidhu et al, J.mol.biol.338 (2): 299-310 (2004); lee et al, J.mol.biol.340 (5): 1073-1093 (2004); fellouse, proc. Natl. Acad. Sci. USA 101 (34): 12467-12472 (2004); lee et al, J.Immunol.methods 284 (1-2): 119-132 (2004).
In some phage display methods, VH and VL gene banks are separately cloned by Polymerase Chain Reaction (PCR) and randomly recombined in phage libraries, which can then be screened against antigen-binding phage, as described by Winter et al, ann. Rev. Immunol.12:433-455 (1994). Phage typically display antibody fragments as single chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, a natural (nave) repertoire can be cloned (e.g., by humans) to provide a single source of antibody to multiple non-self antigens as well as self antigens without the need for any immunization, as described by Griffiths et al, EMBO J, 12. Finally, natural libraries can also be prepared synthetically by: unrearranged V-gene segments were cloned from stem cells and PCR primers containing random sequences were used to encode the hypervariable CDR3 regions and to effect rearrangement in vitro as described in Hoogenboom, J.mol.biol.227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373 and U.S. publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936 and 2009/0002360.
Herein, an antibody or antibody fragment isolated from a human antibody library is considered a human antibody or human antibody fragment.
6. Multispecific antibodies
In certain embodiments, the antibodies provided herein are multispecific antibodies, e.g., bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one binding specificity is for C5 and the other is for another antigen. In certain embodiments, a bispecific antibody can bind two different epitopes of C5. Bispecific antibodies can also be used to localize cytotoxic agents to C5-expressing cells. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see, milstein and Cuello, nature305:537 (1983)), WO 93/08829, and Traunecker et al, EMBO J.10:3655 (1991)), and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be prepared by electrostatic targeting engineered for the preparation of antibody Fc-heterodimeric molecules (WO 2009/089004 A1); crosslinking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al, science,229 (1985)); the use of leucine zippers to prepare bispecific antibodies (see, e.g., kostelny et al, J.Immunol.148 (5): 1547-1553 (1992)); the "diabody" technique is used for the preparation of bispecific antibody fragments (see, e.g., hollinger et al, proc. Natl. Acad. Sci. USA90:6444-6448 (1993)); and the use of single chain Fv (scFv) dimers (see, e.g., gruber et al, J.Immunol.152:5368 (1994)); and making trispecific antibodies as described, for example, in Tutt et al, J.Immunol.147:60 (1991).
Also included herein are engineered antibodies with more than three functional antigen binding sites, including "octopus antibodies" (see, e.g., US 2006/0025576).
Antibodies or fragments herein also include "dual action fabs" or "DAFs" comprising an antigen binding site that binds C5 as well as another, different antigen (see, e.g., US 2008/0069820).
7. Antibody variants
In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to increase the binding affinity and/or other biological properties of an antibody. Amino acid sequence variants of an antibody can be prepared by introducing appropriate modifications to the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into, and/or substitutions of, residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
a. Substitution, insertion and deletion variants
In certain embodiments, antibody variants are provided having one or more amino acid substitutions. Sites of interest for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in table 1 under the heading of "preferred substitutions". Further changes are provided under the heading of "exemplary substitutions" in table 1 and as further described below with respect to amino acid side chain classifications. Amino acid substitutions may be introduced into the antibody of interest and the product screened for the desired activity (e.g., maintained/increased antigen binding, reduced immunogenicity or increased ADCC or CDC).
[ Table 1]
Initial residue | Exemplary permutations | Preference is given to substitution |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Asp,Lys;Arg | Gln |
Asp(D) | Glu;Asn | Glu |
Cys(C) | Ser;Ala | Ser |
Gln(Q) | Asn;Glu | Asn |
Glu(E) | Asp;Gln | Asp |
Gly(G) | Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu; val; met; ala; phe; norleucine | Leu |
Leu(L) | Norleucine; ile; val; met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Trp;Leu;Val;Ile;Ala;Tyr | Tyr |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Val;Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile; leu; met; phc; ala; zhengliang ammoniaAcid(s) | Leu |
Amino acids can be grouped into groups based on common side chain properties: (1) hydrophobicity: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilicity: cys, ser, thr, asn, gln; (3) acidity: asp, glu; (4) basicity: his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromaticity: trp, tyr, phe.
Non-conservative substitutions entail exchanging a member of one of these groups for a member of the other group.
A substitutional variant comprises the substitution of one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Typically, the resulting variant selected for further study will have an alteration (e.g., an increase) in certain biological properties (e.g., increased affinity, decreased immunogenicity) relative to the parent antibody and/or will substantially retain certain biological properties of the parent antibody. Exemplary substitution variants are affinity matured antibodies, which can be routinely prepared, e.g., using phage display-based affinity maturation techniques (such as those described herein). Briefly, one or more HVR residues are mutated and variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).
Alterations (e.g., substitutions) may be made in HVRs, for example, to improve antibody affinity. Such changes can be made in HVR "hot spots", i.e., residues encoded by codons that are mutated at high frequency during the somatic maturation process (see, e.g., chowdhury, methods mol. Biol.207:179-196 (2008)), and/or residues that are contacted with antigen, and the resulting variant VH or VL is tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries has been described, for example, in Hoogenboom et al, methods in Molecular Biology178:1-37 (O' Brien et al, ed., human Press, totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide-directed mutagenesis). Secondary libraries were then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity includes HVR-directed methods, in which several HVR residues (e.g., 4-6 residues at the same time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are generally targeted.
In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs, so long as such changes do not significantly reduce the ability of the antibody to bind antigen. For example, conservative changes that do not significantly reduce binding affinity (e.g., conservative substitutions as described herein) can be made in HVRs. Such changes may be, for example, outside of the residues that contact the antigen in the HVR. In certain embodiments of the variant VH and VL sequences provided above, each HVR is unaltered, or contains no more than one, two, or three amino acid substitutions.
A method that can be used to identify antibody residues or regions that can be targeted for mutagenesis is referred to as "alanine scanning mutagenesis" as described by Cunningham, science 244, 1081-1085 (1989). In this method, a residue or set of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced with a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether to affect the interaction of an antibody with an antigen. Further substitutions may be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively, or in addition, the crystal structure of the antigen-antibody complex to determine the contact points between the antibody and the antigen. Such contact residues and adjacent residues may be targeted or excluded as candidates for replacement. Variants can be screened to determine if they have the desired properties.
Amino acid sequence insertions include amino-terminal and/or carboxy-terminal fusions ranging in length from one residue to polypeptides containing over a hundred residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion of the N-or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or polypeptide that increases the serum half-life of the antibody.
b. Glycosylation variants
In certain embodiments, the antibodies provided herein are altered to increase or decrease the degree to which the antibody is glycosylated. The addition of glycosylation sites to an antibody or deletion of glycosylation sites can be readily accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.
When the antibody comprises an Fc region, the carbohydrate to which it is attached may be altered. Natural antibodies produced by mammalian cells typically comprise a branched, bifurcated (biantennary) oligosaccharide, which is usually linked to Asn297 of the CH2 domain of the Fc region by an N-linkage. See, e.g., wright et al, TIBTECH 15 (1997). Oligosaccharides may include a variety of carbohydrates, for example, mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, as well as fucose attached to GlcNAc in the "stem" of a bifurcated oligosaccharide structure. In some embodiments, modifications of oligosaccharides in the antibodies of the invention can be made to produce antibody variants with specific improved properties.
In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such an antibody may be 1% to 80%,1% to 65%,5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297 relative to the sum of all sugar structures (e.g. complex, hybrid and high mannose structures) associated with Asn297, as measured by MALDI-TOF mass spectrometry, as described in WO2008/077546, for example. Asn297 refers to an aspartic acid residue located near position 297 of the Fc region (Eu numbering of Fc region residues); however, due to small sequence variations in the antibody, asn297 may also be located about +/-3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants may have an improved ADCC function. See, for example, U.S. patent publication No. US 2003/0157108 (Presta, l.); US 2004/0093621 (Kyowa Hakko Kogyo Co., ltd.). Disclosed example variants involving "defucosylated" or "fucose-deficient" antibodies include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO 2005/053742; WO 2002/031140; okazaki et al, J.mol.biol.336:1239-1249 (2004); yamane-Ohnuki et al, biotech.Bioeng.87:614 (2004). Examples of cell lines capable of producing defucosylated antibodies include protein fucosylation deficient Lec13 CHO cells (Ripka et al, arch. Biochem. Biophys.249:533-545 (1986); US 2003/0157108, presta, L; and WO2004/056312, adams et al, especially example 11), as well as knockout cell lines, such as the alpha-1, 6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., yamane-Ohnuki et al, biotech. Bioeng.87:614 (2004); kanda et al, biotechnol. Bioeng.94 (4): 680-688 (2006); and WO 2003/085107).
Antibody variants having bisected oligosaccharides, for example, wherein a bisected oligosaccharide connected to the Fc region of the antibody is bisected by GlcNAc, are also provided. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003/011878 (Jean-Mairet et al); U.S. Pat. No. 6,602,684 (Umana et al); and US 2005/0123546 (Umana et al). Also provided are antibody variants having at least one galactose residue in an oligosaccharide attached to an Fc region. Such antibody variants may have increased CDC function. Such antibody variants are described, for example, in WO 1997/30087 (Patel et al); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).
Fc region variants
In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of the antibodies provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, igG2, igG3, or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
In certain embodiments, the invention contemplates antibody variants that have some, but not all, effector functions, which make them ideal candidates for applications where the in vivo half-life of the antibody is important and where certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and/or in vivo cytotoxicity assays may be performed to confirm the reduction/elimination of CDC and/or ADCC activity. For example, fc receptor (FcR) binding assays may be performed to ensure that the antibody lacks fcyr binding (and thus may lack ADCC activity), but retains FcRn binding ability. The primary cell mediating ADCC, NK cells, expresses only Fc γ RIII, whereas monocytes express Fc γ RI, fc γ RII and Fc γ RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of ravatch and Kinet, annu.Rev.Immunol.9:457-492 (1991). Non-limiting examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. patent nos. 5,500,362 (see, e.g., hellstrom et al proc.nat 'l acad.sci.usa 83 7059-7063 (1986)) and Hellstrom et al proc.nat' l acad.sci.usa 82 1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann et al, J.Exp. Med.166:1351-1361 (1987)). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry TM Non-radioactive cytotoxicity assay (CellTechnology, inc. Mountain View, CA); and CytoTox 96 (registered trademark) non-radioactive cytotoxicity assay (Promega, madison, WI)). Effector cells that can be used in such assays include Peripheral Blood Mononuclear Cells (PBMCs) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of a molecule of interest can be assessed in vivo, for example in an animal model as described in Clynes et al proc.nat' l acad.sci.usa 95. A C1q binding assay may also be performed to confirm that the antibody is unable to bind C1q and therefore lacks CDC activity. See, e.g., C1q and C3C binding ELISA in WO2006/029879 and WO 2005/100402. To assess complement activation, CDC assays can be performed (see, e.g., gazzano-Santoro et al, J.Immunol. Methods 202 (1996); cragg et al, blood 101-1045-1052 (2003); and Cragg et al, blood 103. FcRn binding and in vivo clearance/half-life assays can also be performed using methods known in the art(see, e.g., petkova et al, int' l. Immunol.18 (12): 1759-1769 (2006)).
Antibodies with reduced effector function include antibodies with substitutions of one or more of residues 238, 265, 269, 270, 297, 327 and 329 of the Fc region (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants having substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including so-called "DANA" Fc mutants having substitutions of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
Certain antibody variants with increased or decreased binding to FcR are described. ( See, for example, U.S. Pat. nos. 6,737,056; WO 2004/056312, and Shields et al, J.biol.chem.9 (2): 6591-6604 (2001). )
In certain embodiments, the antibody variant comprises an Fc region having one or more amino acid substitutions that improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 (EU numbering of residues) of the Fc region.
In some embodiments, alterations are made in the Fc region that result in altered (i.e., increased or decreased) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO1999/51642, and Idusogene et al, J.Immunol.164:4178-4184 (2000).
Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn) (J.Immunol.117: 587 (1976) and Kim et al, J.Immunol.24:249 (1994)) responsible for the transfer of maternal IgG to the fetus are described in US2005/0014934 (Hinton et al). The antibody comprises an Fc region having one or more substitutions therein that increase binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more of the following Fc region residues: 238 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, for example, a substitution of residue 434 in the Fc region (U.S. Pat. No. 7,371,826).
See also, duncan, nature 322-40 (1988); U.S. Pat. nos. 5,648,260; U.S. Pat. nos. 5,624,821; and WO 1994/29351 relating to other examples of variants of the Fc region.
d. Cysteine engineered antibody variants
In certain embodiments, it may be desirable to prepare cysteine engineered antibodies, e.g., "thiomabs," in which one or more residues of the antibody are substituted with a cysteine residue. In particular embodiments, the substituted residue occurs at an access site of the antibody. By replacing the residue with cysteine, a reactive thiol group is thereby placed at the access site of the antibody and can be used to conjugate the antibody to other moieties, such as a drug moiety or linker-drug moiety, thereby producing an immunoconjugate, as further described herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: v205 of the light chain (Kabat numbering); a118 of the heavy chain (EU numbering); and S400 of the heavy chain Fc region (EU numbering). Cysteine engineered antibodies can be produced as described, for example, in U.S. Pat. No. 7,521,541.
e. Antibody derivatives
In certain embodiments, the antibodies provided herein can be further modified to contain additional non-protein moieties known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous in preparation due to its stability in water. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, it can be the same or different molecules. In general, since the amount and/or type of derivatized polymer can be determined based on considerations including, but not limited to, the specific properties or functions of the antibody to be improved, whether the antibody derivative is useful for therapy under defined conditions, and the like.
In another embodiment, conjugates of an antibody and a non-protein moiety are provided that can be selectively heated by exposure to radiation. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al, proc.natl.acad.sci.usa 102. The radiation can be of any wavelength, and includes, but is not limited to, wavelengths that do not damage normal cells, but heat the non-protein portion to a temperature at which cells adjacent to the antibody-non-protein portion are killed.
B. Recombinant methods and compositions
Antibodies can be prepared using recombinant methods and compositions, for example, as described in U.S. Pat. No. 4,816,567. In one embodiment, an isolated nucleic acid is provided that encodes an anti-C5 antibody described herein. Such nucleic acids may encode an amino acid sequence comprising an antibody VL and/or an amino acid sequence comprising an antibody VH (e.g., a light chain and/or a heavy chain of an antibody). In another embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acids are provided. In another embodiment, host cells comprising such nucleic acids are provided. In one such embodiment, the host cell comprises (e.g., is transformed with): (1) A vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL and an amino acid sequence comprising an antibody VH, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL and a second vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VH. In one embodiment, the host cell is eukaryotic, e.g., a Chinese Hamster Ovary (CHO) cell or a lymphocyte (e.g., Y0, NS0, sp20 cell). In one embodiment, a method of making an anti-C5 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody under conditions suitable for expression of the antibody as described above, and optionally recovering the antibody from the host cell (or host cell culture medium).
For recombinant production of anti-C5 antibodies, nucleic acids encoding the antibodies, e.g., as described above, are isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acids can be readily isolated and sequenced using conventional methods (e.g., using oligonucleotide probes that are capable of specifically binding to genes encoding the heavy and light chains of an antibody).
Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be made in bacteria, particularly when glycosylation and Fc effector function are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. nos. 5,648,237,5,789,199 and 5,840,523. (see also, charlton, methods in Molecular Biology, vol.248 (B.K.C.Lo, ed., humana Press, totowa, NJ, 2003), pp.245-254, which describes the expression of antibody fragments in E.coli). After expression, the antibody can be isolated from the bacterial cell paste into a soluble fraction and can be further purified.
In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains in which the glycosylation pathway has been "humanized" resulting in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, nat. Biotech.22:1409-1414 (2004), and Li et al, nat. Biotech.24:210-215 (2006).
Host cells suitable for expression of glycosylated antibodies also originate from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Various baculovirus strains have been identified which can be used with insect cells, particularly for transfecting Spodoptera frugiperda (Spodoptera frugiperda) cells.
Plant cell cultures may also be used as hosts. See, for example, U.S. Pat. Nos. 5,959,177,6,040,498,6,420,548,7,125,978 and 6,417,429 (which describe PLANTIBODIIES for the production of antibodies in transgenic plants TM A technique).
Vertebrate cells can also be used as hosts. For example, mammalian cell lines suitable for suspension culture may be useful. Other examples of useful mammalian host cell lines are the SV40 (COS-7) transformed monkey kidney CV1 cell line; human embryonic kidney cell lines (293 or 293 cells as described, for example, in Graham et al, J.Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM 4 cells, as described, for example, in Mather, biol. Reprod.23:243-251 (1980)); monkey kidney cells (CV 1); VERO cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK; buffalo mouse hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells as described, for example, in Mather et al, annals N.Y.Acad.Sci.383:44-68 (1982); MRC 5 cells, and FS4 cells other useful mammalian host cell lines include Chinese Hamster Ovary (CHO) cells, including DHFR - CHO cells (Urlaub et al, proc.Natl.Acad.Sci.USA 77; and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., yazaki and Wu, methods in Molecular Biology, vol.248 (b.k.c.lo, ed., humana Press, totowa, NJ), pp.255-268 (2003).
Polyclonal antibodies are preferably prepared in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and adjuvant. It may be useful to use bifunctional or derivatizing reagents, for example, maleimidobenzoate succinimido ester (conjugated via a cysteine residue), N-hydroxysuccinimido (conjugated via a lysine residue), glutaraldehyde, succinic anhydride, SOCl 2 Or R is 1 N = C = NR, wherein R and R 1 Are different alkyl groups, and the relevant antigen is conjugated to a protein that is immunogenic in the species to be immunized (e.g., keyhole limpet hemocyanin (keyhole limpet hemocyanin), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor).
Animals (typically non-human mammals) are immunized against an antigen, immunogenic conjugate or derivative by combining, for example, 100 μ g or 5 μ g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, animals were boosted with 1/5 to 1/10 of the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. After 7 to 14 days, the animals were bled and the serum was assayed for antibody titer. Animals were boosted until titer plateaus. Preferably, the animal is boosted with conjugates of the same antigen conjugated to different proteins and/or conjugated through different cross-linking agents. Conjugates can also be prepared as protein fusions in recombinant cell culture. In addition, aggregating agents such as alum are useful for enhancing immune responses.
Monoclonal antibodies are obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translational modifications (e.g., isomerization, amidation) that may be present in minor amounts. Thus, the phrase "monoclonal" indicates the antibody characteristics as not being a mixture of separate antibodies.
For example, monoclonal antibodies can be prepared using the hybridoma method first described by Kohler et al, nature 256 (5517): 495-497 (1975). In the hybridoma method, a mouse or other suitable host animal (such as a hamster) is immunized as described above to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro.
The immunological agent will typically comprise an antigenic protein or a fusion variant thereof. Typically, peripheral Blood Lymphocytes (PBLs) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian origin are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusion agent, such as polyethylene glycol, to form a hybridoma cell (Goding, monoclonal Antibodies: principles and Practice, academic Press (1986), pp. 59-103).
Immortalized cell lines are generally transformed mammalian cells, in particular myeloma cells of rodent, bovine and human origin. Typically, rat or mouse myeloma cell lines are employed. The hybridoma cells thus prepared are seeded and cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the non-fused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will contain hypoxanthine, aminopterin, and thymidine (HAT medium), which are substances that prevent the growth of HGPRT-deficient cells.
Preferred immortalized myeloma cells are those that fuse efficiently, support stable high-level production of antibodies by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred are murine myeloma Cell lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, san Diego, calif. USA, and SP-2 cells (and derivatives thereof, e.g., X63-Ag 8-653) available from the American Type Culture Collection (American Type Culture Collection, manassas, virginia USA). Human myeloma and mouse-human hybrid myeloma cell lines have also been described as useful for the Production of human Monoclonal antibodies (Kozbor et al J immunol.133 (6): 3001-3005 (1984); brodeur et al, monoclonal Antibody Production Techniques and Applications, marcel Dekker, inc., new York (1987), pp.51-63).
For the production of monoclonal antibodies against the antigen, the medium in which the hybridoma cells are cultured is determined. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as Radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques and assays are known in the art. For example, binding affinity can be determined by Scatchard analysis of Munson, anal. Biochem.107 (1): 220-239 (1980).
After identifying hybridoma cells that produce antibodies with the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution methods and cultured by standard methods (Goding, supra). A medium suitable for this purpose includes, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells can be cultured in vivo in mammals as tumors.
The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid or serum by conventional immunoglobulin purification methods such as, for example, protein a-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
Antibodies can be prepared by immunizing a suitable host animal against an antigen. In one embodiment, the antigen is a polypeptide comprising full length C5. In one embodiment, the antigen is a polypeptide comprising the beta chain of C5 (SEQ ID NO: 40). In one embodiment, the antigen is a polypeptide comprising the MG1-MG2 domain of the C5 beta chain (SEQ ID NO: 43). In one embodiment, the antigen is a polypeptide comprising the MG1 domain of the C5 beta chain (SEQ ID NO: 41). In one embodiment, the antigen is a polypeptide comprising a region corresponding to amino acids at positions 19 to 180 of the beta chain of C5. In one embodiment, the antigen is a polypeptide comprising a region corresponding to amino acids at positions 33 to 124 of the β chain of C5. In one embodiment, the antigen is a polypeptide comprising a fragment of at least one amino acid 47-57, 70-76 and 107-110 selected from the group consisting of C5 beta chain (SEQ ID NO: 40). In one embodiment, the antigen is a polypeptide comprising a fragment of the beta chain of C5 comprising at least one amino acid selected from the group consisting of: thr47, glu48, ala49, phe50, asp51, ala52, thr53, lys57, his70, val71, his72, ser74, glu76, val107, ser108, lys109, and His110. In one embodiment, the antigen is a polypeptide comprising a fragment of the β chain of C5, said fragment comprising at least one amino acid selected from the group consisting of: glu48, asp51, his70, his72, lys109, and His110. Also included in the invention are antibodies prepared by immunizing an animal against the antigen. The antibody may bind any of the features described above in the "exemplary anti-C5 antibody" (alone or in combination).
C. Measurement of
The anti-C5 antibodies provided herein can be identified, screened or characterized for physical/chemical properties and/or biological activity by a variety of assays known in the art.
1. Binding assays and other assays
In one aspect, for example, the antigen binding activity of the antibody of the present invention is tested by a known method such as ELISA, western blot, BIACORE (registered trademark), and the like.
In another aspect, a competition assay can be used to identify antibodies that compete with anti-C5 antibodies described herein for binding to C5. In certain embodiments, when such a competing antibody is present in excess, it blocks (e.g., reduces) the binding of the reference antibody to C5 by at least 10%,15%,20%,25%,30%,35%,40%,45%,50%,55%,60%,65%,70%,75%, or more. In some cases, binding is inhibited by at least 80%,85%,90%,95% or more. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or conformational epitope) as an anti-C5 antibody described herein (e.g., an anti-C5 antibody described in table 2). A detailed exemplary method for Mapping the Epitope to which an antibody binds is provided in Morris "Epitope Mapping Protocols," Methods in Molecular Biology vol.66 (Humana Press, totowa, NJ) (1996).
In an exemplary competition assay, immobilized C5 is incubated in a solution comprising a first labeled (reference) antibody that binds to C5 and a second unlabeled antibody that is tested for its ability to compete with the first antibody for binding to C5. The second antibody may be present in the hybridoma supernatant. As a control, immobilized C5 was incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow the first antibody to bind to C5, excess unbound antibody is removed and the amount of label bound to the immobilized C5 is measured. If the amount of label bound to immobilized C5 is significantly reduced in the test sample relative to the control sample, this indicates that the second antibody competes with the first antibody for binding to C5. See, harlow and Lane, antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, cold Spring Harbor, N.Y.) (1988).
In another exemplary competition assay, BIACORE (registered trademark) analysis is used to determine the ability of a test anti-C5 antibody to compete with a second (reference) anti-C5 antibody for binding to C5. In another aspect of operating the BIACORE (registered trademark) instrument (e.g., BIACORE (registered trademark) 3000) according to the manufacturer's recommendations, the C5 protein is captured on a CM5BIACORE (registered trademark) chip using standard techniques known in the art to produce a C5 coated surface. Typically, 200-800 response units of C5 are coupled to the chip (the amount readily provides a measurable level of binding and can be readily saturated by the concentration of test antibody used). Two antibodies to be evaluated for their ability to compete with each other (i.e., the test antibody and the reference antibody) were mixed in a suitable buffer at a 1. When calculating the concentration based on the binding sites, the molecular weight of the test or reference antibody is assumed to be the total molecular weight of the corresponding antibody divided by the number of C5 binding sites on the antibody. The concentration of each antibody (i.e., test antibody and reference antibody) in the test mixture should be sufficiently high to readily saturate the binding sites for the antibodies captured on the C5 molecules on the BIACORE (registered trademark) chip. The test and reference antibodies in the mixture are at the same molar concentration (based on binding), typically 1.00 to 1.5 μ M (based on binding site). Separate solutions containing only the test antibody and only the reference antibody were also prepared. The test and reference antibodies in these solutions should be in the same buffer and at the same concentrations and conditions as in the test mixture. Test mixtures containing test and reference antibodies were passed over C5 coated BIACORE (registered trade mark) chips and the total amount bound was recorded. The chip is then treated to remove the bound test or reference antibody without destroying the C5 bound to the chip. Typically, this is done by treating the chip with 30mM HC1 for 60 seconds. A solution of the test antibody alone was then passed over the C5 coated surface and the amount of binding was recorded. The chip was again treated to remove all bound antibody without destroying the C5 bound to the chip. A solution of the reference antibody alone was then passed over the C5 coated surface and the amount of binding recorded. The maximum theoretical binding of the mixture of test and reference antibodies, which is the sum of the binding of each antibody (i.e., test and reference) when passed individually over the C5 surface, was next calculated. If the binding of the mixture actually recorded is less than this theoretical maximum, the test antibody and the reference antibody compete with each other for binding to C5. Thus, typically, the competition test anti-C5 antibody is one that binds C5 in the BIACORE (registered trademark) blocking assay above such that during the assay and in the presence of the reference anti-C5 antibody, the binding recorded is 80% to 0.1% (e.g. 80% > to 4%) of the maximum theoretical binding (as defined above) of the combination of the test antibody and the reference antibody, specifically 75% to 0.1% (e.g. 75% to 4%) of the maximum theoretical binding, and more specifically 70% to 0.1% (e.g. 70% to 4%) of the maximum theoretical binding.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from antibodies CFA0341 and CFA 0330. In some embodiments, the anti-C5 antibody competes for binding to C5 with an antibody selected from the group consisting of: CFA0538, CFA0501, CFA0599, CFA0307, CFA0366, CFA0675, and CFA0672. In some embodiments, the anti-C5 antibody competes with antibody CFA0329 for binding to C5. In some embodiments, the anti-C5 antibody competes with antibody CFA0666 for binding to C5.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising the VH and VL pair of antibody CFA0305 or 305LO 5.
In further embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH. In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: CFA0538, CFA0501, CFA0599, CFA0307, CFA0366, CFA0675, and CFA0672. In some embodiments, the anti-C5 antibody competes with antibody CFA0666 for binding to C5. In another embodiment, the anti-C5 antibody binds C5 with greater affinity at pH7.4 than at pH 5.8.
In further embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH. In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising the VH and VL pair of antibody CFA0305 or 305LO 5. In another embodiment, the anti-C5 antibody binds C5 with greater affinity at pH7.4 than at pH 5.8.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: VH of SEQ ID NO. 22 and VL of SEQ ID NO. 26, or VH of SEQ ID NO. 21 and VL of SEQ ID NO. 25. In some embodiments, the anti-C5 antibody competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (b) the VH of SEQ ID NO:4 and the VL of SEQ ID NO: 14; (c) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (d) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (e) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (f) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (g) the VH of SEQ ID NO:9 and the VL of SEQ ID NO: 19; (h) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; and (i) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18. In some embodiments, the anti-C5 antibody competes for binding to C5 with an antibody comprising the VH of SEQ ID NO. 23 and the VL of SEQ ID NO. 27. In some embodiments, the anti-C5 antibody competes for binding to C5 with an antibody comprising the VH of SEQ ID NO. 7 and the VL of SEQ ID NO. 17.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (b) the VH of SEQ ID NO:22 and the VL of SEQ ID NO: 26; (c) the VH of SEQ ID NO:21 and the VL of SEQ ID NO: 25; (d) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (e) the VH of SEQ ID NO:4 and the VL of SEQ ID NO: 14; (f) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (g) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (h) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (i) the VH of SEQ ID NO:9 and the VL of SEQ ID NO: 19; (j) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; (k) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18; (l) the VH of SEQ ID NO:23 and the VL of SEQ ID NO: 27; and (m) the VH of SEQ ID NO:10 and the VL of SEQ ID NO: 20.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:22 and the VL of SEQ ID NO: 26; (b) the VH of SEQ ID NO:21 and the VL of SEQ ID NO: 25; (c) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (d) the VH of SEQ ID NO. 4 and the VL of SEQ ID NO. 14; (e) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (f) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (g) the VH of SEQ ID NO:3 and the VL of SEQ ID NO: 13; (h) the VH of SEQ ID NO 9 and the VL of SEQ ID NO 19; (i) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; (j) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18; (k) the VH of SEQ ID NO:23 and the VL of SEQ ID NO: 27.
In certain embodiments, an anti-C5 antibody of the invention competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of the VH of SEQ ID NO. 1 and the VL of SEQ ID NO. 11, or the VH of SEQ ID NO. 10 and the VL of SEQ ID NO. 20.
In further embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH. In certain embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH and competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (b) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (c) the VH of SEQ ID NO. 4 and the VL of SEQ ID NO. 14; (d) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (e) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (f) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (g) the VH of SEQ ID NO:9 and the VL of SEQ ID NO: 19; (h) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; (i) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18; and (j) the VH of SEQ ID NO:10 and the VL of SEQ ID NO: 20. In another embodiment, the anti-C5 antibody binds C5 with greater affinity at pH7.4 than at pH 5.8.
In some embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH and competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of: (a) the VH of SEQ ID NO:5 and the VL of SEQ ID NO: 15; (b) the VH of SEQ ID NO:4 and the VL of SEQ ID NO: 14; (c) the VH of SEQ ID NO:6 and the VL of SEQ ID NO: 16; (d) the VH of SEQ ID NO:2 and the VL of SEQ ID NO: 12; (e) the VH of SEQ ID NO 3 and the VL of SEQ ID NO 13; (f) the VH of SEQ ID NO:1 and the VL of SEQ ID NO: 11; (g) the VH of SEQ ID NO 9 and the VL of SEQ ID NO 19; (h) the VH of SEQ ID NO:7 and the VL of SEQ ID NO: 17; and (i) the VH of SEQ ID NO:8 and the VL of SEQ ID NO: 18. In another embodiment, the anti-C5 antibody binds C5 with higher affinity at pH7.4 than at pH 5.8.
In some embodiments, the anti-C5 antibody binds C5 with higher affinity at neutral pH than at acidic pH and competes for binding to C5 with an antibody comprising a VH and VL pair selected from the group consisting of the VH of SEQ ID NO:1 and the VL of SEQ ID NO:11, or the VH of SEQ ID NO:10 and the VL of SEQ ID NO: 20. In another embodiment, the anti-C5 antibody binds C5 with greater affinity at pH7.4 than at pH 5.8.
In certain embodiments, whether an anti-C5 antibody of the invention binds a particular epitope can be determined as follows: a C5 site mutant in which an amino acid on C5 (except alanine) was substituted for alanine was expressed in 293 cells, and binding of the anti-C5 antibody to the C5 mutant was tested via ELISA, western blot or BIACORE (registered trademark); wherein a significant reduction or elimination of the binding of the anti-C5 antibody to the C5 mutant relative to its binding to wild type C5 indicates that the anti-C5 antibody binds to an epitope on C5 comprising said amino acid. In certain embodiments, the amino acid to be substituted with alanine on C5 is selected from the group consisting of: glu48, asp51, his70, his72, lys109, and His110 of the C5 beta strand (SEQ ID NO: 40). In another embodiment, the amino acid to be substituted with alanine on C5 is Asp51 or Lys109 of the beta chain of C5 (SEQ ID NO: 40).
In another embodiment, whether an anti-C5 antibody with pH-dependent binding characteristics binds to a particular epitope can be determined as follows: a C5 site mutant in which the histidine residue on C5 was substituted with another amino acid (e.g., tyrosine) was expressed in 293 cells, and binding of the anti-C5 antibody to the C5 mutant was tested via ELISA, western blot or BIACORE (registered trademark); wherein binding of the anti-C5 antibody to wild-type C5 is significantly reduced at acidic pH relative to its binding to the C5 mutant at acidic pH, indicating that the anti-C5 antibody binds to an epitope on C5 comprising said histidine residue. In further embodiments, the binding of the anti-C5 antibody to wild-type C5 at neutral pH is not significantly reduced relative to its binding to the C5 mutant at neutral pH. In certain embodiments, the histidine residue on C5 to be substituted with another amino acid is selected from the group consisting of: his70, his72, and His110 of the C5 beta strand (SEQ ID NO: 40). In another embodiment, the histidine residue His70 is replaced with tyrosine.
2. Activity assay
In one aspect, assays are provided for identifying anti-C5 antibodies having biological activity. Biological activities may include, for example, inhibiting activation of C5, preventing C5 from being cleaved to form C5a and C5b, preventing C5 convertase access to cleavage sites on C5, blocking hemolytic activity caused by activation of C5, and the like. Antibodies having such in vivo and/or in vitro biological activity are also provided.
In certain embodiments, the antibodies of the invention are tested for such biological activity.
In certain embodiments, whether a test antibody inhibits cleavage of C5 into C5a and C5b is determined by methods such as those described in Isenman et al, J Immunol.124 (1): 326-331 (1980). In another embodiment, this is determined by a method for specifically detecting cleaved C5a and/or C5b proteins (e.g., ELISA or western blot). When a decrease in the amount of cleavage products (i.e., C5a and/or C5 b) of C5 is detected in the presence of (or after contact with) the test antibody, the test antibody is identified as an antibody capable of inhibiting C5 cleavage. In certain embodiments, the concentration and/or physiological activity of C5a can be determined by methods such as chemotaxis assays, RIA or ELISA (see, e.g., ward and Zvaiffer J. Clin. Invest.50 (3): 606-616 (1971)).
In certain embodiments, whether the test antibody prevents C5 convertase access to C5 is determined by a method for detecting protein interactions between C5 convertase and C5 (e.g., ELISA or BIACORE (registered trademark)). When the interaction is reduced in the presence of (or after contact with) the test antibody, the test antibody is identified as an antibody that prevents access of C5 convertase to C5.
In certain embodiments, C5 activity may be measured as a function of its cytolytic capacity in a body fluid of the subject. The cytolytic capacity of C5 or its reduction can be measured by methods known in the art, e.g.conventional hemolytic assays, such as the hemolytic assay described by Kabat and Mayer (eds.), experimental biochemistry, 2 nd edition, 135-240, springfield, IL, CC Thomas (1961), pages 135-139, or conventional variations of said assays, such as the chicken erythrocyte hemolytic method described, for example, in Hillmen et al, N.Engl.J.Med.350 (6): 552-559 (2004). In certain embodiments, the CH50eq assay is used to quantify C5 activity or inhibition thereof. The CH50eq assay is a method for measuring total classical complement activity in serum. The test is a lysis assay that uses antibody-sensitized red blood cells as activators of the classical complement pathway, and different dilutions of test sera to determine the amount required to produce 50% lysis (CH 50). The percentage of hemolysis can be determined, for example, using a spectrophotometer. The CH50eq assay provides an indirect measurement of final complement complex (TCC) formation, as TCC itself is directly responsible for the measured hemolysis. Inhibition of C5 activation may also be detected and/or measured using the methods given and exemplified in the working examples. Using these or other suitable types of assays, candidate antibodies that are capable of inhibiting C5 activation can be screened. In certain embodiments, inhibiting C5 activation comprises: c5 activation is reduced in the assay by at least 5%,10%,15%,20%,25%,30%,35%, or more than 40% as compared to the effect of a negative control under similar conditions. In some embodiments, it refers to inhibiting C5 activation by at least 45%,50%,55%,60%,65%,70%,75%,80%,85%,90%, or 95% or more.
D. Immunoconjugates
The invention also provides immunoconjugates comprising an anti-C5 antibody herein conjugated to one or more cytotoxic agents such as a chemotherapeutic agent or drug, a growth inhibitory agent, a toxin (e.g., a protein toxin, an enzymatically active toxin of bacterial, fungal, plant or animal origin, or a fragment thereof), or a radioisotope.
In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) in which the antibody is conjugated to one or more drugs, including but not limited to maytansinoids (see U.S. Pat. No. 5,208,020,5,416,064 and european patent EP 0 425 235 B1); auristatins such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. nos. 5,635,483 and 5,780,588, and 7,498,298); dolastatin (dolastatin); calicheamicin (calicheamicin) or a derivative thereof (see U.S. Pat. Nos. 5,712,374,5,714,586,5,739,116,5,767,285,5,770,701,5,770,710,5,773,001 and 5,877,296 Hinman et al, cancer Res.53:3336-3342 (1993); and Lode et al, cancer Res.58:2925-2928 (1998)); anthracyclines (anthracyclines) such as daunomycin (daunomycin) or doxorubicin (doxorubicin) (see Kratz et al, current Med. Chem.13:477-523 (2006); jeffrey et al, bioorganic & Med. Chem. Letters 16; methotrexate (methotrexate); vindesine (vindesine); taxanes (taxanes) such as docetaxel (docetaxel), paclitaxel (paclitaxel), larotaxel (larotaxel), tesetaxel (tesetaxel) and otetaxel (ortataxel); crescent toxin (trichothecene); and CC1065.
In another embodiment, the immunoconjugate comprises an antibody described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria a chain, a non-binding active fragment of diphtheria toxin, exotoxin a chain (from Pseudomonas aeruginosa), ricin a chain, abrin a chain, anemonin a chain, α -sarcina, aleurites fordii protein, dianthin protein, phytolacca Americana protein (PAPI, PAPII, and PAP-S), momordica charantia (momordia) inhibitor, leprosy toxin protein, croton toxin protein, saponaria officinalis (sapaonaria officinalis) inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and triene toxin (tricothecene).
In another embodiment, the immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for making radioconjugates. Examples include At 211 ,I 131 ,I 125 ,Y 90 ,Re 186 ,Re 188 ,Sm 153 ,Bi 212 ,P 32 ,Pb 212 And radioactive isotopes of Lu. When the radioconjugate is used for detection, it may contain radioactive atoms for scintillation studies, for example tc99m or I123, or spin labels for Nuclear Magnetic Resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 (again), iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
Conjugates of the antibody and cytotoxic agent can be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3- (2-pyridyldithio) propionate (SPDP), succinimidyl-4- (N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane hydrochloride (IT), bifunctional derivatives of imidoesters (such as dimethyladipate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), diazide compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazo derivatives (such as bis- (p-diazoniumbenzoyl) -ethylenediamine), diisocyanates (such as toluene 2, 6-diisocyanate), and bis-active fluorine compounds (such as 1, 5-difluoro-2, 4-dinitrobenzene). For example, ricin immunotoxins may be prepared as described in Vitetta et al, science 238 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelator for conjugating radionuclides to antibodies. See WO94/11026. The linker may be a "cleavable linker" which aids in the release of the cytotoxic drug in the cell. For example, acid labile linkers, peptidase sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers can be used (Chari et al, cancer Res.52:127-131 (1992); U.S. Pat. No. 5,208,020).
Immunoconjugates or ADCs herein expressly contemplate, but are not limited to, such conjugates prepared using crosslinker agents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, thio-EMCS, thio-GMBS, thio-KMUS, thio-MBS, thio-SIAB, thio-SMCC and thio-SMPB, and SVSB (succinimidyl- (4-vinylsulfone) benzoate), which are commercially available (e.g., from Pierce Biotechnology, inc., rockford, il., u.s.a.).
E. Methods and compositions for diagnosis and detection
In certain embodiments, any of the anti-C5 antibodies provided herein can be used to detect the presence of C5 in a biological sample. As used herein, the term "detecting" includes quantitative or qualitative detection. In certain embodiments, the biological sample comprises a cell or tissue, such as serum, whole blood, plasma, biopsy sample, tissue sample, cell suspension, saliva, sputum, oral fluid, cerebrospinal fluid, amniotic fluid, ascites, milk, colostrum, mammary secretion, lymph fluid, urine, sweat, tears, gastric fluid, synovial fluid, peritoneal fluid, ocular lens fluid, and mucus.
In one embodiment, anti-C5 antibodies are provided for use in diagnostic or detection methods. In another aspect, a method of detecting the presence of C5 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-C5 antibody as described herein under conditions that allow the anti-C5 antibody to bind to C5, and detecting whether a complex is formed between the anti-C5 antibody and C5. Such methods may be in vitro or in vivo. In one embodiment, the anti-C5 antibody is used to select a subject suitable for treatment with the anti-C5 antibody, e.g., where C5 is a biomarker for selecting a patient.
In another embodiment, the invention provides a method of selecting an individual having a complement-mediated disease or a disorder involving excessive or uncontrolled C5 activation as a suitable therapy for a therapy comprising an anti-C5 antibody of the invention. In certain embodiments, the method comprises: (a) Detecting a genetic change in C5 derived from an individual, and (b) selecting the individual as a therapy suitable for comprising an anti-C5 antibody of the invention when a genetic change is detected in C5 derived from the individual. In another embodiment, the invention provides a method of selecting a therapy for an individual having a complement-mediated disease or a disorder involving excessive or uncontrolled C5 activation. In certain embodiments, the method comprises: (a) Detecting a genetic change in C5 derived from an individual, and (b) selecting for the individual a therapy comprising an anti-C5 antibody of the invention when a genetic change is detected in C5 derived from the individual.
In another embodiment, the invention provides a method of treating an individual having a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In certain embodiments, the method comprises: (ii) (a) detecting a genetic change in C5 derived from an individual, (b) selecting the individual as a therapy suitable for comprising an anti-C5 antibody of the invention when a genetic change is detected in C5 derived from the individual, and (C) administering an anti-C5 antibody of the invention to the individual.
In another embodiment, the invention provides an anti-C5 antibody of the invention for use in treating an individual having a complement-mediated disease or a disorder involving excessive or uncontrolled C5 activation. In certain embodiments, the anti-C5 antibodies of the invention are used to treat the individual when a genetic change is detected in C5 derived from the individual.
In another embodiment, the invention provides an in vitro use of a genetic alteration of C5 for selecting an individual suffering from a complement-mediated disease or a disorder involving excessive or uncontrolled C5 activation as suitable for a therapy comprising an anti-C5 antibody of the invention. In certain embodiments, the individual is selected as appropriate for the therapy when a genetic change is detected in C5 derived from the individual. In another embodiment, the invention provides an in vitro use of a genetic alteration of C5 for selecting a therapy for an individual suffering from a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In certain embodiments, a therapy comprising an anti-C5 antibody of the invention is selected for the individual when a genetic change is detected in C5 derived from the individual.
Some patients with genetic changes in C5 reportedly show poor response to therapies containing existing anti-C5 antibodies (Nishimura et al, n.engl.j.med.370:632-639 (2014)). It is recommended that such patients be treated with a therapy comprising an anti-C5 antibody of the invention, since such antibodies have inhibitory activity on the activation of both C5 variants as well as wild-type C5, as demonstrated in the examples below.
Genetic changes in C5 can be detected by using methods known in the art. Such methods may include, but are not limited to, sequencing, PCR, RT-PCR and hybridization-based methods such as southern blotting or northern blotting. The C5 variant may comprise at least one genetic change. The genetic change may be selected from the group consisting of: V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N and E1437D. Herein, for example, R885H means the genetic change at position 885 with replacement of the arginine by histidine. In certain embodiments, the C5 variant has similar biological activity as wild-type C5.
Exemplary conditions that can be diagnosed using the antibodies of the invention include: rheumatoid Arthritis (RA); systemic Lupus Erythematosus (SLE); lupus nephritis; ischemia Reperfusion Injury (IRI); asthma; paroxysmal Nocturnal Hemoglobinuria (PNH); hemolytic Uremic Syndrome (HUS) (e.g., atypical hemolytic uremic syndrome (aHUS)); dense Deposit Disease (DDD); neuromyelitis optica (NMO); multifocal Motor Neuropathy (MMN); multiple Sclerosis (MS); systemic hardening; macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome; thrombotic Thrombocytopenic Purpura (TTP); spontaneous abortion; epidermolysis bullosa; recurrent abortion; pre-eclampsia (pre-eclampsia); traumatic brain injury; myasthenia gravis; cold agglutinin disease; sjogren's syndrome (Sjogren's syndrome); dermatomyositis; bullous pemphigoid; phototoxic reaction; shiga toxin e.coli-related hemolytic uremic syndrome (Shiga toxin e.coli-related hemolytic uremic syndrome); typical or infectious hemolytic uremic syndrome (tHUS); c3 glomerulonephritis; anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis; humoral and vascular graft rejection; acute antibody-mediated rejection (AMR); graft dysfunction; myocardial infarction; transplanting allogenic body; sepsis; coronary artery disease; hereditary angioedema; dermatomyositis; graves' disease; atherosclerosis; alzheimer's Disease (AD); huntington's disease; creutzfeld-Jacob disease (Creutzfeld-Jacob disease); parkinson's disease; cancer; trauma; septic shock (septic shock); spinal cord injury; uveitis; diabetic eye disease; retinopathy of prematurity; glomerulonephritis; membranous nephritis; immunoglobulin a nephropathy; adult Respiratory Distress Syndrome (ARDS); chronic Obstructive Pulmonary Disease (COPD); cystic fibrosis; hemolytic anemia; paroxysmal cold hemoglobinuria; anaphylactic shock; allergies; osteoporosis; osteoarthritis; hashimoto's thyroiditis; type I diabetes; psoriasis; pemphigus; autoimmune hemolytic anemia (AIHA); idiopathic Thrombocytopenic Purpura (ITP); goodpasture syndrome (Goodpasture syndrome); degos disease (Degos disease); antiphospholipid syndrome (APS); catastrophic APS (casatrophic APS, CAPS)); cardiovascular diseases; myocarditis; cerebrovascular disorders; peripheral vascular disease; renal vascular disease; mesenteric/intestinal vascular disease; vasculitis; henoch-Schonlein purpura nephritis (Henoch-Schonlein purpura nephritis); high's disease (Takayasu's disease); dilated cardiomyopathy; diabetic vascular disease; kawasaki's disease (arteritis); venous Gas Embolism (VGE), restenosis after stent placement; rotational atherectomy (rotational atherectomy); membranous nephropathy; guillain-Barre syndrome (GBS); fisher syndrome (Fisher syndrome); antigen-induced arthritis; inflammation of the synovium; viral infection; bacterial infection; fungal infections; and damage caused by myocardial infarction, cardiopulmonary bypass, and hemodialysis.
In certain embodiments, labeled anti-C5 antibodies are provided. Labels include, but are not limited to, labels or moieties that are directly detected (e.g., fluorescent, chromophore, electron density, chemiluminescent, and radioactive labels), as well as moieties that are indirectly detected, such as enzymes or ligands, for example, by enzymatic reactions or molecular interactions. Exemplary labels include, but are not limited to, radioisotopes 32 P, 14 C, 125 I, 3 H, and 131 fluorophores such as rare earth chelates or fluoresceins andderivatives thereof, rhodamine and derivatives thereof, dansyl, umbelliferone, luciferases such as firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinedione, horseradish peroxidase (HRP), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, carbohydrate oxidase, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidase such as uricase and xanthine oxidase, coupled with an enzyme using hydrogen peroxide to oxidize a dye precursor such as HRP, lactose peroxidase, or microperoxidase, biotin/avidin, spin label, phage label, stable free radical, and the like.
F. Pharmaceutical preparation
Pharmaceutical formulations of anti-C5 antibodies as described herein are prepared in lyophilized formulations or aqueous solutions by mixing the antibody with the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16 th edition, osol, a.ed. (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g. octadecyl dimethyl benzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl p-hydroxybenzoate esters such as methyl or propyl p-hydroxybenzoate; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, aspartic acid, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., zn-protein complexes); and/or a non-ionic surfactant such as polyethylene glycol (PEG). Exemplary pharmaceutical carriers herein also include interstitial drug dispersing agents such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), e.g., human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENEX (registered trademark), baxter International, inc.). Certain exemplary shasegps and methods of use, including rHuPH20, are described in U.S. publication nos. 2005/0260186 and 2006/0104968. In one aspect, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinase.
Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO 2006/044908, the latter formulations comprising a histidine-acetate buffer.
When desired, the formulations herein may also contain more than one active ingredient for a particular indication of treatment, preferably those having complementary activities that do not adversely affect each other. Such active ingredients are suitably present in the combination in an amount effective for the intended use.
The active ingredients can be encapsulated, for example, in microcapsules prepared by coacervation techniques or by interfacial polymerization of, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. This technique is disclosed in Remington's Pharmaceutical Sciences 16 th edition, osol, a.ed. (1980).
Sustained release formulations can be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
Formulations useful for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.
G. Therapeutic methods and compositions
Any of the anti-C5 antibodies provided herein can be used in a method of treatment.
In one aspect, an anti-C5 antibody for use as a medicament is provided. In a further aspect, anti-C5 antibodies are provided for use in treating complement-mediated diseases or disorders involving excessive or uncontrolled C5 activation. In certain embodiments, anti-C5 antibodies for use in a method of treatment are provided. In certain embodiments, the invention provides anti-C5 antibodies for use in a method of treating an individual having a complement-mediated disease or a disorder involving excessive or uncontrolled C5 activation, the method comprising administering to the individual an effective amount of an anti-C5 antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. An "individual" according to any of the above embodiments is preferably a human.
When the antigen is a soluble protein, binding of the antibody to its antigen can result in an increased half-life of the antigen in plasma (i.e., reduced clearance of the antigen from the plasma) because the antibody itself has a longer half-life in plasma and acts as a carrier for the antigen. This is due to the recycling of antigen-antibody complexes by FcRn via the endosomal pathway in cells (ropenian, nat. Rev. Immunol.7 (9): 715-725 (2007)). However, antibodies with pH-dependent binding properties, which bind their antigen in a neutral extracellular environment and release the antigen into an acidic endosomal compartment upon entry into the cell, are expected to have superior properties with respect to their pH-independent binding counterparts in terms of antigen neutralization and clearance (Igawa et al, nat. Biotech., 28 (11): 1203-1207 (2010); devanaboyina et al, mAbs 5 (6): 851-859 (2013); WO 2009/125825).
In another embodiment, the invention provides anti-C5 antibodies for enhancing clearance of C5 from plasma. In certain embodiments, the present invention provides an anti-C5 antibody for use in a method of enhancing clearance of C5 from plasma in an individual, the method comprising administering to the individual an effective amount of the anti-C5 antibody to enhance clearance of C5 from plasma. In one embodiment, the anti-C5 antibody enhances clearance of C5 from plasma compared to a conventional anti-C5 antibody that does not have pH-dependent binding characteristics. An "individual" according to any of the above embodiments is preferably a human.
In another embodiment, the invention provides anti-C5 antibodies for inhibiting the accumulation of C5 in plasma. In certain embodiments, the present invention provides an anti-C5 antibody for use in a method of inhibiting the accumulation of C5 in plasma in an individual, the method comprising administering to the individual an effective amount of the anti-C5 antibody to inhibit the accumulation of C5 in plasma. In one embodiment, the accumulation of C5 in the plasma is the result of the formation of antigen-antibody complexes. In another embodiment, the anti-C5 antibody inhibits the accumulation of C5 in plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. An "individual" according to any of the above embodiments is preferably a human.
The anti-C5 antibodies of the invention can inhibit activation of C5. In another embodiment, the invention provides anti-C5 antibodies for inhibiting the activation of C5. In certain embodiments, the invention provides an anti-C5 antibody for use in a method of inhibiting activation of C5 in an individual, the method comprising administering to the individual an effective amount of an anti-C5 antibody to inhibit activation of C5. In one embodiment, C5-mediated cytotoxicity is inhibited by inhibiting activation of C5. An "individual" according to any of the above embodiments is preferably a human.
In another aspect, the invention provides the use of an anti-C5 antibody in the manufacture or formulation of a medicament. In one embodiment, the medicament is for treating a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In another embodiment, the medicament is for use in a method of treating a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation, the method comprising administering to an individual having a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. An "individual" according to any of the above embodiments is preferably a human.
In another embodiment, the medicament is for enhancing clearance of C5 from plasma. In another embodiment, the medicament is for use in a method of enhancing clearance of C5 from plasma in an individual, the method comprising administering to the individual an effective amount of the medicament to enhance clearance of C5 from plasma. In one embodiment, the anti-C5 antibody enhances clearance of C5 from plasma compared to a conventional anti-C5 antibody that does not have pH-dependent binding characteristics. An "individual" according to any of the above embodiments may be a human.
In another embodiment, the medicament is for inhibiting the accumulation of C5 in plasma. In another embodiment, the medicament is for use in a method of inhibiting the accumulation of C5 in plasma in an individual, the method comprising administering to the individual an effective amount of the medicament to inhibit the accumulation of C5 in plasma. In one embodiment, the accumulation of C5 in plasma is the result of the formation of antigen-antibody complexes. In another embodiment, the anti-C5 antibody inhibits the accumulation of C5 in plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. An "individual" according to any of the above embodiments may be a human.
The anti-C5 antibodies of the invention can inhibit activation of C5. In another embodiment, the medicament is for inhibiting activation of C5. In another embodiment, the medicament is for use in a method of inhibiting activation of C5 in an individual, the method comprising administering to the individual an effective amount of the medicament to inhibit activation of C5. In one embodiment, C5-mediated cytotoxicity is inhibited by inhibiting activation of C5. An "individual" according to any of the above embodiments may be a human.
In another aspect, the invention provides methods for treating complement-mediated diseases or conditions involving excessive or uncontrolled C5 activation. In one embodiment, the method comprises administering to an individual having the complement-mediated disease or disorder involving excessive or uncontrolled C5 activation an effective amount of an anti-C5 antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. An "individual" according to any of the above embodiments may be a human.
In another aspect, the invention provides methods for enhancing clearance of C5 from plasma in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-C5 antibody to enhance clearance of C5 from plasma. In one embodiment, the anti-C5 antibody enhances C5 clearance from plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. In one embodiment, the "individual" is a human.
In another aspect, the invention provides a method for inhibiting the accumulation of C5 in plasma in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-C5 antibody to inhibit the accumulation of C5 in plasma. In one embodiment, the accumulation of C5 in the plasma is the result of the formation of antigen-antibody complexes. In another embodiment, the anti-C5 antibody inhibits the accumulation of C5 in plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. In one embodiment, the "individual" is a human.
The anti-C5 antibodies of the invention can inhibit activation of C5. In another aspect, the invention provides a method for inhibiting activation of C5 in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an anti-C5 antibody to inhibit activation of C5. In one embodiment, C5-mediated cytotoxicity is inhibited by inhibiting activation of C5. In one embodiment, the "individual" is a human.
In another aspect, the invention provides a pharmaceutical formulation comprising any of the anti-C5 antibodies provided herein, e.g., for use in any of the above-described methods of treatment. In one embodiment, the pharmaceutical formulation comprises any of the anti-C5 antibodies provided herein and a pharmaceutically acceptable carrier. In another embodiment, the pharmaceutical formulation comprises any of the anti-C5 antibodies provided herein and at least one additional therapeutic agent.
In another aspect, the pharmaceutical formulation is used to treat a complement-mediated disease or a condition involving excessive or uncontrolled C5 activation. In another embodiment, the pharmaceutical formulation is for enhancing clearance of C5 from plasma. In one embodiment, the anti-C5 antibody enhances C5 clearance from plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. In another embodiment, the pharmaceutical formulation is for inhibiting the accumulation of C5 in plasma. In one embodiment, the accumulation of C5 in plasma is the result of the formation of antigen-antibody complexes. In another embodiment, the anti-C5 antibody inhibits the accumulation of C5 in plasma compared to a conventional anti-C5 antibody that does not have a pH-dependent binding profile. The anti-C5 antibodies of the invention can inhibit activation of C5. In another embodiment, the pharmaceutical formulation is for inhibiting activation of C5. In one embodiment, C5-mediated cytotoxicity is inhibited by inhibiting activation of C5. In another embodiment, the pharmaceutical formulation is administered to an individual suffering from a complement-mediated disease or involving excessive or uncontrolled C5 activation. An "individual" according to any of the above embodiments is preferably a human.
In one aspect, the individual has wild-type C5. In another aspect, the individual has a C5 variant. In certain embodiments, the C5 variant has similar biological activity as wild-type C5. Such C5 variants may comprise at least one change selected from the group consisting of: V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N and E1437D. Here, for example, R885H means a genetic change in which the arginine at position 885 is replaced with histidine.
In another aspect, the invention provides a method for preparing a medicament or pharmaceutical formulation, the method comprising admixing any of the anti-C5 antibodies provided herein with a pharmaceutically acceptable carrier, e.g., for use in any of the above-described methods of treatment. In one embodiment, the method for preparing a medicament or pharmaceutical formulation further comprises adding at least one additional therapeutic agent to the medicament or pharmaceutical formulation.
In certain embodiments, the complement-mediated disease or disorder involving excessive or uncontrolled C5 activation is selected from the group consisting of: rheumatoid Arthritis (RA); systemic Lupus Erythematosus (SLE); lupus nephritis; ischemia Reperfusion Injury (IRI); asthma; paroxysmal Nocturnal Hemoglobinuria (PNH); hemolytic Uremic Syndrome (HUS) (e.g., atypical hemolytic uremic syndrome (aHUS)); dense Deposit Disease (DDD); neuromyelitis optica (NMO); multifocal Motor Neuropathy (MMN); multiple Sclerosis (MS); systemic hardening; macular degeneration (e.g., age-related macular degeneration (AMD)); hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome; thrombotic Thrombocytopenic Purpura (TTP); spontaneous abortion; epidermolysis bullosa; recurrent abortion; pre-eclampsia; traumatic brain injury; myasthenia gravis; cold agglutinin disease; sjogren's syndrome; dermatomyositis; bullous pemphigoid; phototoxic reaction; shiga toxin escherichia coli-associated hemolytic uremic syndrome; typical or infectious hemolytic uremic syndrome (tHUS); c3 glomerulonephritis; anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis; humoral and vascular graft rejection; acute antibody-mediated rejection (AMR); graft dysfunction; myocardial infarction; transplanting allogenic body; sepsis; coronary artery disease; hereditary angioedema; dermatomyositis; graves' disease; atherosclerosis; alzheimer's Disease (AD); huntington's disease; creutzfeldt-Jakob disease; parkinson's disease; cancer; trauma; septic shock; spinal cord injury; uveitis; diabetic eye disease; retinopathy of prematurity; glomerulonephritis; membranous nephritis; immunoglobulin a nephropathy; adult Respiratory Distress Syndrome (ARDS); chronic Obstructive Pulmonary Disease (COPD); cystic fibrosis; hemolytic anemia; paroxysmal cold hemoglobinuria; anaphylactic shock; allergies; osteoporosis; osteoarthritis; hashimoto's thyroiditis; type I diabetes; psoriasis; pemphigus; autoimmune hemolytic anemia (AIHA); idiopathic Thrombocytopenic Purpura (ITP); goodpasture's syndrome; degos' disease; antiphospholipid syndrome (APS); catastrophic APS (CAPS); cardiovascular diseases; myocarditis; cerebrovascular disorders; peripheral vascular disease; renal vascular disease; mesenteric/intestinal vascular disease; vasculitis; allergic purpuric nephritis; high security disease; dilated cardiomyopathy; diabetic vascular disease; kawasaki disease (arteritis); venous Gas Embolism (VGE), restenosis after stent placement; performing rotational grinding; membranous nephropathy; guillain-Barre syndrome (GBS); fisher's syndrome; antigen-induced arthritis; inflammation of the synovium; viral infection; bacterial infection; fungal infections; and damage caused by myocardial infarction, cardiopulmonary bypass, and hemodialysis.
In certain embodiments, the complement-mediated disease or disorder is an ocular disease or disorder. In another embodiment, the ocular disorder is macular degeneration. In another embodiment, the macular degeneration is AMD. In another embodiment, the AMD is dry form AMD.
In certain embodiments, the complement-mediated disease or disorder is PNH.
In certain embodiments, the complement-mediated disease or disorder is myocardial infarction.
In certain embodiments, the complement-mediated disease or disorder is RA.
In certain embodiments, the complement-mediated disease or disorder is osteoporosis or osteoarthritis.
In certain embodiments, the complement-mediated disease or disorder is inflammation.
In certain embodiments, the complement-mediated disease or disorder is cancer.
The antibodies of the invention may be used therapeutically alone or in combination with other agents. For example, an antibody of the invention can be co-administered with at least one additional therapeutic agent.
Such combination therapies described above include both combined administration (where two or more therapeutic agents are contained in the same or separate formulations) and separate administration, in which case administration of the antibody of the invention may occur prior to, concurrently with, and/or after administration of the additional therapeutic agent or agents. In one embodiment, administration of the anti-C5 antibody and administration of the additional therapeutic agent occur within about one month of each other, or within about one week, two weeks, or three weeks, or within about one day, two days, three days, four days, five days, or six days of each other.
The antibodies of the invention (and any additional therapeutic agents) may be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if topical treatment is desired, intralesional. Parenteral infusion includes intramuscular administration, intravenous administration, intraarterial administration, intraperitoneal administration, or subcutaneous administration. Administration may be by any suitable route, e.g., by injection, such as intravenous or subcutaneous injection, depending in part on whether administration is transient or chronic. Various dosing regimens are contemplated herein, including but not limited to a single administration or multiple administrations at multiple time points, bolus administration, and pulsed infusion.
The antibodies of the invention can be formulated, administered and administered in a manner consistent with good medical practice. Factors to be considered in this context include the particular disease being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause, the site of agent delivery, the method of administration, the timing of administration, and other factors known to medical practitioners. The antibodies need not be, but are optionally, formulated with one or more agents currently used to prevent or treat the target disease. The effective amount of such other agents will depend on the amount of antibody present in the formulation, the type of disease or treatment, and other factors discussed above. These are generally used at the same dosages and routes of administration as described herein, or at about 1 to 99% of the dosages described herein, or at any dosage and any route empirically/clinically determined to be appropriate.
For the prevention or treatment of disease, the appropriate dosage of an antibody of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for prophylactic or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The antibody is suitably administered to the patient at once or over a series of treatments. Depending on the type and severity of the disease, about 1 μ g/kg to 15mg/kg (e.g., 0.1mg/kg-10 mg/kg) of the antibody may be an initial candidate dose for administration to a patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dose may be from about 1. Mu.g/kg to over 100mg/kg, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the conditions, the treatment will generally be continued until the desired suppression of disease symptoms occurs. An exemplary dose of the antibody is about 0.05mg/kg to about 10mg/kg. Thus, one or more doses, about 0.5mg/kg,2.0mg/kg,4.0mg/kg or 10mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g., once per week or once per three weeks (e.g., such that the patient receives about two to about twenty, or, e.g., about six doses of antibody). An initial higher loading dose may be administered followed by one or more lower doses. The course of treatment can be readily monitored by conventional techniques and assays.
It is to be understood that any of the above formulations or methods of treatment may be carried out using the immunoconjugates of the invention (either in place of or in addition to the anti-C5 antibody).
H. Article of manufacture
In another aspect of the invention, articles of manufacture are provided that comprise materials useful in the treatment, prevention and/or diagnosis of the above-mentioned diseases. The article comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The container may be made of a variety of materials, such as glass or plastic. The container holds a composition, either alone or in combination with another composition effective for treating, preventing and/or diagnosing a condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The indicia or package insert indicates that the composition is for use in treating the selected condition. Further, the article of manufacture may comprise (a) a first container having a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container having a composition contained therein, wherein the composition further comprises a cytotoxic or other therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the composition may be used to treat a particular condition. Alternatively, or in addition, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, ringer's solution and dextrose solution. It may also contain other materials as desired by the commercial or user, including other buffers, diluents, fillers, needles and syringes.
It is to be understood that any of the above-described preparations may include an immunoconjugate of the invention in place of, or in addition to, an anti-C5 antibody.
Examples
The following are examples of the methods and compositions of the present invention. It is to be understood that various other embodiments may be practiced given the general description provided above.
Example 1
Preparation of C5
1.1. Expression and purification of recombinant human and cynomolgus C5
Recombinant human C5 (NCBI GenBank accession: NP-001726.2, SEQ ID NO. Conditioned medium expressing human C5 was diluted with an equal volume of milliQ water and then applied to a Q-sepharose FF or Q-sepharose HP anion exchange column (GE healthcare, uppsala, sweden) followed by elution with a NaCl gradient. The fractions containing human C5 were pooled and then the salt concentration and pH were adjusted to 80mM NaCl and pH6.4, respectively. The resulting sample was applied to an SP-sepharose HP cation exchange column (GE healthcare, uppsala, sweden) and eluted with a NaCl gradient. Fractions containing human C5 were pooled and passed through a CHT ceramic hydroxyapatite column (Bio-Rad Laboratories, hercules, calif., USA). The human C5 eluate was then applied to a Superdex 200 gel filtration column (GE healthcare, uppsala, sweden). Fractions containing human C5 were pooled and stored at-150 ℃.
Expression and purification of recombinant cynomolgus monkey C5 (NCBI GenBank accession # XP-005580972, SEQ ID NO.
1.2. Purification of cynomolgus monkey from plasma C5 (cynoC 5)
Plasma samples from cynomolgus monkeys were applied to SSL 7-agarose (Invivogen, san Diego, CA, USA) followed by elution with 100mM sodium acetate ph 3.5. The fraction containing cynoC5 was immediately neutralized and passed through a protein a HP column (GE healthcare, uppsala, sweden) together with peptide M sepharose (Invivogen, san Diego, CA, USA). The flow-through fraction was then applied to a Superdex 200 gel filtration column (GE healthcare, uppsala, sweden). The fractions containing cynoC5 were pooled and stored at-80 ℃.
Example 2
Generation of anti-C5 antibodies
2.1. Antibody screening
anti-C5 antibodies were prepared, selected and assayed as follows:
NZW rabbits 12-16 weeks old were immunized intradermally with human C5 and/or monkey C5 (50-100. Mu.g/dose/rabbit). This dose was repeated 4-5 times over a 2 month period. One week after the final immunization, spleen and blood were collected from the immunized rabbits. Antigen-specific B-cells were stained with labeled antigen, sorted with FCM Cell sorter (FACS aria III, BD), and plated at a density of one Cell/well in 96-well plates with 25,000 cells/well of EL4 cells (European Collection of Cell Cultures) and 20-fold diluted activated rabbit T-Cell conditioned medium, and cultured for 7-12 days. EL4 cells were treated with mitomycin C (Sigma, cat # M4287) for 2 hours and washed 3 times in advance. Activated rabbit T-cell conditioned media was prepared by culturing rabbit thymocytes in RPMI-1640 containing phytohemagglutinin-M (Roche, catalog No. 1 1082132-001), phorbol 12-myristate 13-acetate (Sigma, catalog No. P1585) and 2% FBS. After incubation, the B-cell culture supernatant was collected for further analysis and the cell pellet (pellet) was frozen.
An ELISA assay was used to test the specificity of the antibodies in the B-cell culture supernatant. 50nM streptavidin in PBS (GeneScript, cat. No. Z02043) was coated on 384-well MAXISORP (Nunc, cat. No. 164688) for 1 hour at room temperature. The plates were then blocked with Blocking One (Nacalai Tesque, cat. No. 03953-95) diluted 5-fold. Human or monkey C5 was labeled with NHS-PEG 4-biotin (PIERCE, cat # 21329) and added to the blocked ELISA plate, incubated for 1 hour and washed. B-cell culture supernatant was added to ELISA plates, incubated for 1 hour and washed. Binding was detected by goat anti-rabbit IgG-horseradish peroxidase (BETHYL, cat. No. A120-111P) followed by additional ABTS (KPL, cat. No. 50-66-06).
An ELISA assay was used to assess pH-dependent binding of the antibody to C5. Goat anti-rabbit IgG-Fc (BETHYL, cat. No. A120-111A) diluted to 1. Mu.g/ml with PBS (-) was added to 384-well MAXISORP (Nunc, cat. No. 164688),incubate for 1 hour at room temperature and block with Blocking One (Nacalai Tesque, cat. No. 03953-95) diluted 5-fold. After incubation, the plates were washed and B-cell culture supernatant was added. Plates were incubated for 1 hour, washed, and 500pM biotinylated human or monkey C5 was added and incubated for 1 hour. After incubation, the plates were washed and incubated with pH7.4MES buffer (20mM MES,150mM NaCl and 1.2mM CaCl) 2 ) Or pH5.8 MES buffer (20mM MES,150mM NaCl and 1mM EDTA) at room temperature for 1 hour. After incubation, binding of biotinylated C5 was detected by streptavidin-horseradish peroxidase conjugate (Thermo Scientific, catalog No. 21132) followed by addition of ABTS (KPL, catalog No. 50-66-06).
The Octet RED384 system (Pall Life Sciences) was used to assess the affinity and pH-dependent binding of antibodies to C5. Secreted antibodies in B-cell culture supernatants were loaded onto protein a biosensor tips (Pall Life Sciences) and immersed in 50nM human or monkey C5 in ph7.4 MES buffer to analyze binding kinetics. Dissociation kinetics were analyzed in pH7.4 MES buffer and pH5.8 MES buffer.
A total of 41,439B-cell lines were screened for affinity and pH-dependent binding to human or monkey C5 and 677 cell lines were selected and designated CFA0001-0677. RNA from the selected cell lines was purified from the cryopreserved cell pellets using the ZR-96Quick-RNA kit (ZYMO RESEARCH, cat. No. R1053). The DNA encoding the heavy chain variable region of the antibody in the selected cell line was amplified by reverse transcription PCR and recombined with the DNA encoding the constant region of the heavy chain of F760G4 (SEQ ID NO: 33) or F939G4 (SEQ ID NO: 34). The DNA encoding the antibody light chain variable region was amplified by reverse transcription PCR and recombined with the DNA encoding the k0MTC light chain constant region (SEQ ID NO: 36). The heavy and light chain genes of the existing humanized anti-C5 antibody eculizumab (EcuH-G2G 4, SEQ ID NO:29 and EcuL-k0, SEQ ID NO: 30) were synthesized separately. The DNA encoding VH (EcuH, SEQ ID NO: 31) was fused in-frame with the DNA encoding modified human IgG4 CH (F760G 4, SEQ ID NO: 33), and the DNA encoding VL (EcuL, SEQ ID NO: 32) was fused in-frame with the DNA encoding the k0 light chain constant region (SEQ ID NO: 37). The coding sequence of each fusion was also cloned into an expression vector. Placing the antibody in FreeStyle TM 293-F cells (Invit)rogen) and purified from culture supernatants to assess functional activity. The neutralizing activity of the antibodies was assessed by testing for inhibition of complement activity using a liposome lysis assay, as described in example 5.1.
2.2. Epitope-framing by sandwich ELISA
anti-C5 antibodies with high affinity, pH-dependent or neutralizing activity were selected for further analysis. Sandwich ELISA assays were used to group selected antibodies into different epitope boxes that bind the same or overlapping epitopes of C5 protein. Unlabeled capture antibody was diluted to 1. Mu.g/ml with PBS (-) and added to 384-well MAXISORP plates (Nunc, cat. No. 164688). The plates were incubated at room temperature for 1 hour and blocked with 5-fold diluted Blocking One (Nacalai Tesque, cat. No. 03953-95). The plates were incubated for 1 hour, washed, and 2nM human C5 was added and incubated for 1 hour. After incubation, the plates were washed and labeled detection antibody (1. Mu.g/mL, biotinylated by NHS-PEG 4-biotin) was added. After 1 hour incubation, binding of biotinylated antibody was detected by streptavidin-horseradish peroxidase conjugate (Thermo Scientific, cat. No. 21132) followed by addition of ABTS (KPL, cat. No. 50-66-06).
All anti-C5 antibodies were used as both capture and detection antibodies and were fully paired. As shown in fig. 1, competing antibodies were classified into 7 epitope boxes: CFA0668, CFA0334 and CFA0319 are grouped into epitope a, CFA0647, CFA0589, CFA0341, CFA0639, CFA0635, CFA0330 and CFA0318 are grouped into epitope B, CFA0538, CFA0501, CFA0599, CFA0307, CFA0366, CFA0305, CFA0675, CFA0666 and CFA0672 are grouped into epitope C, eculizumab and CFA0322 are grouped into epitope D, CFA0329 is grouped into epitope E, CFA0359 and CFA0217 are grouped into epitope F, and CFA0579, CFA0328 and CFA0272 are grouped into epitope G. FIG. 1 shows the epitope boxes of some anti-C5 chimeric antibodies. The VH and VL sequences of the anti-C5 antibodies grouped into epitope C are listed in table 2.
[ Table 2]
anti-C5 antibodies grouped into epitope C
2.3. Humanization and optimization
The variable regions of some anti-C5 antibodies are humanized to reduce the potential immunogenicity of the antibody. The Complementarity Determining Regions (CDRs) of an anti-C5 rabbit antibody were grafted onto a homologous human antibody Framework (FR) using a conventional CDR grafting method (Nature 321-522 (1986)). Genes encoding humanized VH and VL were synthesized and combined with modified human IgG4 CH (SG 402, SEQ ID NO: 35) and human CL (SK 1, SEQ ID NO: 38), respectively, and the sequences of each combination were cloned into an expression vector.
Several mutations and combinations of mutations were detected to identify mutations and combinations of mutations that improve the binding properties of some of the lead antibodies. Multiple mutations are then introduced into the humanized variable regions to enhance the binding affinity to C5 at neutral pH or to reduce the binding affinity to C5 at acidic pH. Thus an optimized variant was produced by CFA0305, 305LO5 (VH, SEQ ID NO:10 VL, SEQ ID NO:20 HVR-H1, SEQ ID NO:54 HVR-H2, SEQ ID NO:64 HVR-H3, SEQ ID NO:74 HVR-L1, SEQ ID NO:84 HVR-L2, SEQ ID NO:94; and HVR-L3, SEQ ID NO: 104.
The antibodies were expressed in HEK293 cells co-transfected with a mixture of heavy and light chain expression vectors and purified by protein a.
Example 3
Binding characterization of anti-C5 antibodies
3.1. Expression and purification of recombinant antibodies
Recombinant antibodies were transiently expressed using FreeStyle293-F cell line (Thermo Fisher, carlsbad, calif., USA). Purification from conditioned media expressing antibodies was performed using protein a using conventional methods. If necessary, further gel filtration was performed.
3.2. Evaluation of pH dependence
Kinetic parameters of anti-C5 antibody against recombinant human C5 were evaluated at pH7.4 and pH5.8 using BIACORE (registered trademark) T200 instrument (GE Healthcare). ProA/G (Pier) was prepared using an amine coupling kit (GE Healthcare) according to the GE Healthcare recommended settings ce) is fixed on the CM4 sensor chip. The antibody and analyte were diluted to the respective running buffers ACES pH7.4 and pH5.8 (20mM ACES,150mM NaCl,1.2mM CaCl 2 ,0.05%Tween20,0.005%NaN 3 ) In (1). Each antibody was captured on the sensor surface by ProA/G. Antibody capture levels are typically 60-90 Response Units (RU). Recombinant human C5 was then injected at concentrations of 10 and 20nM or 20 and 40nM, followed by dissociation. The surface was regenerated using 25mM NaOH. Kinetic parameters were determined under two pH conditions by fitting sensorgrams using a 1. The sensorgrams for all antibodies are shown in fig. 2A and 2B. The binding rate (ka), dissociation rate (KD) and binding affinity (KD) of the antibodies are listed in table 3. All antibodies except CFA0330 (VH, SEQ ID NO:21 and VL, SEQ ID NO: 25) and CFA0341 (VH, SEQ ID NO:22 and VL, SEQ ID NO: 26) all showed a relatively faster off-rate at pH5.8 than at pH 7.4.
[ Table 3]
Kinetic parameters of anti-C5 antibody at pH7.4 and pH5.8
3.3. Cross-reactivity check
In order to observe the cross-reactivity of the anti-C5 antibody to human C5 (hC 5) and cynomolgus monkey C5 (cynoC 5), BIACORE (registered trademark) kinetic analysis was performed. The assay settings were as described in example 3.2, and recombinant cynoC5 was injected at concentrations of 2, 10 and 50 nM. Kinetic parameters were determined by the same data fit as described in example 3.2. The binding kinetics and affinity at pH7.4 are shown in Table 4. The kinetic parameters for hC5 given in table 4 are the results of example 3.2. All anti-C5 antibodies except CFA0672 showed comparable KD for hC5 and cynoC 5. The KD of CFA0672 for cynoC5 is 8 times weaker than the KD for hC 5.
[ Table 4]
Binding kinetics and affinity of anti-C5 antibodies to hC5 and cynoC5 at pH7.4
Example 4
Epitope mapping of anti-C5 antibodies
4.1. anti-C5 MAb binding to C5 beta-chain derived peptides
The binding of anti-C5 monoclonal antibodies (mabs) to C5 β -chain derived peptides was detected in western blot analysis. C5 peptide fused to GST-tag (pGEX-4T-1, GE Healthcare Life sciences, 28-9545-49): 19-180, 161-340, 321-500 and 481-660 were expressed in E.coli (DH 5. Alpha., TOYOBO, DNA-903). Coli samples were harvested after 5 hours incubation with 1mM isopropyl beta-D-1-thiogalactopyranoside (IPTG) at 37 ℃ and centrifuged at 20000x g for 1min to obtain a pellet. The pellet was suspended with sample buffer (2 ME +) (Wako, 191-13272) and used for Western blot analysis. The expression of each peptide was confirmed using an anti-GST antibody (Abcam, ab 9085) (fig. 3). Arrows indicate GST-fused C5 peptides (46-49 kDa). anti-C5 MAb: CFA0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA0675, bound C5 19-180 (FIG. 3).
4.2. Expression and purification of MG1-MG2 Domain (1-225) of human C5
The recombinant MG1-MG2 domain of the human C5. Beta. -chain (SEQ ID NO: 43) was expressed transiently using FreeStyle293-F cell line (Thermo Fisher, carlsbad, CA, USA). The conditioned medium expressing the MG1-MG2 domain was diluted with 1/2 volume of milliQ water before being applied to a Q-sepharose FF anion exchange column (GE healthcare, uppsala, sweden). The flow-through fraction from the anion exchange column was adjusted to pH 5.0 and applied to an SP-sepharose HP cation exchange column (GE healthcare, uppsala, sweden) and eluted with a NaCl gradient. The fractions containing the MG1-MG2 domains were collected from the eluate and subsequently passed through a Superdex 75 gel filtration column (GE healthcare, uppsala, sweden) equilibrated with 1 XPBS. The MG1-MG2 domain containing fractions were then pooled and stored at-80 ℃.
4.3. Ability to bind to the MG1-MG2 domain
The same assay setup as described in example 3.2 was used to measure the binding capacity of anti-C5 antibodies to the MG1-MG2 domain, except that the measurement was performed only under ph7.4 conditions. The MG1-MG2 domains were injected at concentrations of 20nM and 40 nM. As shown in figure 4, all antibodies except eculizumab-F760G 4 showed increased binding reactions, indicating that these antibodies were MG1-MG2 binding agents. eculizumab-F760G 4, a known alpha-chain binding agent, did not show binding to the MG1-MG2 domain.
4.4. anti-C5 MAb binding to C5 MG1-MG2 Domain derived peptides
anti-C5 MAb binding to MG1-MG2 domain derived peptides was tested in Western blot analysis. C5 peptide to be fused to GST-tag: 33-124, 45-124, 52-124, 33-111, 33-108, and 45-111 (SEQ ID NO: 40) are expressed in E.coli. Coli samples were harvested after 5 hours incubation with 1mM IPTG at 37 ℃ and centrifuged at 20000x g for 1min to obtain a pellet. The pellet was suspended with sample buffer (2 ME +) and used for western blot analysis. Expression of C5-derived peptides was confirmed using anti-GST antibody (fig. 5A). CFA0305 only binds 33-124 peptides (FIG. 5B). CFA0305 binds the beta-chain (about 70 kDa) of recombinant human C5 (rhC 5), which is used as a control. FIG. 5C summarizes the reaction of anti-C5 MAb with C5-derived peptides.
4.5. Binding of anti-C5 MAb to C5 mutants
Since three amino acid residues in the C5 β -chain are predicted by crystal structure analysis: e48 D51 and K109, are involved in the binding between C5 and anti-C5-MAb, so the anti-C5 MAb was tested for binding to human C5 point mutants in Western blot analysis. C5 point mutants in which any of E48, D51 and K109 was substituted with alanine by lipofection were expressed in FS293 cells. The medium was harvested 5 days after lipofection and then used for western blotting. SDS-PAGE was performed under reducing conditions. The results are shown in fig. 6. Eculizumab binds to the α -chain of Wild Type (WT) C5 and three C5-site mutants, whereas CFA0305 binds strongly to the β -chain of WT C5, weakly to the β -chain of the E48A C5 mutant, and does not bind to the β -chains of the D51A and K109A C5 mutants, indicating that these 3 amino acid residues are involved in the antibody/antigen interaction. Table 5 gives a summary of western blot analysis of anti-C5 mabs (CFA 0305, CFA0307, CFA0366, CFA0501, CFA0538, CFA0599, CFA0666, CFA0672, and CFA 0675). anti-C5 MAbs were grouped into the same epitope C, but the binding pattern between antibodies was slightly different, indicating that the binding regions of C5 to anti-C5 MAbs were not identical but adjacent to each other.
[ Table 5]
Overview of anti-C5 MAb reaction with C5 mutants
4.6. BIACORE (registered trademark) binding assay of anti-C5 antibody to C5 mutant
To test whether residues E48, G51 and K109 are actually involved in the antibody/antigen interaction, BIACORE (registered trademark) binding assays were performed. Three C5 mutants were prepared: E48A, G51A and K109A as described in example 4.5. A sample of culture supernatant containing mutant C5 overexpressed in FS293 cells was prepared, wherein the mutant C5 was 40. Mu.g/ml. For BIACORE (registered trademark) binding assays, samples were diluted 10X with BIACORE (registered trademark) running buffer (ACES pH7.4, 10mg/ml BSA,1mg/ml carboxymethyl dextran) to a final sample concentration of 4. Mu.g/ml mutant C5.
The interaction of the three C5 mutants with anti-C5 antibodies was evaluated at 37 ℃ using BIACORE (registered trademark) T200 instrument (GE Healthcare) using the assay conditions described in example 3.2. ACES pH7.4 buffer containing 10mg/ml BSA,1mg/ml carboxymethyl dextran was used as running buffer. eculizumab-F760G 4 and 305LO5 were captured on different flow chambers by monoclonal mouse anti-human IgG, fc fragment specific antibody (GE Healthcare). The flow cell 1 is used as a reference surface. Wild type and mutant C5 proteins were injected at a concentration of 4 μ g/ml onto the sensor surface to interact with the captured antibodies. At the end of each analysis cycle, the sensor surface was treated with 3MMgCl 2 And (4) regenerating. The results were analyzed using Bia Evaluation software, version 2.0 (GE Healthcare). The curves for the reference flow cell (flow cell 1) and the blank running buffer injection were subtracted from the curve for the flow cell with captured antibody.
As shown in figure 7, three C5 mutants were able to bind eculizumab with similar binding characteristics compared to wild-type C5. For 305LO5, all three mutants showed lower binding response to 305LO5 compared to wild type C5. The D51A and K109A mutants attenuated the binding of 305LO5 to C5 to baseline levels.
Identification of His residues on C5 that contribute to pH-dependent interactions between anti-C5 antibodies and C5
Crystal structure analysis revealed that 3 histidine residues on human C5 are located at the antibody/antigen interface. Histidine residues with a typical pKa of about 6.0 are known to aid in pH-dependent protein-protein interactions (Igawa et al, biochim Biophys Acta 1844 (11): 1943-1950 (2014)). To investigate which His residues on the antibody/antigen interface contribute to the pH-dependent interaction between anti-C5 antibody and C5, BIACORE (registered trademark) binding assays were performed. Three human C5 mutants with a single His mutation (H70Y, H72Y and H110Y) and mutants with a double His mutation (H70Y + H110Y) were prepared as follows: single His mutants in which any of H70, H72 and H110 was substituted with tyrosine and double His mutants in which both H70 and H110 were substituted with tyrosine were expressed in FS293 cells by lipofection. C5 The antigen binding properties of the His mutant to 305LO5 (pH-dependent anti-C5 antibody) were determined by a modified BIACORE (registered trademark) assay, as described in example 4.6. Briefly, an additional dissociation phase at pH5.8 was integrated into the BIACORE (registered trademark) assay, which immediately follows the dissociation phase at pH7.4, to assess pH-dependent dissociation between antibody and antigen from complexes formed at pH 7.4. The dissociation rate at pH5.8 was determined by processing and fitting the data using Scrubber 2.0 (BioLogic Software) curve fitting Software.
As shown in fig. 8, the C5 single and double His mutations at H70 or H110 (H70 + H110) did not affect C5 binding to 305LO5 at neutral pH. At the same time, a single His mutation at H72 showed a significant impairment of C5 binding to 305LO 5. C5 The dissociation rates of His mutant and C5-wt protein at pH5.8 are shown in Table 6. As shown in table 6, C5-wt showed the fastest dissociation from 305LO5 at ph5.8 among the tested C5 antigens. The single His mutation at H70 showed almost twice as slow off-rate at ph5.8 and the single His mutation at H110 resulted in a slightly slower off-rate at ph5.8 compared to C5-wt. The double His mutations at H70 and H110 resulted in a large effect on pH-dependent binding, with the off-rate at pH5.8 being almost three times slower than C5-wt.
[ Table 6]
C5 Dissociation rate value of His mutant combined with 305LO5 and pH5.8
pH5.8 dissociation rate value for C5 His mutants binding to 305LO5
Example 5
Inhibitory Activity of anti-C5 antibody against C5 activation
5.1. Liposomal lysis with anti-C5 MAb inhibition of complement activation
The inhibition of complement activity by anti-C5 MAb was tested by a liposome lysis assay. mu.L of normal human serum (6.7%) (Biopredic, SER 018) was mixed with 20. Mu.L of diluted MAb in a 96-well plate and incubated for 30min at 25 ℃ on a shaker. Liposomes sensitized with antibodies against dinitrophenyl (Autokit CH50, wako, 995-40801) were transferred to each well and the plates were placed on a shaker at 25 ℃ for 2min. Add 50. Mu.L of substrate solution (Autokit CH 50) to each well and mix with shaking at 25 ℃ for 2min. The final mixture was incubated at 37 ℃ for 40 minutes, after which the OD of the mixture at 340nm was measured. The percentage of liposome lysis was defined as 100 × [ (OD) MAb -OD Serum and liposome background )]/[(OD MAb-free -OD Serum and liposome background )]. Fig. 9A shows anti-C5 Mab: CFA0305, 0307, 0366, 0501, 0538, 0599, 0666, 0672, and 0675, inhibit liposome lysis. Two pH-independent antibodies: CFA0330 and 0341, also inhibited lysis (fig. 9B).
5.2. anti-C5 MAb inhibits C5a production
anti-C5 MAb was tested for C5a production during liposome solubilization to confirm that anti-C5 MAb inhibits C5 cleavage into C5a and C5b. C5a levels in the supernatant from the liposome lysis assay were quantified using a C5a ELISA kit (R & D systems, DY 2037). All mabs inhibited C5a production in the supernatant in a dose-dependent manner (fig. 10A and 10B).
5.3. anti-C5 MAb inhibits hemolysis of complement activation
The inhibition of classical complement activity of anti-C5 MAb was tested in a hemolytic assay. Chicken red blood cells (cRBC) (Innovative research, IC 05-0810) were incubated with MgCl containing 0.5mM 2 And 0.15mM CaCl 2 (GVB + +) washed in gelatin/barbital buffered saline (Boston BioProducts, IBB-300X) and then sensitized with 1. Mu.g/ml of anti-chicken RBC antibody (Rockland 103-4139) for 15 min at 4 ℃. Cells were then washed with GVB + + and washed at 5X10 7 Individual cells/ml were suspended in the same buffer. In a separate round bottom 96-well micro test plate, 50 μ L of normal human serum (20%) (Biopredic, SER 019) was mixed with 50 μ L of diluted Mab and incubated for 30 min at 37 ℃ on a shaker. Then 60 μ L of the sensitized cRBC suspension was added to the serum-containing wells and the antibody mixture was incubated at 37 ℃ for 30 minutes. After incubation, the plates were centrifuged at 1000 × g for 2 min at 4 ℃. The supernatant (100. Mu.L) was transferred to wells of a flat-bottomed 96-well microtest plate for measuring OD at 415nm, with a reference wavelength of 630nm. Percent hemolysis was defined as 100 × [ (OD) MAb -OD Serum and cRBC )]/[(OD MAb-free -OD Serum and cRBC background )]. FIG. 11 shows anti-C5 Mab: CFA0305 and 305LO5, inhibit hemolysis of crbcs.
5.4. anti-C5 MAb inhibits the alternative complement pathway
Hemolysis assay for the alternative pathway was performed in a similar manner to the classical pathway hemolysis assay. Blood collected from new zealand white rabbits (InVivos) was mixed with the same volume of alserver solution (Sigma, a 3551) and the mixture was used as rabbit RBCs (RBCs). rRBC was supplemented with 2mM MgCl 2 GVB Wash with 10mM EGTA and 7X10 8 Each cell/ml was suspended in the same buffer. In a round bottom 96-well microtest plate, 40. Mu.L of normal human serum (25%) (Biopredic, SER 019) was mixed with 40. Mu.L of diluted Mab and incubated for 30 min at 37 ℃ on a shaker. Then 20 μ L of the rRBC suspension was added to the serum-containing wells, andthe antibody mixture was incubated at 37 ℃ for 60 minutes. After incubation, the plates were centrifuged at 1000 × g for 2 min at 4 ℃. The supernatant (70. Mu.L) was transferred to wells on a flat-bottomed 96-well microtest plate for measuring OD at 415nm, with a reference wavelength of 630nm. FIG. 12 shows anti-C5 Mab: CFA0305 and CFA0672, inhibit hemolysis of rbcs, indicating that these antibodies inhibit the alternative complement pathway.
Example 6
Pharmacokinetic Studies of anti-C5 monoclonal antibodies with human C5 in mice
6.1. In vivo testing Using C57BL/6 mice
The In vivo kinetics of human C5 (Calbiochem) and anti-human C5 antibodies were evaluated after administration of human C5 alone or human C5 and anti-human C5 antibodies to C57BL/6 mice (In vivo or Biological Resource center, singapore). Solutions of human C5 solution (0.01 mg/ml) or mixtures containing human C5 and anti-human C5 antibodies (0.01 mg/ml and 2mg/ml (CFA 0305-F760G4, CFA0307-F760G4, CFA0366-F760G4, CFA0501-F760G4, CFA0538-F760G4, CFA0599-F760G4, CFA0666-F760G4, CFA0672-F760G4 and CFA0675-F G4) or 0.2mg/ml (CFA 0330-F760G4 and CFA0341-F760G 4), respectively) were administered in single doses of 10ml/kg into the tail vein. In this case, the anti-human C5 antibody is present in excess relative to human C5, and therefore it is considered that almost everyone C5 binds to the antibody. Blood was collected at 5 minutes, 7 hours, 1 day, 2 days, 3 days and 7 days after administration. The collected blood was immediately centrifuged at 14,000rpm at 4 ℃ for 10 minutes to separate plasma. The separated plasma was stored in a-80 ℃ freezer until assayed. The anti-human C5 antibodies used were CFA0305-F760G4, CFA0307-F760G4, CFA0330-F760G4, CFA0341-F760G4, CFA0366-F760G4, CFA0501-F760G4, CFA0538-F760G4, CFA0599-F760G4, CFA0666-F760G4, CFA0672-F760G4 and CFA0675-F760G4 as described above.
6.2. Measurement of total human C5 plasma concentration by Electrochemiluminescence (ECL) assay
The total concentration of human C5 in mouse plasma was measured by ECL.
In the presence of CFA0330-F760G4, CFA0341-F760G4, or human C5 alone in plasma samples, the following procedure was used. Anti-human C5 antibody (Santa Cruz) was dispensed onto a Multi-ARRAY 96-well bare plate (Meso Scale Discovery) and allowed to stand overnight at 4 ℃ to prepare anti-human C5-immobilized plates. Calibration curve samples were prepared and more than 100-fold mouse plasma samples diluted with 1. Mu.g/ml of injected antibody (CFA 0330-F760G4 or CFA0341-F760G 4) and incubated for 30 minutes at 37 ℃. Subsequently, the sample was dispensed onto a plate on which anti-human C5 was fixed, and allowed to stand at room temperature for 1 hour. Then, a SULFO-TAG labeled anti-human IgG antibody (Meso Scale Discovery) was added to react at room temperature for one hour, and washed. Read buffer T (x 4) (Meso Scale Discovery) was then dispensed immediately and measured using Sector Imager 2400 (Meso Scale Discovery).
In the case where CFA0305-F760G4, CFA0307-F760G4, CFA0366-F760G4, CFA0501-F760G4, CFA0538-F760G4, CFA0599-F760G4, CFA0666-F760G4, CFA0672-F760G4, or CFA0675-F760G4 is present in the plasma sample, the following method is used. Anti-human C5 antibodies (CFA 0329-F939G4; VH, SEQ ID NO:23, and VL, SEQ ID NO: 27) were dispensed onto a multiple-ARRAY 96-well bare plate (Meso Scale Discovery) and left to stand overnight at 4 ℃ to prepare anti-human C5 immobilized plates. Calibration curve samples and mouse plasma samples diluted 100-fold more with an acidic solution (pH 5.5) were prepared and incubated at 37 ℃ for 30 minutes. Subsequently, the sample was dispensed onto a plate on which anti-human C5 was fixed, and allowed to stand at room temperature for 1 hour. Then, SULFO-TAG labeled anti-human C5 antibody (CFA 0300-F939G4; VH, SEQ ID NO:24, and VL, SEQ ID NO: 28) was added to react at room temperature for one hour, and washed. Read buffer T (x 4) (Meso Scale Discovery) was then immediately dispensed and measured using Sector Imager 2400 (Meso Scale Discovery).
Based on the response of the calibration curve, human C5 concentration was calculated using analytical software SOFTmax PRO (Molecular Devices). The time course of plasma human C5 concentrations after intravenous administration as measured by this method is shown in figure 13. Data are plotted as the percentage remaining compared to plasma human C5 concentration at 5 minutes.
6.3. Measurement of anti-human C5 antibody plasma concentrations by ECL assay
The concentration of anti-human C5 antibody in mouse plasma was measured by ECL. Anti-human IgG (gamma-chain specific) F (ab') 2 Antibody fragment (Sigma) or anti-human IgG kappa chain Antibody (Antibody Solutions) was dispensed onto a Multi-ARRAY 96-well bare plate (Meso Scale Discovery) and left to stand overnight at 4 ℃ to prepare a plate immobilized with anti-human IgG. Calibration curve samples and mouse plasma samples diluted 100-fold or more were prepared. Subsequently, the sample was dispensed onto a plate on which anti-human IgG was immobilized, and allowed to stand at room temperature for 1 hour. Then, a biotinylated anti-human IgG antibody or a SULFO-TAG labeled anti-human IgG Fc antibody (southern biotech) was added to react at room temperature for one hour, and washed. Subsequently, only when a biotinylated anti-human IgG antibody was used, SULFO-TAG labeled streptavidin (Meso Scale Discovery) was added to react at room temperature for one hour, and washed. Read buffer T (x 4) (Meso Scale Discovery) was then immediately dispensed and measured using Sector Imager 2400 (Meso Scale Discovery). Based on the response of the calibration curve, the anti-human C5 antibody concentration was calculated using the analytical software SOFTmax PRO (Molecular Devices). The time course of plasma anti-human C5 antibody concentrations after intravenous administration measured by this method is shown in fig. 14. Data are plotted as the percentage remaining compared to plasma anti-human C5 antibody concentration at 5 minutes.
Effect of pH-dependent anti-human C5 antibody binding on human C5 clearance in vivo
The pH-dependent anti-human C5 antibodies (CFA 0305-F760G4, CFA0307-F760G4, CFA0366-F760G4, CFA0501-F760G4, CFA0538-F760G4, CFA0599-F760G4, CFA0666-F760G4, CFA0672-F760G4, and CFA0675-F760G 4) and the pH-independent anti-human C5 antibodies (CFA 0341-F033G 4) were tested in vivo and the resulting plasma anti-human C5 antibody concentrations and plasma human C5 concentrations were compared. As shown in fig. 14, antibody exposure was comparable. At the same time, clearance of human C5 administered simultaneously with the pH-dependent anti-human C5 antibody was accelerated compared to the pH-independent anti-human C5 antibody (fig. 13).
Example 7
Optimized anti-C5 monoclonal antibody (305 variant)
Several mutations were introduced into the optimized variable region of anti-C5 antibody 305LO5 to further improve its properties and to generate optimized variable regions 305LO15, 305LO16, 305LO18, 305LO19, 305LO20, 305LO22 and 305LO 23. The amino acid sequences of VH and VL of 305 variants are listed in tables 7 and 8, respectively. The gene encoding the humanized VH was combined with modified human IgG1 CH variant SG115 (SEQ ID NO: 114), and modified human IgG4 CH variant SG422 (SEQ ID NO: 115) or SG429 (SEQ ID NO: 116). The gene encoding the humanized VL was combined with human CL (SK 1, SEQ ID NO: 38). Heavy and light chain genes encoding humanized anti-C5 antibody BNJ441 (BNJ 441H, SEQ ID NO:149, BNJ441L, SEQ ID NO.
The antibodies were expressed in HEK293 cells co-transfected with a combination of heavy and light chain expression vectors and purified by protein a.
[ Table 7]
305 VH amino acid sequence of variant
[ Table 8]
305 variant VL amino acid sequence
Example 8
Binding characterization of anti-C5 antibody (305 variant)
Kinetic parameters of anti-C5 antibody against recombinant human C5 were evaluated at 37 ℃ under three different conditions using BIACORE (registered trademark) T200 instrument (GE Healthcare); (1) both binding and dissociation are at pH7.4, (2) both binding and dissociation are at pH5.8, and (3) binding is at pH7.4 and dissociation is at pH5.8. The ProA/G (Pierce) was fixed onto the CM1 sensor chip using an amine coupling kit (GE Healthcare) according to the settings recommended by GE Healthcare. The antibody and analyte of conditions (1) and (3) were diluted in ACES pH7.4 buffer (20mM ACES,150mM NaCl,1.2mM CaCl 2 ,0.05%Tween 20,0.005%NaN 3 ) Neutralizing and diluting the antibody and analyte of condition (2) in ACES pH5.8 buffer (20mM ACES,150mM NaCl,1.2mM CaCl 2 ,0.05%Tween 20,0.005%NaN 3 ) In (1). Each antibody was captured on the sensor surface by ProA/G. Antibody capture levels are typically 60-90 Response Units (RU). Recombinant human C5 was then injected at 3 to 27nM or 13.3 to 120nM (prepared by three-fold serial dilution) before dissociation. The surface was regenerated with 25mM NaOH. The kinetic parameters of conditions (1) and (2) were determined by fitting a sensorgram with a 1. The pH dependence of all antibodies is shown as the ratio of the off-rates of conditions (2) and (1).
The on-rate (ka), off-rate (KD), binding affinity (KD) and pH dependence are listed in table 9. All antibodies showed a faster off-rate at pH5.8 than at pH7.4 and a pH dependence of about 20-fold.
[ Table 9]
Kinetic parameters of anti-C5 antibody variants at pH7.4 and pH5.8
The binding affinity of anti-C5 antibodies (BNJ 441, eculizumab and 305 variant) to recombinant human C5 at pH7.4 and pH5.8 was determined at 37 ℃ using BIACORE (registered trademark) T200 instrument (GE Healthcare) to evaluate the effect of pH on antigen binding. Goat anti-human IgG (Fc) polyclonal antibody (KPL # 01-10-20) was immobilized onto CM4 sensor chip using an amine coupling kit (GE Healthcare) according to the manufacturer's recommended settings. The antibody and analyte were diluted in a medium containing 20mM ACES,150mM NaCl,1.2mM CaCl 2 0.05% Tween 20 and 0.005% NaN 3 In ACES pH7.4 buffer or ACES pH5.8 buffer. The antibody is captured on the sensor surface using an anti-Fc method, typically at a level of 50-80 Response Units (RU). Recombinant human C5 was prepared by three-fold serial dilution starting from 27nM (for pH7.4 assay conditions) or 135nM (for pH5.8 assay conditions). The surface was regenerated with 20mM HCl,0.01% Tween 20. Using BiaEvaluation 2.0 software (GE Healthcare), Data were processed and fitted with a 1.
BNJ441, eculizumab and 305 variant at ph7.4 and ph5.8 binding affinities (KD) for recombinant human C5 are shown in table 10. The 305 variant showed a (KD at pH 5.8)/(KD at pH 7.4) ratio of almost 800, which is 8 times higher than BNJ441 which showed a (KD at pH 5.8)/(KD at pH 7.4) ratio of only 93.
[ Table 10]
Example 9
Inhibitory Activity of anti-C5 antibody (305 variant) on C5 activation
9.1. Liposomal lysis with anti-C5 MAb inhibition of complement activation
The anti-C5 MAb was tested for inhibition of complement activity by a liposome lysis assay. mu.L of normal human serum (6.7%) (Biopredic, SER 019) was mixed with 20. Mu.L of diluted MAb in a 96-well plate and incubated on a shaker at room temperature for 30min. The liposome solution sensitized with antibodies against dinitrophenyl (Autokit CH50, wako, 995-40801) was transferred to each well and placed on a shaker at 37 ℃ for 2min. mu.L of substrate solution (Autokit CH 50) was added to each well and mixed with shaking at 37 ℃ for 2min. The final mixture was incubated at 37 ℃ for 40 minutes, after which OD at 340nm was measured. The percentage of liposome lysis was defined as 100 × [ (OD) MAb -OD Serum and liposome background )]/[(OD MAb-free -OD Serum and liposome background )]. FIG. 15 shows anti-C5 Mab:305LO15-SG422, 305LO16-SG422, 305LO18-SG422, 305LO19-SG422, 305LO20-SG422 and 305LO20-SG115 inhibit liposome lysis. Two antibodies with Fc variants: 305LO15-SG115 and 305LO23-SG429, and also showed inhibition of liposome lysis (FIG. 16).
The inhibition of recombinant human C5 (SEQ ID NO: 39) of anti-C5 MAb was tested. mu.L of human serum lacking C5 (Sigma, C1163) was mixed with 20. Mu.L of diluted MAb and 20. Mu.L of recombinant C5 (0.1. Mu.g/mL) in a 96-well plate and incubated for 1 hour at 37 ℃ on a shaker. Liposomes (Autokit CH 50) were transferred to each well and placed on a shaker at 37 ℃ for 2min. mu.L of substrate solution (Autokit CH 50) was added to each well and mixed with shaking at 37 ℃ for 2min. The final mixture was incubated at 37 ℃ for 180 minutes, after which the OD at 340nm was measured. The percentage of liposome solubilization is defined above. FIG. 17 shows anti-C5 Mab:305LO22-SG115, 305LO22-SG422, 305LO23-SG115 and 305LO23-SG422, inhibit liposome lysis.
9.2. anti-C5 MAb inhibits C5a production
anti-C5 MAb was tested for C5a production during liposome solubilization to confirm that anti-C5 MAb inhibits C5 cleavage into C5a and C5b. C5a levels in the supernatant from the liposome lysis assay were quantified using a C5a ELISA kit (R & D systems, DY 2037). All mabs inhibited C5a production in the supernatant in a dose-dependent manner (fig. 18 and 19).
9.3. Measurement of complement Activity in cynomolgus monkey plasma
Inhibition of complement activity of anti-C5 MAb was tested in cynomolgus monkey plasma. anti-C5 MAb was administered internally to monkeys (20 mg/kg), and plasma samples were collected periodically until day 56. Chicken red blood cells (cRBC) (Innovative research, IC 05-0810) were incubated with a solution containing 0.5mM MgCl 2 And 0.15mM CaCl 2 (GVB + +) washed in gelatin/barbital buffered saline (Boston BioProducts, IBB-300X) and then sensitized with 1. Mu.g/ml anti-chicken RBC antibody (Rockland 103-4139) at 4 ℃ for 15 minutes. Cells were then washed with GVB + + and 1X10 8 Individual cells/ml were suspended in the same buffer. Monkey plasma was incubated with sensitized crbcs for 20 minutes at 37 ℃ in separate round bottom 96-well micro-assay plates. After incubation, the plates were centrifuged at 1000 × g for 2 min at 4 ℃. The supernatant was transferred to wells on a flat-bottomed 96-well microtest plate for measuring the OD at 415nm, with a reference wavelength of 630nm. Percent hemolysis was defined as 100 × [ (OD) After application -OD Plasma and cRBC background )]/[(OD Before application -OD Plasma and cRBC background )]. FIG. 20 shows anti-C5 Mab:305LO15-SG422, 305LO15-SG115, 305LO16-SG422, 305LO18-SG422, 305LO19-SG422, 305LO20-SG422, 305LO20-SG115, and 305LO23-SG115, inhibit complement activity in plasma.
9.4. anti-C5 MAb inhibits the biological activity of C5 variants
Testing of recombinant human C5 variants of anti-C5 MAb: inhibition of V145I, R449G, V802I, R885H, R928Q, D966Y, S1310N, and E1437D. PNH patients with the R885H mutation in C5 are reported to show poor response to eculizumab (see, e.g., nishimura et al, new Engl. J. Med.370:632-639 (2014)). Individual C5 variants were expressed in FS293 cells and the supernatants were used for subsequent studies. mu.L of human serum lacking C5 (Sigma, C1163) was mixed with 20. Mu.L of diluted MAb and 20. Mu.L of cell culture medium containing recombinant C5 variants (2-3. Mu.g/mL) in 96-well plates and incubated on a shaker at 37 ℃ for 0.5 h. Liposomes (Autokit CH 50) were transferred to each well and placed on a shaker at 37 ℃ for 2min. mu.L of substrate solution (Autokit CH 50) was added to each well and mixed with shaking at 37 ℃ for 2min. The final mixture was incubated at 37 ℃ for 90 minutes, after which the OD at 340nm was measured. The percentage of liposome solubilization is defined above. Figure 21 shows that anti-C5 MAb (eculizumab) does not inhibit the R885H C5 variant, but inhibits other variants tested. Figure 22 shows that anti-C5 MAb (305 variant) inhibits all tested C5 variants.
9.5. Liposomal lysis with anti-C5 MAb inhibition of complement activation
The anti-C5 MAb was tested for inhibition of complement activity by a liposome lysis assay. mu.L of normal human serum (6.7%) (Biopredic, SER 019) was mixed with 20. Mu.L of diluted MAb in a 96-well plate and incubated on a shaker at room temperature for 30min. The liposome solution sensitized with antibodies against dinitrophenyl (Autokit CH50, wako, 995-40801) was transferred to each well and placed on a shaker at 25 ℃ for 2min. mu.L of substrate solution (Autokit CH 50) was added to each well and mixed with shaking at 25 ℃ for 2min. The final mixture was incubated at 37 ℃ for 45 minutes, after which the OD at 340nm was measured. The percent inhibition of liposome solubilization was defined as 100 × [ (OD) MAb -OD Serum and liposome background )]/[(OD MAb-free -OD Serum and liposome background )]. Figure 23 shows that anti-C5 MAb, BNJ441 and the 305 variant inhibit liposome lysis, and the inhibitory activity of the 305 variant is stronger than BNJ441.
Example 10
Pharmacokinetic study of anti-C5 monoclonal antibody (305 variant) in cynomolgus monkeys
10.1. In vivo testing using cynomolgus monkeys
After administration of the anti-human C5 antibody in cynomolgus monkeys (Shin Nippon biological Laboratories, ltd., japan), the in vivo kinetics of the anti-human C5 antibody was evaluated. A solution of anti-human C5 antibody (2.5 mg/ml) was administered in a single dose of approximately 8ml/kg into the cephalic vein of the forearm by 30 minute infusion. Blood was collected before administration and 5 minutes, 7 hours, 1 day, 2 days, 3 days, 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, and 56 days after administration. The collected blood was immediately centrifuged at 1,700x g at 4 ℃ for 10 minutes to separate plasma. The separated plasma was stored in a freezer below-70 ℃ until assayed. Anti-human C5 antibodies were prepared as described in example 7.
10.2. Measurement of cynomolgus monkey C5 Total plasma concentration by ELISA assay
Total concentration of cynomolgus C5 in cynomolgus monkey plasma was measured by ELISA. Anti-human C5 antibody (internal antibody generated using the method described in example 2) was dispensed onto Nunc-ImmunoPlate MaxiSorp (Nalge Nunc International) and left to stand overnight at 4 ℃ to prepare plates immobilized with anti-cynomolgus C5. Calibration curve samples were prepared and 20000-fold cynomolgus plasma samples diluted with 0.4. Mu.g/ml of injected antibody and incubated for 60 min at 37 ℃. Subsequently, the sample was dispensed onto the anti-cynomolgus monkey C5-immobilized plate and allowed to stand at room temperature for 1 hour. Then, HRP-labeled anti-human IgG antibody (southern biotech) was added to react at room temperature for 30 minutes, and washed. Subsequently, ABTS ELISA HRP substrate (KPL) was added. The signal was measured by a microplate reader at a wavelength of 405 nm. Cynomolgus C5 concentrations were calculated based on the response of the calibration curves using the analytical software SOFTmax PRO (Molecular Devices). The time course of plasma cynomolgus C5 concentration after intravenous administration as measured by this method is shown in figure 24. Data are plotted as the remaining percentage compared to plasma cynomolgus C5 concentration prior to administration. The pH-dependent anti-human C5 antibodies (305 LO15-SG422, 305LO15-SG115, 305LO16-SG422, 305LO18-SG422, 305LO19-SG422, 305LO20-SG115, 305LO22-SG422, 305LO23-SG422, and 305LO23-SG 115) showed lower plasma C5 accumulation compared to the non-pH-dependent anti-human C5 antibodies.
10.3. Measurement of anti-human C5 antibody plasma concentrations by ELISA assay
The concentration of anti-human C5 antibody in cynomolgus monkey plasma was measured by ELISA. Anti-human IgG kappa chain antibodies (Antibody Solutions) were distributed onto Nunc-ImmunoPlate MaxiSorp (Nalge Nunc International) and left to stand overnight at 4 ℃ to prepare plates immobilized with anti-human IgG. Calibration curve samples and cynomolgus plasma samples diluted 100-fold more were prepared. Subsequently, the sample was dispensed onto a plate on which anti-human IgG was immobilized, and allowed to stand at room temperature for 1 hour. Then, HRP-labeled anti-human IgG antibody (southern biotech) was added to react at room temperature for 30 minutes, and washed. Subsequently, ABTS ELISA HRP substrate (KPL) was added. The signal was measured by a microplate reader at a wavelength of 405 nm. Based on the response of the calibration curve, the anti-human C5 antibody concentration was calculated using the analytical software SOFTmax PRO (Molecular Devices). The time course of plasma anti-human C5 antibody concentrations after intravenous administration as measured by this method is shown in fig. 25. The pH-dependent anti-human C5 antibodies (305 LO15-SG422, 305LO15-SG115, 305LO16-SG422, 305LO18-SG422, 305LO19-SG422, 305LO20-SG115, 305LO22-SG422, 305LO23-SG422, and 305LO23-SG 115) exhibited longer half-lives compared to the non-pH-dependent anti-human C5 antibodies.
Example 11
X-ray crystal structure analysis of 305 variant Fab and human C5-MG1 domain complexes
11.1. Expression and purification of the MG1 Domain (20-124) of human C5
The MG1 domain (amino acid residues 20-124 of SEQ ID NO: 39) (GST-MG 1) fused to the GST-tag via a thrombin-cleavable linker was expressed in E.coli strain BL21 DE3 pLysS (Promega) using pGEX-4T-1 vector (GE healthcare). Protein expression was induced with 0.1mM isopropyl beta-D-1-thiogalactopyranoside (IPTG) for 5 hours at 25 ℃. Bacterial cell pellets were lysed with Bugbuster (Merck) supplemented with lysonase (Merck) and complete protease inhibitor cocktail (Roche), followed by purification of gstap-MG 1 from the soluble fraction using a GSTrap column (GE healthcare) according to the manufacturer's instructions. The GST tag was cleaved with thrombin (Sigma) and the resulting MG1 domain was further purified using Superdex 75 gel filtration column (GE healthcare). MG1 domain containing fractions were pooled and stored at-80 ℃.
11.2. Preparation of 305 variant Fab fragments
Fab fragments from one of the optimized variants of 305 were prepared by conventional methods using limited digestion with papain (Roche Diagnostics, catalog No. 1047825), followed by loading onto a protein a column (mabselect SuRe, GE Healthcare) to remove Fc fragments, and onto cation exchange columns (HiTrap SP HP, GE Healthcare) and gel filtration columns (Superdex 20016/60, GE Healthcare). The fractions containing Fab fragments were pooled and stored at-80 ℃.
11.3. Preparation of 305 variant Fab and human C5-MG1 Domain complexes
The purified recombinant human C5-MG1 domain was mixed with the purified 305 variant Fab fragment at a 1. The complex was purified by gel filtration chromatography (Superdex 200/300 increments, GE Healthcare) using a column equilibrated with 25mM HEPES pH 7.5, 100mM NaCl.
11.4. Crystallization of
The purified complex was concentrated to about 10mg/mL and crystallized by the sitting drop vapor diffusion method (drop vapor diffusion method) in combination with seed-crystal method at 4 ℃. The mother liquor consisted of 0.2M magnesium formate dehydrate, 15.0% w/v polyethylene glycol 3350. This successfully produced plate-like crystals over several days. The crystals were soaked in a solution of 0.2M magnesium formate dehydrate, 25.0% w/v polyethylene glycol 3350 and 20% glycerol.
11.5. Data collection and structure determination
X-ray diffraction data were measured at SPring-8 by BL32 XU. During the measurement, the crystal was kept frozen by being placed in a nitrogen flow at-178 ℃ and a total of 180X-ray diffraction images were collected using a MX-225HS CCD detector (RAYONIX) connected to the beam line while rotating the crystal 1.0 degree at a time. Determination of cell parameters, indexing of diffraction points and processing of diffraction data obtained from diffraction images were performed using the Xia2 program (J.apple.Crystal.43: 186-190 (2010), XDS software package (acta.Crystal.D66: 125-132 (2010)) and Scala (acta.Crystal.D62: 72-82 (2006)), and finally diffraction intensity data up to a resolution of 2.11 angstroms were obtained.
[ Table 11]
X-ray data collection and refinement statistics
a;R merge =∑hkl∑j|Ij(hkl)-<I(hkl)>I/Sigma hkl Sigma jIj (hkl) | where Ij (hkl) and<I(hkl)>the intensity of measurement j and the average intensity of the reflection with the index hkl are respectively.
b; r factor = ∑ hkl | F calc (hkl)|-|F obs (hkl)|/∑hkl|F obs (hkl) |, wherein F obs And F calc Are respectively
Observed and calculated mechanistic factor amplitudes.
c;R free Calculated using randomly picked 5% reflections.
The structure was determined by molecular replacement using the program Phaser (J.appl.Crystal.40: 658-674 (2007)). The search model for the Fab domain was derived from the published human IgG4 Fab crystal structure (PDB code: 1 BBJ), while the search model for the MG1 domain was derived from the published human C5 crystal structure (PDB code: 3CU7, nat. Immunol.9. The model was built using the Coot program (Acta Crystal.D66: 486-501 (2010)) and refined using the program Refmac5 (Acta Crystal.D67: 355-367 (2011)). The crystallographic reliability factor (R) for the 25-2.11 Angstrom diffraction intensity data is 20.42%, while the Free R value is 26.44%. The structure refinement statistics are shown in table 11.
11.6.305 Overall Structure of variant Fab and C5-MG1 Domain complexes
The Fab fragment ("305 Fab") from the optimized variant of 305 binds to the human C5-MG1 domain ("MG 1") in a 1: 1 ratio, and the asymmetric unit of crystal structure comprises two complexes, molecules 1 and 2, as shown in figure 26A. Molecules 1 and 2 can be well aligned with 0.717 angstrom RMSD using the ca atom position in all residues, as shown in fig. 26B. The figures discussed below were prepared using molecule 1.
In fig. 27A and 27B, the epitope of the 305Fab contact region is plotted in the MG1 amino acid sequence and in the crystal structure, respectively. The epitope includes amino acid residues of MG1 that contain one or more atoms located within a distance of 4.5 angstroms from any portion of the 305Fab in the crystal structure. Furthermore, epitopes within 3.0 angstroms are highlighted in fig. 27A.
11.7 interaction of D51 and K109 with E48
The anti-C5 MAb comprising the 305 antibody series was tested for binding to three human C5 point mutants E48A, D51A and K109A by western blot and BIACORE (registered trade mark) binding assays as described in examples 4.5 and 4.6. Although the 305 variants strongly bind WT C5, they only weakly bind the E48A C5 mutant and do not bind the D51A and K109A mutants. The crystal structure of the 305Fab and MG1 complex revealed that the three amino acids E48, D51 and K109 were all within 3.0 angstroms of the 305Fab, forming several hydrogen bonds with the Fab, as shown in fig. 28A. According to a more detailed study, the K109 residue of MG1 was embedded in a groove formed in the interface of the heavy chain of Fab and interacted tightly with Fab by three hydrogen bonds to H-CDR3_ G97, H-CDR3_ Y100 and H-CDR3_ T100b and a salt bridge to H-CDR3_ D95 (fig. 28D). D51 is located between the heavy chains of MG1 and 305Fab and forms two hydrogen bonds with H-CDR1_ Ser32 and H-CDR2_ Ser54 to fill the space (fig. 28C). These indicate that both K109 and D51 of C5 are critical residues for binding of the 305 antibody series. On the other hand, E48 was located next to the surface and formed only one hydrogen bond with Fab, indicating that its contribution to antibody binding was less than that of K109 and E51 (fig. 28B). These relationships are consistent with the results of western blot and BIACORE (registered trademark) binding analysis of human C5 mutants (examples 4.5 and 4.6). And (4) supplementary prompting: residue numbering of Fab amino acids is based on the Kabat numbering scheme. (Kabat et al, sequences of Proteins of Immunological Interest,5th Ed. Public Health service, national Institutes of Health, bethesda, md., 1991)
11.8. Interaction of H70, H72 and H110 of human C5 with the 305 antibody series
Crystal structure analysis revealed that three histidine residues on human C5, i.e., H70, H72 and H110, were contained in the epitope of the 305 variant Fab, as shown in fig. 27A and 29A. BIACORE (registered trade mark) binding assays were performed to investigate the contribution of these histidine residues to pH-dependent protein-protein interactions between human C5 and 305 variant fabs, using human C5 mutants H70Y, H72Y, H110Y and H70Y + H110Y (example 4.7). H72Y resulted in a complete loss of binding of 305 variant Fab to C5. This C5 residue is located in the pocket formed by the CDR2 loop of the 305Fab heavy chain and the loops of MG1 (L73, S74 and E76) and tightly fills this space as shown in fig. 29C. In addition, the H72 residue of C5 forms a hydrogen bond with H-CDR2_ Y58. It is expected that the H72Y mutation will not be tolerated because there is not enough room to accommodate the more bulky side chain of tyrosine. The hydrogen bond with H-CDR2_ Y58 is not maintained. Regarding the pH-dependent contribution of H70 and H110, the H70Y and H110Y mutations resulted in slower dissociation of the 305 variant Fab from C5 at pH 5.8. H70 forms an intramolecular hydrogen bond with T53 of MG1, which is believed to be disrupted when protonation of H70 of C5 causes a conformational change in the corresponding portion of the interaction interface of MG1 at pH 5.8 (fig. 29B). For H110, protonation of this C5 residue is expected to cause charge repulsion to the 305Fab, and protonation of the adjacent histidine residue H-CDR3_ H100C can enhance the repulsion (fig. 29D).
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the description and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.
Claims (29)
1. An antibody that binds C5 for use in treating a complement-mediated disease or disorder involving excessive or uncontrolled activation of C5, wherein the antibody binds an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH.
2. An antibody that binds C5 for use in enhancing clearance of C5 from plasma, wherein the antibody binds an epitope within the β chain of C5 with higher affinity at neutral pH than at acidic pH.
3. Use of an antibody that binds C5 in the manufacture of a medicament for treating a complement-mediated disease or disorder involving excessive or uncontrolled activation of C5, wherein the antibody binds to an epitope within the β chain of C5 with higher affinity at neutral pH than at acidic pH.
4. Use of an antibody that binds C5 in the manufacture of a medicament for enhancing clearance of C5 from plasma, wherein the antibody binds to an epitope within the β chain of C5 with a higher affinity at neutral pH than at acidic pH.
5. A method of treating a subject having a complement-mediated disease or disorder involving excessive or uncontrolled activation of C5, the method comprising administering to the subject an effective amount of an antibody that binds C5, wherein the antibody binds to an epitope within the β chain of C5 with higher affinity at neutral pH than at acidic pH.
6. A method of enhancing clearance of C5 from plasma in an individual comprising administering to the individual an effective amount of an antibody that binds C5 to enhance clearance of C5 from plasma, wherein the antibody binds an epitope within the β chain of C5 with higher affinity at neutral pH than at acidic pH.
7. The antibody for use, the use or the method of any one of claims 1 to 6, wherein the antibody has a characteristic selected from the group consisting of:
(a) The antibody contacts amino acids D51 and K109 of C5 (SEQ ID NO: 39);
(b) The affinity of the antibody for C5 (SEQ ID NO: 39) is greater than the affinity of the antibody for a polypeptide consisting of SEQ ID NO:39 of the C5 mutant consisting of the E48A substitution; and
(c) The antibody binds at ph7.4 to a polypeptide consisting of SEQ ID NO:40, but does not bind to C5 protein consisting of the amino acid sequence of SEQ ID No. 39 with the H72Y substitution at ph 7.4.
8. The antibody for use, the use or the method of any one of claims 1 to 6, wherein the antibody competes for binding to C5 with an antibody comprising a VH and VL pairing selected from the group consisting of:
(a) VH of SEQ ID NO. 1 and VL of SEQ ID NO. 11;
(b) VH of SEQ ID NO. 5 and VL of SEQ ID NO. 15;
(c) VH of SEQ ID NO. 4 and VL of SEQ ID NO. 14;
(d) VH of SEQ ID NO 6 and VL of SEQ ID NO 16;
(e) VH of SEQ ID NO 2 and VL of SEQ ID NO 12;
(f) VH of SEQ ID NO 3 and VL of SEQ ID NO 13;
(g) VH of SEQ ID NO 9 and VL of SEQ ID NO 19;
(h) VH of SEQ ID NO. 7 and VL of SEQ ID NO. 17;
(i) VH of SEQ ID NO 8 and VL of SEQ ID NO 18; and
(j) VH of SEQ ID NO 10 and VL of SEQ ID NO 20.
9. The antibody for use, the use or the method of any one of claims 1 to 8, wherein the antibody binds to an epitope within the MG1-MG2 domain of the beta chain of C5.
10. The antibody for use, the use or the method of any one of claims 1 to 9, wherein the antibody binds to an epitope within a fragment consisting of amino acids 33-124 of the beta chain of C5 (SEQ ID NO: 40).
11. The antibody for use, the use or the method of any one of claims 1 to 10, wherein said antibody binds to an epitope within the beta chain of C5 (SEQ ID NO: 40) comprising at least one fragment selected from the group consisting of amino acids 47-57, 70-76 and 107-110.
12. The antibody for use, the use or the method of any one of claims 1 to 11, wherein the antibody binds to an epitope within a fragment of the beta chain of C5 (SEQ ID NO: 40) comprising at least one amino acid selected from the group consisting of Glu48, asp51, his70, his72, lys109 and His 110.
13. The antibody for use, the use or the method of any one of claims 1 to 12, wherein the antibody binds to the same epitope as the antibodies described in tables 2,7 and 8.
14. The antibody for use, the use or the method of any one of claims 1 to 13, wherein the antibody inhibits the activation of C5.
15. The antibody for use, the use or the method of any one of claims 1 to 14, wherein the antibody inhibits activation of C5 variant R885H.
16. The antibody for use, the use or the method of any one of claims 1 to 15, wherein the antibody is a monoclonal antibody.
17. The antibody for use, the use or the method of any one of claims 1 to 16, wherein the antibody is a human, humanized or chimeric antibody.
18. The antibody for use, the use or the method of any one of claims 1 to 17, wherein the antibody is an antibody fragment that binds to C5.
19. The antibody for use, the use or the method of any one of claims 1 to 18, wherein the antibody comprises (a) HVR-H3, comprising the amino acid sequence DX 1 GYX 2 X 3 PTHAMX 4 X 5 Wherein X is 1 Is G or A, X 2 Is V, Q or D, X 3 Is T or Y, X 4 Is Y or H, X 5 Is L or Y (SEQ ID NO: 128), (b) HVR-L3 comprising the amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131), and (c) HVR-H2 comprising amino acid sequence X 1 IX 2 TGSGAX 3 YX 4 AX 5 WX 6 KG, wherein X 1 Is C, A or G, X 2 Is Y or F, X 3 Is T, D or E, X 4 Is Y, K or Q, X 5 Is S, D or E, X 6 Is A or V (SEQ ID NO: 127).
20. The antibody for use, the use or the method of any one of claims 1 to 18, wherein the antibody comprises (a) HVR-H1, which comprises the amino acid sequence SSYYX 1 X 2 Wherein X is 1 Is M or V, X 2 Is C or A (SEQ ID NO: 126), (b) HVR-H2, comprising amino acid sequence X 1 IX 2 TGSGAX 3 YX 4 AX 5 WX 6 KG, wherein X 1 Is C, A or G, X 2 Is Y or F, X 3 Is T, D or E, X 4 Is Y, K or Q, X 5 Is S, D or E, X 6 Is A or V (SEQ ID NO: 127), and (c) HVR-H3 comprising amino acid sequence DX 1 GYX 2 X 3 PTHAMX 4 X 5 Wherein X is 1 Is G or A, X 2 Is V, Q or D, X 3 Is T or Y, X 4 Is Y or H, X 5 Is L or Y (SEQ ID NO: 128).
21. The antibody for use, the use or the method of claim 20, wherein the antibody further comprises (a) HVR-L1, comprising the amino acid sequence X 1 ASQX 2 IX 3 SX 4 LA, wherein X 1 Is Q or R, X 2 Is N, Q or G, X 3 Is G or S, X 4 Is D, K or S (SEQ ID NO: 129); (b) HVR-L2 comprising the amino acid sequence GASX 1 X 2 X 3 S, wherein X 1 Is K, E or T, X 2 Is L or T, X 3 Is A, H, E or Q (SEQ ID NO: 130); and (c) HVR-L3 comprising the amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131).
22. Use according to any one of claims 1 to 18An antibody, use or method, wherein the antibody comprises (a) HVR-L1, comprising the amino acid sequence X 1 ASQX 2 IX 3 SX 4 LA, wherein X 1 Is Q or R, X 2 Is N, Q or G, X 3 Is G or S, X 4 Is D, K or S (SEQ ID NO: 129); (b) HVR-L2 comprising the amino acid sequence GASX 1 X 2 X 3 S, wherein X 1 Is K, E or T, X 2 Is L or T, X 3 Is A, H, E or Q (SEQ ID NO: 130); and (c) HVR-L3 comprising the amino acid sequence QX 1 TX 2 VGSSYGNX 3 Wherein X is 1 Is S, C, N or T, X 2 Is F or K, X 3 Is A, T or H (SEQ ID NO: 131).
23. The antibody for use, the use or the method of claim 20, wherein the antibody further comprises: a heavy chain variable domain framework FR1 comprising the amino acid sequence of any one of SEQ ID NOS 132-134; heavy chain variable domain framework FR2 comprising the amino acid sequence of any one of SEQ ID NOS 135-136; a heavy chain variable domain framework FR3 comprising the amino acid sequence of any one of SEQ ID NOS 137-139; and a heavy chain variable domain framework FR4 comprising the amino acid sequence of any one of SEQ ID NOS 140-141.
24. The antibody for use, the use or the method of claim 22, wherein the antibody further comprises: a light chain variable domain framework FR1 comprising the amino acid sequence of any one of SEQ ID NOS 142-143; a light chain variable domain framework FR2 comprising the amino acid sequence of any one of SEQ ID NOS 144-145; a light chain variable domain framework FR3 comprising the amino acid sequence of any one of SEQ ID NOS 146-147; and a light chain variable domain framework FR4 comprising the amino acid sequence of SEQ ID NO: 148.
25. The antibody for use, the use or the method of any one of claims 1 to 18, wherein the antibody comprises: (a) A VH sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs 10, 106-110; (b) A VL sequence having at least 95% sequence identity to the amino acid sequence of any of SEQ ID NOS 20, 111-113; or (c) a VH sequence according to (a) and a VL sequence according to (b).
26. The antibody for use, the use or the method of claim 25, wherein the antibody comprises a VH sequence of any one of SEQ ID NOs 10, 106 to 110.
27. The antibody for use, the use or the method of claim 25, wherein the antibody comprises a VL sequence of any one of SEQ ID NOs 20, 111-113.
28. The antibody for use, the use or the method of claim 26 or 27, wherein the antibody comprises a VH sequence of any one of SEQ ID NOs 10, 106 to 110 and a VL sequence of any one of SEQ ID NOs 20, 111 to 113.
29. The antibody for use, the use or the method of any one of claims 1 to 28, wherein the antibody is a full length IgG1 or IgG4 antibody.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-120325 | 2016-06-17 | ||
JP2016120325 | 2016-06-17 | ||
CN201780036916.4A CN109312326B (en) | 2016-06-17 | 2017-06-16 | anti-C5 antibodies and methods of use |
PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780036916.4A Division CN109312326B (en) | 2016-06-17 | 2017-06-16 | anti-C5 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115960223A true CN115960223A (en) | 2023-04-14 |
Family
ID=59969459
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211023851.9A Pending CN115925922A (en) | 2016-06-17 | 2017-06-16 | Anti-C5 antibodies and methods of use |
CN201780036916.4A Active CN109312326B (en) | 2016-06-17 | 2017-06-16 | anti-C5 antibodies and methods of use |
CN202211018018.5A Pending CN115960223A (en) | 2016-06-17 | 2017-06-16 | anti-C5 antibodies and methods of use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211023851.9A Pending CN115925922A (en) | 2016-06-17 | 2017-06-16 | Anti-C5 antibodies and methods of use |
CN201780036916.4A Active CN109312326B (en) | 2016-06-17 | 2017-06-16 | anti-C5 antibodies and methods of use |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP3472316A4 (en) |
JP (3) | JP6202774B1 (en) |
KR (2) | KR102226975B1 (en) |
CN (3) | CN115925922A (en) |
AU (1) | AU2017285763B2 (en) |
BR (1) | BR112018075688A2 (en) |
CA (1) | CA3021956A1 (en) |
CL (1) | CL2018003573A1 (en) |
CR (1) | CR20190013A (en) |
EA (1) | EA201990018A1 (en) |
IL (2) | IL300611A (en) |
MX (2) | MX2018015030A (en) |
MY (1) | MY187848A (en) |
PE (1) | PE20190394A1 (en) |
PH (1) | PH12018502354A1 (en) |
SG (2) | SG10201800265UA (en) |
TW (4) | TWI610941B (en) |
UA (1) | UA126561C2 (en) |
WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
KR102469853B1 (en) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
RU2746356C2 (en) | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | C5 antibodies and their application methods |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
MY187848A (en) * | 2016-06-17 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
CN116251182A (en) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
MX2020003619A (en) * | 2017-10-04 | 2020-10-28 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis. |
AU2018383751A1 (en) | 2017-12-13 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
US20220177556A1 (en) * | 2018-09-06 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
MX2021012997A (en) * | 2019-04-24 | 2022-03-04 | Univ Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof. |
CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
WO2002102110A1 (en) | 2001-06-12 | 2002-12-19 | Telefonaktiebolaget Lm Ericsson (Publ) | Synchronisation in a umts terrestrial radio access network (utran) |
CN100391537C (en) | 2001-08-17 | 2008-06-04 | 建南德克公司 | Complement pathway inhibitors binding to C5 and C5A without preventing formation of C5B |
JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
JP2010521194A (en) * | 2007-03-22 | 2010-06-24 | ノバルティス アーゲー | C5 antigen and uses thereof |
WO2008126921A1 (en) | 2007-04-11 | 2008-10-23 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
KR102469853B1 (en) * | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EA027575B1 (en) * | 2008-08-05 | 2017-08-31 | Новартис Аг | Antibody or antigen binding fragment thereof, binding human c5 protein, composition comprising same, nucleic acid encoding antibody or antigen binding fragment thereof, vector and host cell comprising said acid, and use of antibody or antigen binding fragment thereof |
KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
WO2011111007A2 (en) * | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
WO2014028354A1 (en) * | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
CA2899589C (en) * | 2013-01-31 | 2022-02-22 | Seoul National University R & Db Foundation | C5 antibody and method for preventing and treating complement-related diseases |
ES2768648T3 (en) * | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Compositions and methods for increasing serum half-life of a complement C5-targeted therapeutic agent |
NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
RU2746356C2 (en) * | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | C5 antibodies and their application methods |
PL3390442T3 (en) * | 2015-12-18 | 2024-03-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
MY187848A (en) * | 2016-06-17 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107207607B (en) | anti-C5 antibodies and methods of use | |
JP7208299B2 (en) | Anti-C5 Antibodies and Methods of Use | |
CN109312326B (en) | anti-C5 antibodies and methods of use | |
EA041632B1 (en) | ANTIBODIES TO C5 AND METHODS FOR THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40085591 Country of ref document: HK |